[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Aju Pharm Co., Ltd.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":397},{"warningLetters":4,"total":396},[5,30,53,70,90,116,137,155,173,192,213,231,249,268,288,306,326,342,359,379],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},811,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-06-24T04:00:00Z\">06\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-05-21T04:00:00Z\">05\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faju-pharm-co-ltd-704823-05212025\">Aju Pharm Co., Ltd.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tae Hoon Kim\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aju Pharm Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Room 201, Room 207, Bl A Bundangtekeunopakeu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>697 Pangyo-Ro\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bundang-gu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Seongnam-si\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gyeonggi-do\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>13511\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 21, 2025\u003Cbr>\u003Cbr>Dear Tae Hoon Kim:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Seongnam-Si, Gyeonggi, South Korea on January 20, 2025, through January 23, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Class II Fixone Hybrid Knotless Anchor and the Class II Fixone Biocomposite Anchor. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The inspection also revealed that your firm failed to adequately establish and maintain medical device report procedures, as required by 21 C.F.R. § 803.17.\u003C\u002Fp>\u003Cp>We received a response from Lee Seung Hoon, Quality Manager dated February 12, 2025 (received by the FDA on February 11, 2025) concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish procedures for validating the device design, as required by 21 CFR 820.30(g).\u003C\u002Fp>\u003Cp>For example, although you have been distributing the Fixone Hybrid Knotless Anchor in the United States since 2023, your firm has not followed your Design and Development Procedure, Document # AJP-OP-702, and has not performed design validation activities to ensure that the device conforms to defined user needs and intended uses, including testing of production units under actual or simulated use conditions.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your response acknowledged absence of design validation. You also state that your planned actions are expected to be completed by April 30, 2025. As part of your actions, your firm has opened a corrective and preventative action (CAPA) and you plan to conduct a comparative evaluation during the validation stage and to train your staff. Your response is not adequate because it is unclear how the comparative evaluation will assess operative conditions and if the comparator product you will use has undergone adequate design validation. Additionally, your corrective action plan does not include a systemic approach to address the adequacy of all applicable procedures or other devices distributed by your firm. Furthermore, you have not assessed if the distributed devices meet their specifications and if any additional action is necessary to minimize risk to patients.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>For example, a review of your firm’s 2022 and 2023 analysis of complaint data revealed that the firm has yet to initiate CAPAs to address the following identified suture anchor issues:\u003Cbr>a) For 2022\u003Cbr>i. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>ii. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>iii. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>b) For 2023\u003Cbr>i. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>ii. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>iii. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>iv. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>v. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>vi. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your response acknowledged the absence of CAPA implementation for these nonconformities. You plan to conduct CAPA for nonconformities and take corrective actions based on the results of your data analysis. Your response is not adequate because your corrective action plan does not include a systemic approach to address any applicable CAPA procedures or to retrospectively review other issues identified to date by your firm to determine if additional CAPA activities are necessary. Per your Annual Complaint Handling Trend Analysis Reports for 2022 and 2023, corrective actions were proposed to address the device issues cited above. However, you have not implemented corrective actions in compliance with 21 CFR 820.100 because there was no evidence that your firm adequately investigated the cause of these nonconformities. Additionally, you have not provided any information to evaluate if distributed devices meet their specifications and if any additional action is necessary to minimize risk to patients. We recommend that your response include a thorough investigation of the cause of these nonconformities and identification of any actions necessary to correct and prevent their recurrence. Additionally, we recommend that you verify or validate that any actions taken because of CAPA are effective at addressing the root cause of these issues without adversely affecting the device specifications. And you state that your planned actions are expected to be completed by April 30, 2025.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>For example, twenty (20) complaint files from 2022 to 2024 were reviewed during the inspection. Our inspection revealed that all 20 complaint files randomly selected for review during the inspection did not include sufficient event information on complaint evaluation for MDR reportability.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your response acknowledged absence of complaint review for MDR reportability during the complaint handling process. As part of your actions, your firm has opened a CAPA and you plan to document the reporting criteria in the customer complaint handling procedure. Your response is not adequate as your corrective action plan does not include a systemic approach to address this observation such as performing a retrospective evaluation of all past complaints to determine MDR reportability. We recommend that your response addresses the specific complaints identified during our inspection and that all other complaints have been procedurally processed, and if applicable, that investigation of the issues has been initiated. And you state that your planned actions are expected to be completed by April 30, 2025.\u003C\u002Fp>\u003Cp>4. Failure to adequately establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\u003C\u002Fp>\u003Cp>a) For example, the following suppliers and contractors were not evaluated based on their ability to meet specified requirements, including quality requirements:\u003C\u002Fp>\u003Cp>i. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>ii. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>iii. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>iv. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>v. \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. You acknowledged the absence of supplier evaluations. As part of your actions, your firm has opened a CAPA and plan to re-evaluate your current suppliers to identify approved suppliers. You also plan to document supplier requirements and register key facilities in accordance with FDA regulations. Your response is not adequate because your corrective actions do not include a systemic approach to address all purchasing control procedures. Additionally, you did not conduct a retrospective evaluation of all products and services received and whether those products and services met predetermined specifications and quality requirements. We recommend that your corrective actions also evaluate whether any additional action is necessary for distributed devices to minimize risk to patients. And you state that your planned actions are expected to be completed by April 30, 2025.\u003C\u002Fp>\u003Cp>b) As another example, your firm is currently using the poly(lactic-co-glycolic) acid (PLGA) and β-tricalcium phosphate (β-TCP) to manufacture biocomposite anchors for the Fixone Anchor System. However, the product label for the β-TCP states that this product is “For R&amp;D use only.” Your firm has not evaluated this material from the supplier to ensure it meets predetermined specifications.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. As part of your actions, your firm opened a CAPA and you reached out to the supplier of this manufacturing material to clarify its use in routine manufacturing. Per your response, the supplier (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) confirmed that this raw material (β-TCP) can be used in research, synthesis, and processing. You also noted that this raw material was purchased through an \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), \u003Cstrong>(b)(4)\u003C\u002Fstrong> than being \u003Cstrong>(b)(4)\u003C\u002Fstrong> from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You noted that you have \u003Cstrong>(b)(4)\u003C\u002Fstrong> with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and you plan to conduct a quality evaluation for this \u003Cstrong>(b)(4)\u003C\u002Fstrong> supplier.\u003C\u002Fp>\u003Cp>Your response is not adequate because you have not provided an evaluation of the monitoring and control of component characteristics that confirms the suitability of this β-TCP, and it is unclear if the chemical composition of this manufacturing material meets predetermined specifications. This is critically important considering what appears to be, in comparison to sales data, a high rate of device defects (ascertained via complaints), such as broken suture anchors during insertion, anchor bending, and fix suture loosening. Additionally, your response is not adequate because your corrective action plan does not include a systemic approach to address this observation such as performing an assessment of monitoring and control of component characteristics. We recommend that you perform a risk assessment that evaluates if distributed devices are non-conforming to their specifications and if any additional actions are necessary to minimize risk to patients. Additionally, we recommend that additional training be performed for any changes to production and process control procedures. And you state that your planned actions are expected to be completed by April 30, 2025.\u003C\u002Fp>\u003Cp>5. Failure to adequately establish and maintain process control procedures that describe any process controls necessary to ensure conformance to specifications, where deviations from device specifications could occur because of the manufacturing process, per 21 CFR 820 70(a).\u003C\u002Fp>\u003Cp>For example, your firm's mixing procedure (for the biocomposite anchors), Document #AJP-WS-02, is incomplete in that it fails to include the thawing requirements\u002Fprocedures of the frozen poly (lactic-co-glycolic acid) (PLGA) prior to mixing. The product label for the PLGA states that the “content must be at room temperature before opening.”\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. You acknowledged that the procedure for adequate handling of this critical raw material (PLGA) during the mixing process was not documented. As part of your actions, your firm has opened a CAPA and you plan to revise the relevant procedures for processing this raw material. You state that your planned actions are expected to be completed by April 30, 2025.\u003C\u002Fp>\u003Cp>Your response is not adequate because it did not include plans for training on the revised procedures and it did not include a retrospective evaluation to determine if inappropriate handling of this manufacturing material may have led to the distribution of non-conforming product. Additionally, your corrective actions do not include a systemic approach to address all other process controls used in the manufacturing of your medical devices. As inappropriate manufacturing of the PLGA could lead to changes in the device function and degradation, we recommend that you perform a risk assessment that evaluates if devices distributed are non-conforming to their specifications and if any additional actions is necessary to minimize risk to patients. In comparison to sales data, there appears to be a high rate of device defects (ascertained via complaints), such as broken suture anchors during insertion, anchor bending, and fix suture loosening.\u003C\u002Fp>\u003Cp>6. Failure to adequately establish and maintain procedures to ensure that sampling methods are adequate for their intended use and to ensure that when changes occur the sampling plans are reviewed, as required by 21 CFR 820.250(b).\u003C\u002Fp>\u003Cp>For example, your firm’s in-process testing (after injection) of the bone anchors of the Fixone Hybrid Anchor system are limited to only a few samples and is not based on a valid statistical rationale.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. You acknowledged that your “\u003Cem>sampling plan had no statistical basis in the process test at the semi-finished product (injection) stage\u003C\u002Fem>.” You also state that the planned actions are expected to be completed by April 30, 2025. As part of your actions, your firm has opened a CAPA and you plan to change the injection process sampling criteria to conform to a valid statistical plan.\u003C\u002Fp>\u003Cp>Your firm’s response is not adequate because your corrective actions do not include a systemic approach and do not include an assessment of sampling methods used for all other devices manufactured by your firm. Additionally, you do not include procedural updates to prevent the recurrence of this issue, and do not include any staff training. We recommend that your response includes a statistically justified sampling plan for in-process testing for all manufactured devices.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm failed to establish or maintain a record or report required under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Failing to maintain a record or report required under section 519 of the Act is a prohibited act under section 301(e) of the Act. Specifically, your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\u003C\u002Fp>\u003Cp>During the inspection, your firm presented a document titled “Safety Information Report”, Doc. No. AJP-OP-807, Ver. No. 4, dated 2024-04-19, where Section 6 is defined as their FDA Medical Device Reporting procedure. After reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>a) The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner are inadequate because although Section 6.1 references the criteria for report submission and Section 6.3 clarifies what information must be included in the report, the procedure does not define the steps and timeframes the firm will follow to evaluate information received, determine whether certain information is reportable and submit the report accordingly].\u003C\u002Fp>\u003Cp>b) The procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example:\u003C\u002Fp>\u003Cp>i. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\u003Cbr>ii. The procedure, as written, does not specify who makes the decision for reporting events to FDA.\u003C\u002Fp>\u003Cp>c) The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically:\u003C\u002Fp>\u003Cp>i. The procedure does not contain instructions for how your firm will comply with 21 C.F.R. § 803.12(a)’s requirement to submit reports to FDA in an electronic format that the FDA can process, review, and archive. Although Section 6.3 states that the FDA 3500A form much be submitted electronically, it does not identify how employees are to ensure that the form will be submitted to FDA in a format that FDA can process, review, and archive.\u003Cbr>ii. The procedure does not include a description of the steps for how the firm will ensure that electronic reports are adequately processed and submitted to FDA within the required timeframe.\u003C\u002Fp>\u003Cp>d) The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\\\u003C\u002Fp>\u003Cp>i. Documentation of adverse event related information maintained as MDR event files.\u003Cbr>ii. Information that was evaluated to determine if an event was reportable.\u003Cbr>iii. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\u003C\u002Fp>\u003Cp>In your response, you state that the planned actions are expected to be completed by April 30, 2025. As part of your actions, you plan to implement corrective actions to adhere to MDR reporting requirements. A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.”\u003C\u002Fp>\u003Cp>The adequacy of your response cannot be determined at this time. Although your response indicates that actions are expected to be completed by April 30, 2025, your firm has not yet provided a revised procedure as evidence of implementing the above listed issues.\u003C\u002Fp>\u003Cp>Given the serious nature of the violations of the Act by your firm, the Fixone Hybrid Knotless Anchor and the Fixone Biocomposite Anchors that your firm manufactures are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. To remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violations described in this letter. We will notify you regarding the adequacy of your firm’s response and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Avenue, Silver Spring, MD 20993. Refer to CMS case #704823 when replying. If you have any questions about the contents of this letter, please contact: Christopher Ferreira at\u003Cbr>christopher.ferreira@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>RDML Raquel Peat, Ph.D., M.P.H., USPHS&nbsp;&nbsp;\u003Cbr>Director&nbsp;&nbsp;\u003Cbr>OHT 6: Office of Orthopedic Devices\u003Cbr>Office of Product Evaluation and Quality&nbsp;&nbsp;\u003Cbr>Center for Devices and Radiological Health&nbsp;\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Peter Chung\u003Cbr>300 Atwood Street\u003Cbr>Pittsburgh, Pennsylvania 15213\u003Cbr>Phone: 412-512-8802\u003Cbr>Email: peterchung210@gmail.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nTae Hoon Kim\n\nRecipient Title\n\nPresident and CEO\n\nAju Pharm Co., Ltd.\n\nRoom 201, Room 207, Bl A Bundangtekeunopakeu\n\n697 Pangyo-Ro\n\nBundang-gu\n\nSeongnam-si\n\nGyeonggi-do\n\n13511\n\nSouth Korea\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nMay 21, 2025\n\nDear Tae Hoon Kim:\nDuring an inspection of your firm located in Seongnam-Si, Gyeonggi, South Korea on January 20, 2025, through January 23, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Class II Fixone Hybrid Knotless Anchor and the Class II Fixone Biocomposite Anchor. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The inspection also revealed that your firm failed to adequately establish and maintain medical device report procedures, as required by 21 C.F.R. § 803.17.\nWe received a response from Lee Seung Hoon, Quality Manager dated February 12, 2025 (received by the FDA on February 11, 2025) concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish procedures for validating the device design, as required by 21 CFR 820.30(g).\nFor example, although you have been distributing the Fixone Hybrid Knotless Anchor in the United States since 2023, your firm has not followed your Design and Development Procedure, Document # AJP-OP-702, and has not performed design validation activities to ensure that the device conforms to defined user needs and intended uses, including testing of production units under actual or simulated use conditions.\nWe reviewed your firm’s response and concluded that it is not adequate. Your response acknowledged absence of design validation. You also state that your planned actions are expected to be completed by April 30, 2025. As part of your actions, your firm has opened a corrective and preventative action (CAPA) and you plan to conduct a comparative evaluation during the validation stage and to train your staff. Your response is not adequate because it is unclear how the comparative evaluation will assess operative conditions and if the comparator product you will use has undergone adequate design validation. Additionally, your corrective action plan does not include a systemic approach to address the adequacy of all applicable procedures or other devices distributed by your firm. Furthermore, you have not assessed if the distributed devices meet their specifications and if any additional action is necessary to minimize risk to patients.\n2. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\nFor example, a review of your firm’s 2022 and 2023 analysis of complaint data revealed that the firm has yet to initiate CAPAs to address the following identified suture anchor issues:\na) For 2022\ni. (b)(4)\nii. (b)(4)\niii. (b)(4)\nb) For 2023\ni. (b)(4)\nii. (b)(4)\niii. (b)(4)\niv. (b)(4)\nv. (b)(4)\nvi. (b)(4)\nWe reviewed your firm’s response and concluded that it is not adequate. Your response acknowledged the absence of CAPA implementation for these nonconformities. You plan to conduct CAPA for nonconformities and take corrective actions based on the results of your data analysis. Your response is not adequate because your corrective action plan does not include a systemic approach to address any applicable CAPA procedures or to retrospectively review other issues identified to date by your firm to determine if additional CAPA activities are necessary. Per your Annual Complaint Handling Trend Analysis Reports for 2022 and 2023, corrective actions were proposed to address the device issues cited above. However, you have not implemented corrective actions in compliance with 21 CFR 820.100 because there was no evidence that your firm adequately investigated the cause of these nonconformities. Additionally, you have not provided any information to evaluate if distributed devices meet their specifications and if any additional action is necessary to minimize risk to patients. We recommend that your response include a thorough investigation of the cause of these nonconformities and identification of any actions necessary to correct and prevent their recurrence. Additionally, we recommend that you verify or validate that any actions taken because of CAPA are effective at addressing the root cause of these issues without adversely affecting the device specifications. And you state that your planned actions are expected to be completed by April 30, 2025.\n3. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\nFor example, twenty (20) complaint files from 2022 to 2024 were reviewed during the inspection. Our inspection revealed that all 20 complaint files randomly selected for review during the inspection did not include sufficient event information on complaint evaluation for MDR reportability.\nWe reviewed your firm’s response and concluded that it is not adequate. Your response acknowledged absence of complaint review for MDR reportability during the complaint handling process. As part of your actions, your firm has opened a CAPA and you plan to document the reporting criteria in the customer complaint handling procedure. Your response is not adequate as your corrective action plan does not include a systemic approach to address this observation such as performing a retrospective evaluation of all past complaints to determine MDR reportability. We recommend that your response addresses the specific complaints identified during our inspection and that all other complaints have been procedurally processed, and if applicable, that investigation of the issues has been initiated. And you state that your planned actions are expected to be completed by April 30, 2025.\n4. Failure to adequately establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\na) For example, the following suppliers and contractors were not evaluated based on their ability to meet specified requirements, including quality requirements:\ni. (b)(4)\nii. (b)(4)\niii. (b)(4)\niv. (b)(4)\nv. (b)(4)\nWe reviewed your firm’s response and concluded that it is not adequate. You acknowledged the absence of supplier evaluations. As part of your actions, your firm has opened a CAPA and plan to re-evaluate your current suppliers to identify approved suppliers. You also plan to document supplier requirements and register key facilities in accordance with FDA regulations. Your response is not adequate because your corrective actions do not include a systemic approach to address all purchasing control procedures. Additionally, you did not conduct a retrospective evaluation of all products and services received and whether those products and services met predetermined specifications and quality requirements. We recommend that your corrective actions also evaluate whether any additional action is necessary for distributed devices to minimize risk to patients. And you state that your planned actions are expected to be completed by April 30, 2025.\nb) As another example, your firm is currently using the poly(lactic-co-glycolic) acid (PLGA) and β-tricalcium phosphate (β-TCP) to manufacture biocomposite anchors for the Fixone Anchor System. However, the product label for the β-TCP states that this product is “For R&D use only.” Your firm has not evaluated this material from the supplier to ensure it meets predetermined specifications.\nWe reviewed your firm’s response and concluded that it is not adequate. As part of your actions, your firm opened a CAPA and you reached out to the supplier of this manufacturing material to clarify its use in routine manufacturing. Per your response, the supplier ((b)(4)) confirmed that this raw material (β-TCP) can be used in research, synthesis, and processing. You also noted that this raw material was purchased through an (b)(4) ((b)(4)), (b)(4) than being (b)(4) from (b)(4). You noted that you have (b)(4) with (b)(4), and you plan to conduct a quality evaluation for this (b)(4) supplier.\nYour response is not adequate because you have not provided an evaluation of the monitoring and control of component characteristics that confirms the suitability of this β-TCP, and it is unclear if the chemical composition of this manufacturing material meets predetermined specifications. This is critically important considering what appears to be, in comparison to sales data, a high rate of device defects (ascertained via complaints), such as broken suture anchors during insertion, anchor bending, and fix suture loosening. Additionally, your response is not adequate because your corrective action plan does not include a systemic approach to address this observation such as performing an assessment of monitoring and control of component characteristics. We recommend that you perform a risk assessment that evaluates if distributed devices are non-conforming to their specifications and if any additional actions are necessary to minimize risk to patients. Additionally, we recommend that additional training be performed for any changes to production and process control procedures. And you state that your planned actions are expected to be completed by April 30, 2025.\n5. Failure to adequately establish and maintain process control procedures that describe any process controls necessary to ensure conformance to specifications, where deviations from device specifications could occur because of the manufacturing process, per 21 CFR 820 70(a).\nFor example, your firm's mixing procedure (for the biocomposite anchors), Document #AJP-WS-02, is incomplete in that it fails to include the thawing requirements\u002Fprocedures of the frozen poly (lactic-co-glycolic acid) (PLGA) prior to mixing. The product label for the PLGA states that the “content must be at room temperature before opening.”\nWe reviewed your firm’s response and concluded that it is not adequate. You acknowledged that the procedure for adequate handling of this critical raw material (PLGA) during the mixing process was not documented. As part of your actions, your firm has opened a CAPA and you plan to revise the relevant procedures for processing this raw material. You state that your planned actions are expected to be completed by April 30, 2025.\nYour response is not adequate because it did not include plans for training on the revised procedures and it did not include a retrospective evaluation to determine if inappropriate handling of this manufacturing material may have led to the distribution of non-conforming product. Additionally, your corrective actions do not include a systemic approach to address all other process controls used in the manufacturing of your medical devices. As inappropriate manufacturing of the PLGA could lead to changes in the device function and degradation, we recommend that you perform a risk assessment that evaluates if devices distributed are non-conforming to their specifications and if any additional actions is necessary to minimize risk to patients. In comparison to sales data, there appears to be a high rate of device defects (ascertained via complaints), such as broken suture anchors during insertion, anchor bending, and fix suture loosening.\n6. Failure to adequately establish and maintain procedures to ensure that sampling methods are adequate for their intended use and to ensure that when changes occur the sampling plans are reviewed, as required by 21 CFR 820.250(b).\nFor example, your firm’s in-process testing (after injection) of the bone anchors of the Fixone Hybrid Anchor system are limited to only a few samples and is not based on a valid statistical rationale.\nWe reviewed your firm’s response and concluded that it is not adequate. You acknowledged that your “sampling plan had no statistical basis in the process test at the semi-finished product (injection) stage.” You also state that the planned actions are expected to be completed by April 30, 2025. As part of your actions, your firm has opened a CAPA and you plan to change the injection process sampling criteria to conform to a valid statistical plan.\nYour firm’s response is not adequate because your corrective actions do not include a systemic approach and do not include an assessment of sampling methods used for all other devices manufactured by your firm. Additionally, you do not include procedural updates to prevent the recurrence of this issue, and do not include any staff training. We recommend that your response includes a statistically justified sampling plan for in-process testing for all manufactured devices.\nOur inspection also revealed that your firm failed to establish or maintain a record or report required under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Failing to maintain a record or report required under section 519 of the Act is a prohibited act under section 301(e) of the Act. Specifically, your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\nDuring the inspection, your firm presented a document titled “Safety Information Report”, Doc. No. AJP-OP-807, Ver. No. 4, dated 2024-04-19, where Section 6 is defined as their FDA Medical Device Reporting procedure. After reviewing the procedure, the following deficiencies were noted:\na) The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the instructions for how your firm will evaluate information about an event to make MDR reportability determinations in a timely manner are inadequate because although Section 6.1 references the criteria for report submission and Section 6.3 clarifies what information must be included in the report, the procedure does not define the steps and timeframes the firm will follow to evaluate information received, determine whether certain information is reportable and submit the report accordingly].\nb) The procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example:\ni. There are no instructions for conducting an investigation of each MDR reportable event and evaluating the cause of the event.\nii. The procedure, as written, does not specify who makes the decision for reporting events to FDA.\nc) The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically:\ni. The procedure does not contain instructions for how your firm will comply with 21 C.F.R. § 803.12(a)’s requirement to submit reports to FDA in an electronic format that the FDA can process, review, and archive. Although Section 6.3 states that the FDA 3500A form much be submitted electronically, it does not identify how employees are to ensure that the form will be submitted to FDA in a format that FDA can process, review, and archive.\nii. The procedure does not include a description of the steps for how the firm will ensure that electronic reports are adequately processed and submitted to FDA within the required timeframe.\nd) The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\\\ni. Documentation of adverse event related information maintained as MDR event files.\nii. Information that was evaluated to determine if an event was reportable.\niii. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\nIn your response, you state that the planned actions are expected to be completed by April 30, 2025. As part of your actions, you plan to implement corrective actions to adhere to MDR reporting requirements. A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.”\nThe adequacy of your response cannot be determined at this time. Although your response indicates that actions are expected to be completed by April 30, 2025, your firm has not yet provided a revised procedure as evidence of implementing the above listed issues.\nGiven the serious nature of the violations of the Act by your firm, the Fixone Hybrid Knotless Anchor and the Fixone Biocomposite Anchors that your firm manufactures are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. To remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violations described in this letter. We will notify you regarding the adequacy of your firm’s response and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Avenue, Silver Spring, MD 20993. Refer to CMS case #704823 when replying. If you have any questions about the contents of this letter, please contact: Christopher Ferreira at\nchristopher.ferreira@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nRDML Raquel Peat, Ph.D., M.P.H., USPHS\nDirector\nOHT 6: Office of Orthopedic Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\n\nCC:\nPeter Chung\n300 Atwood Street\nPittsburgh, Pennsylvania 15213\nPhone: 412-512-8802\nEmail: peterchung210@gmail.com","Aju Pharm Co., Ltd.","aju-pharm-co-ltd-704823-05212025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faju-pharm-co-ltd-704823-05212025","2026-10-26T08:07:51.735351+00:00","Warning Letter","Issued","2025-06-24","704823","Medical Devices","Tae Hoon Kim","2026-08-19T16:38:52.649+00:00","2025-05-21",{"id":31,"raw":32,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":48,"body_fetched_at":49,"delivery_method":50,"recipient_title":19,"reference_number":51,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},169,[33,34,35,36,37,13,13,13],"\u003Ctime datetime=\"2026-05-12T04:00:00Z\">05\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-04T04:00:00Z\">05\u002F04\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fido-pharm-co-ltd-723449-05042026\">IDO Pharm Co., Ltd. \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FOTC Finished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-74\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Young Joo Kim\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>IDO Pharm Co., Ltd. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>41 Beonnyeong-ro, 15 beon-gil\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Danwon-gu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ansan-si\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gyeonggi-do\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>15616\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-74\u003C\u002Fp>\u003Cp>May 4, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Kim:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, IDO Pharm Co., Ltd., 3017021001, at 41 Beonnyeong-ro, 15 beon-gil, Danwon-gu District, Ansan-si, Gyeonggi-do, from November 10 to 13, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your December 4, 2025, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture multiple drug products labelled as \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate \u003Cstrong>(b)(4)\u003C\u002Fstrong> System Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm did not establish procedures describing the operation, cleaning, maintenance, or validation of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system, which is used to make a component of your drug products. Hoses were observed to contain stagnant \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and your \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank contained visible particulate matter floating on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> surface, including what appeared to be an insect.\u003C\u002Fp>\u003Cp>In your response, you state that you conducted an immediate inspection of the insanitary conditions in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system, storage tanks, piping, and hoses, and took corrective actions including draining and drying the hose containing stagnant \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You state that you will establish a \u003Cstrong>(b)(4)\u003C\u002Fstrong> system procedure that includes cleaning frequency for tanks, draining and drying criteria for hoses, and controls to prevent stagnant \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also state you will conduct personnel training.\u003C\u002Fp>\u003Cp>Your response is inadequate because your firm continues to manufacture drug products using an unqualified \u003Cstrong>(b)(4)\u003C\u002Fstrong> system that has not been validated for its intended use. You also failed to address the lack of qualification and validation of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Process and Equipment Cleaning Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm did not conduct process validation or equipment cleaning validation for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> over-the-counter drug products.\u003C\u002Fp>\u003Cp>In your response, you state that your firm plans to relocate your facility in April 2026 and that equipment qualification and validation activities which include manufacturing processes, method validation, and cleaning validation will be performed in parallel by July 2026. Your response is inadequate because you failed to provide your interim plans until your corrective actions are completed. You also did not conduct a risk assessment to evaluate the impact of manufacturing with unvalidated processes, nor did you provide an action plan to address any drug product quality or safety risk for batches already distributed to the U.S. market.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See FDA’s guidance document at www.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-validation-general-principles-and-practices for general principles and approaches that FDA considers appropriate elements of process validation.\u003C\u002Fp>\u003Cp>In response to this letter please provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocols and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.\u003Cbr>o A \u003Cstrong>(b)(4)\u003C\u002Fstrong> system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\u003C\u002Fli>\u003Cli>Your total microbial count limits to monitor whether this system is producing \u003Cstrong>(b)(4)\u003C\u002Fstrong> suitable for the intended uses for each of your drug products.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the potential effects of the observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong>, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to appropriately establish and validate your gas chromatographic (GC) method for assay testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your finished drug products. Also, you failed to validate your GC method for determining \u003Cstrong>(b)(4)\u003C\u002Fstrong> and volatile impurities in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material. In addition, you failed to test your \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and volatile impurities.\u003C\u002Fp>\u003Cp>In your response, you state that you will discontinue using the unvalidated methods and intend to establish and validate new GC testing methods. You also state your firm will implement \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> raw material and conduct impurity testing for every lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> per your updated release requirements.\u003C\u002Fp>\u003Cp>Your response is inadequate because you failed to conduct a risk assessment evaluating the impact of using unvalidated methods and did not address testing of finished product retains that may have been manufactured using untested or inadequately tested raw materials.\u003C\u002Fp>\u003Cp>Analytical methods must be validated to demonstrate they are suitable for their intended use and equivalent or better than applicable United States Pharmacopeia compendial methods. Verifying the accuracy, sensitivity, specificity, and reproducibility of your test methods is essential to ensuring that manufactured drug products meet established specifications for chemical and microbial attributes.\u003C\u002Fp>\u003Cp>In your response to this letter please provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug products distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, and methods. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not adequately exercise its authority and responsibilities including, but not limited to, implementing effective procedures and conducting adequate oversight of the drug products you manufacture. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of an appropriate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fli>\u003Cli>Establishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188).\u003C\u002Fli>\u003Cli>Performance of routine calibrations of equipment used in the manufacture, processing, packing, and holding of a drug product (21 CFR 211.68(a)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance documents, as well as for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload and at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload respectively.\u003C\u002Fp>\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\u003Cul>\u003Cli>A determination of whether procedures used by your firm are robust and appropriate.\u003C\u002Fli>\u003Cli>Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003C\u002Fli>\u003Cli>A complete and final review of each batch and its related information before the QU disposition decision.\u003C\u002Fli>\u003Cli>Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on March 31, 2026.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at IDO Pharm Co., Ltd., located at 41 Beonnyeong-ro, 15 beon-gil, Danwon-gu District, Ansan-si, Gyeonggi-do, 15616, Republic of Korea, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3017021001 and ATTN: Yvette Johnson.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Return Receipt Requested\n\nReference #:\n\n320-26-74\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Young Joo Kim\n\nRecipient Title\n\nChief Executive Officer\n\nIDO Pharm Co., Ltd.\n\n41 Beonnyeong-ro, 15 beon-gil\n\nDanwon-gu\n\nAnsan-si\n\nGyeonggi-do\n\n15616\n\nSouth Korea\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-74\nMay 4, 2026\nDear Mr. Kim:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, IDO Pharm Co., Ltd., 3017021001, at 41 Beonnyeong-ro, 15 beon-gil, Danwon-gu District, Ansan-si, Gyeonggi-do, from November 10 to 13, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your December 4, 2025, response to our Form FDA 483 in detail.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYou manufacture multiple drug products labelled as (b)(4).\nInadequate (b)(4) System Validation\nYour firm did not establish procedures describing the operation, cleaning, maintenance, or validation of your (b)(4) system, which is used to make a component of your drug products. Hoses were observed to contain stagnant (b)(4), and your (b)(4) tank contained visible particulate matter floating on the (b)(4) surface, including what appeared to be an insect.\nIn your response, you state that you conducted an immediate inspection of the insanitary conditions in your (b)(4) system, storage tanks, piping, and hoses, and took corrective actions including draining and drying the hose containing stagnant (b)(4). You state that you will establish a (b)(4) system procedure that includes cleaning frequency for tanks, draining and drying criteria for hoses, and controls to prevent stagnant (b)(4). You also state you will conduct personnel training.\nYour response is inadequate because your firm continues to manufacture drug products using an unqualified (b)(4) system that has not been validated for its intended use. You also failed to address the lack of qualification and validation of your (b)(4) system.\nInadequate Process and Equipment Cleaning Validation\nYour firm did not conduct process validation or equipment cleaning validation for your (b)(4) over-the-counter drug products.\nIn your response, you state that your firm plans to relocate your facility in April 2026 and that equipment qualification and validation activities which include manufacturing processes, method validation, and cleaning validation will be performed in parallel by July 2026. Your response is inadequate because you failed to provide your interim plans until your corrective actions are completed. You also did not conduct a risk assessment to evaluate the impact of manufacturing with unvalidated processes, nor did you provide an action plan to address any drug product quality or safety risk for batches already distributed to the U.S. market.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee FDA’s guidance document at www.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-validation-general-principles-and-practices for general principles and approaches that FDA considers appropriate elements of process validation.\nIn response to this letter please provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\nProcess performance protocols and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\nA comprehensive remediation plan for the design, control, and maintenance of the (b)(4) system.\no A (b)(4) system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\nYour total microbial count limits to monitor whether this system is producing (b)(4) suitable for the intended uses for each of your drug products.\nA detailed risk assessment addressing the potential effects of the observed (b)(4) system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\nA procedure for your (b)(4) system monitoring that specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) system.\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces (b)(4) that meets (b)(4), USP monograph specifications and appropriate microbial limits.\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nYou failed to appropriately establish and validate your gas chromatographic (GC) method for assay testing of (b)(4) in your finished drug products. Also, you failed to validate your GC method for determining (b)(4) and volatile impurities in your (b)(4) raw material. In addition, you failed to test your (b)(4) raw material for the presence of (b)(4) and volatile impurities.\nIn your response, you state that you will discontinue using the unvalidated methods and intend to establish and validate new GC testing methods. You also state your firm will implement (b)(4) testing for your (b)(4) raw material and conduct impurity testing for every lot of (b)(4) per your updated release requirements.\nYour response is inadequate because you failed to conduct a risk assessment evaluating the impact of using unvalidated methods and did not address testing of finished product retains that may have been manufactured using untested or inadequately tested raw materials.\nAnalytical methods must be validated to demonstrate they are suitable for their intended use and equivalent or better than applicable United States Pharmacopeia compendial methods. Verifying the accuracy, sensitivity, specificity, and reproducibility of your test methods is essential to ensuring that manufactured drug products meet established specifications for chemical and microbial attributes.\nIn your response to this letter please provide:\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug products distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nA comprehensive independent assessment of your laboratory practices, procedures, and methods. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) did not adequately exercise its authority and responsibilities including, but not limited to, implementing effective procedures and conducting adequate oversight of the drug products you manufacture. For example, your QU failed to ensure:\nEstablishment of an appropriate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\nEstablishment of adequate batch production and control records that contain the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188).\nPerformance of routine calibrations of equipment used in the manufacture, processing, packing, and holding of a drug product (21 CFR 211.68(a)).\nYour firm’s quality systems are inadequate. See FDA’s guidance documents, as well as for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload and at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload respectively.\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\nA determination of whether procedures used by your firm are robust and appropriate.\nProvisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\nA complete and final review of each batch and its related information before the QU disposition decision.\nOversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on March 31, 2026.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at IDO Pharm Co., Ltd., located at 41 Beonnyeong-ro, 15 beon-gil, Danwon-gu District, Ansan-si, Gyeonggi-do, 15616, Republic of Korea, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3017021001 and ATTN: Yvette Johnson.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","IDO Pharm Co., Ltd.","ido-pharm-co-ltd-723449-05042026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fido-pharm-co-ltd-723449-05042026","2026-10-26T08:08:57.317881+00:00","2026-05-12","723449","Drugs","Mr. Young Joo Kim","2026-08-19T04:42:34.135+00:00","Via Electronic Mail - Return Receipt Requested","320-26-74","2026-05-04",{"id":54,"raw":55,"subject":59,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":18,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":19,"body_fetched_at":68,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":69,"medical_device_id":19,"response_letter_date":19},501,[56,57,58,36,59,13,13,13],"\u003Ctime datetime=\"2025-11-05T05:00:00Z\">11\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-03T05:00:00Z\">11\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felle-pharm-718713-11032025\">Elle Pharm\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded\u002FBotox Blitz","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Elle Pharm\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 3, 2025\u003C\u002Fp>\u003Cp>Elle Pharm:\u003C\u002Fp>\u003Cp>This is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.ellepharm.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 503(b), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. As discussed below, FDA has observed that www.ellepharm.com introduces into interstate commerce unapproved and misbranded injectable botulinum toxin drug products.\u003C\u002Fp>\u003Cp>There are inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body’s natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. Accordingly, FDA requests that www.ellepharm.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drugs:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Certain products offered for sale by www.ellepharm.com are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&amp;C Act are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>An example of an unapproved botulinum toxin drug product you offer for sale on www.ellepharm.com is botulinum toxin type A marketed as “Hutox 100ui” and “Hutox 100”. Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claims “blepharospasm correction” and “hyperhidrosis” under “Scope of Hutox 100”.\u003C\u002Fp>\u003Cp>While there are FDA-approved versions of botulinum toxin drug products on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&amp;C Act in effect for “Hutox 100ui” and “Hutox 100”offered by www.ellepharm.com. Currently there are several botulinum toxin products FDA-approved for the U.S. market and these products are only available pursuant to a prescription from a licensed practitioner. Examples of FDA-approved botulinum toxin products with a summary of their indications are: BOTOX® (onabotulinumtoxinA), indicated for the treatment of overactive bladder, neurogenic detrusor overactivity, chronic migraine, spasticity, cervical dystonia, severe primary axillary hyperhidrosis, strabismus, and blepharospasm and prophylaxis of headaches in adults with chronic migraines; DAXXIFY® (daxibotulinumtoxinA-lanm), indicated for the temporary improvement in the appearance of glabellar lines and the treatment of cervical dystonia; and MYOBLOC® (rimabotulinumtoxinB), indicated for the treatment of cervical dystonia and chronic sialorrhea.\u003C\u002Fp>\u003Cp>Furthermore, FDA-approved botulinum toxin drug products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk of distant spread of toxin effect to produce symptoms consistent with botulinum toxin effects. In addition, swallowing and breathing difficulties can be life threatening and there have been reports of death.\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drugs:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. § 352(f)(1)] if its labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)] include those that, because of their toxicity or other potentiality for harmful effect, and\u002For the method of their use, and\u002For the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act, can be used safely only at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Because the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use. Consequently, the labeling for these drug products fail to bear adequate directions for use, causing them to be misbranded under section 502(f)(1) of the FD&amp;C Act. In addition, because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&amp;C Act. By offering these drugs for sale to U.S. consumers, www.ellepharm.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>FDA is sending this warning letter to www.ellepharm.com because of the inherent risks to consumers who purchase misbranded and unapproved new drugs. This letter is not intended to identify all the ways in which your products or operations might be in violation of the law. It is your responsibility to ensure that all products you offer for sale are in compliance with the FD&amp;C Act and its implementing regulations. You should take prompt action to address any violations of the FD&amp;C Act (which may include the offer for sale of similarly misbranded and\u002For unapproved new drugs other than the drug products noted above). We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a use for which they have not been approved by FDA and that you are not distributing misbranded and unapproved drug products in violation of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please notify this office in writing within 15 working days describing the specific steps you have taken to address any violations and to prevent their recurrence. Include an explanation of each step being taken to remedy and prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address this matter may result in legal action, including, without limitation, seizure, and injunction, without further notice. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the corrections. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration within 15 working days.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>Please direct your response and any inquiries to FDA at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Sangeeta Vaswani Chatterjee, Pharm.D.\u003Cbr>Acting Director\u003Cbr>Office of Drug Security, Integrity, and Response\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nElle Pharm\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nNovember 3, 2025\nElle Pharm:\nThis is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.ellepharm.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 503(b), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. As discussed below, FDA has observed that www.ellepharm.com introduces into interstate commerce unapproved and misbranded injectable botulinum toxin drug products.\nThere are inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body’s natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. Accordingly, FDA requests that www.ellepharm.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm.\nUnapproved New Drugs:\nCertain products offered for sale by www.ellepharm.com are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or function of the body. These drugs are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&C Act are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&C Act.\nAn example of an unapproved botulinum toxin drug product you offer for sale on www.ellepharm.com is botulinum toxin type A marketed as “Hutox 100ui” and “Hutox 100”. Evidence obtained from your website establishing that this product is a drug intended for human use (as defined in 21 CFR 201.128) includes the claims “blepharospasm correction” and “hyperhidrosis” under “Scope of Hutox 100”.\nWhile there are FDA-approved versions of botulinum toxin drug products on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for “Hutox 100ui” and “Hutox 100”offered by www.ellepharm.com. Currently there are several botulinum toxin products FDA-approved for the U.S. market and these products are only available pursuant to a prescription from a licensed practitioner. Examples of FDA-approved botulinum toxin products with a summary of their indications are: BOTOX® (onabotulinumtoxinA), indicated for the treatment of overactive bladder, neurogenic detrusor overactivity, chronic migraine, spasticity, cervical dystonia, severe primary axillary hyperhidrosis, strabismus, and blepharospasm and prophylaxis of headaches in adults with chronic migraines; DAXXIFY® (daxibotulinumtoxinA-lanm), indicated for the temporary improvement in the appearance of glabellar lines and the treatment of cervical dystonia; and MYOBLOC® (rimabotulinumtoxinB), indicated for the treatment of cervical dystonia and chronic sialorrhea.\nFurthermore, FDA-approved botulinum toxin drug products bear a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses the risk of distant spread of toxin effect to produce symptoms consistent with botulinum toxin effects. In addition, swallowing and breathing difficulties can be life threatening and there have been reports of death.\nMisbranded Drugs:\nA drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if its labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (see 21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)] include those that, because of their toxicity or other potentiality for harmful effect, and\u002For the method of their use, and\u002For the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act, can be used safely only at the direction, and under the supervision, of a licensed practitioner.\nBecause the aforementioned drug is a prescription drug intended for conditions that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use. Consequently, the labeling for these drug products fail to bear adequate directions for use, causing them to be misbranded under section 502(f)(1) of the FD&C Act. In addition, because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. By offering these drugs for sale to U.S. consumers, www.ellepharm.com is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nFDA is sending this warning letter to www.ellepharm.com because of the inherent risks to consumers who purchase misbranded and unapproved new drugs. This letter is not intended to identify all the ways in which your products or operations might be in violation of the law. It is your responsibility to ensure that all products you offer for sale are in compliance with the FD&C Act and its implementing regulations. You should take prompt action to address any violations of the FD&C Act (which may include the offer for sale of similarly misbranded and\u002For unapproved new drugs other than the drug products noted above). We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a use for which they have not been approved by FDA and that you are not distributing misbranded and unapproved drug products in violation of the FD&C Act.\nPlease notify this office in writing within 15 working days describing the specific steps you have taken to address any violations and to prevent their recurrence. Include an explanation of each step being taken to remedy and prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address this matter may result in legal action, including, without limitation, seizure, and injunction, without further notice. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the corrections. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration within 15 working days.\nIf you are not located in the U.S., please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be unapproved and misbranded products that cannot be legally sold to consumers in the U.S.\nPlease direct your response and any inquiries to FDA at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nSangeeta Vaswani Chatterjee, Pharm.D.\nActing Director\nOffice of Drug Security, Integrity, and Response\nOffice of Compliance\nCenter for Drug Evaluation and Research","Elle Pharm","elle-pharm-718713-11032025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felle-pharm-718713-11032025","2026-10-26T08:08:34.933335+00:00","2025-11-05","718713","2026-08-19T16:10:48.37+00:00","2025-11-03",{"id":71,"raw":72,"subject":77,"body_html":78,"body_text":79,"firm_name":80,"letter_id":81,"created_at":82,"fei_number":19,"letter_url":83,"updated_at":84,"action_type":22,"case_status":23,"posted_date":85,"marcs_cms_no":86,"product_type":47,"closeout_date":19,"issuing_office":76,"recipient_name":87,"body_fetched_at":88,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":89,"medical_device_id":19,"response_letter_date":19},2820,[73,74,75,76,77,13,13,13],"\u003Ctime datetime=\"2022-03-11T15:00:00Z\">03\u002F11\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-10T05:00:00Z\">03\u002F10\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsoda-pharm-626261-03102022\">Soda Pharm\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dawn Combs\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Soda Pharm\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>16671 Burns Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Marysville\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>43040\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ccombs@mockingbirdmeadows.com\"> ccombs@mockingbirdmeadows.com \u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dcombs@mockingbirdmeadows.com\"> dcombs@mockingbirdmeadows.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: March 10, 2022\u003Cbr>\n\u003Cbr>\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fsodapharmlife.com\u002F on February 7, 2022, and March 8, 2022, respectively. We also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002Fsodapharmlife\u002F and https:\u002F\u002Fwww.instagram.com\u002Fsodapharmlife\u002F, where you direct consumers to your website, https:\u002F\u002Fsodapharmlife.com\u002F, to purchase your products. The FDA has observed that your website offers the “Cold\u002FFlu\u002FCOVID Pack,” “Cold and Congestion Loose Leaf Tea,” “Goldenseal Extract,” “Cool Down Loose Leaf Tea,” “Resistance Extract,” “Ache Ease Herbal Drink Syrup,” “Pain Release Extract,” “Headache Blend Extract,” “Vapor Balm,” and the “Mustard Plaster” products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website and your social media websites that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cp>• \u003Cstrong>“Practical Advice For Managing Covid-19 at Home\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Over the past week, I’ve had a number of calls, emails and texts from people who are sick and need advice while managing covid at home. Some have tested positive for some form of COVID-19. It has come to a point that I have said or written some version of the same thing so many times that I thought I would just make a formal post. . . .\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Congestion . . .\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For congestion, you want an expectorant. This is why I created our Cold and Congestion Tea . . . it is filled with plants that aid the body in expelling mucus, but does so without being an irritant to the delicate mucous membranes in the lung. . . .\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Infection\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>It is important to get ahead of infection if you are managing covid at home. My favorite remedy here is our Goldenseal Tincture. Goldenseal has a special affinity for our mucous membranes and is what I reach for when an antibiotic is needed. . . .\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Fever . . .\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>If you are managing covid at home and have a threatening fever that is climbing into the danger zone or if you have a very high fever that is sustained for more than a day, it is good to interfere. This is where cold cloths on the forehead, lukewarm baths, or our Cool Down Tea can be of benefit. . . .\u003C\u002Fp>\n\n\u003Cp>This happens a lot in people who have compromised immune systems . . . particularly in those who as children were given OTC fever medicine. For these folks I have a tincture called Resistance, that is specific for people fighting off a flu-like illness with an unproductive fever mechanism. . . .\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Headache, Body Aches\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Anything that is anti-inflammatory is helpful here. We use our Ache Ease syrup for aches and pains and our Pain Release Tincture or our Headache Tincture to help those who are struggling with pain and\u002For headaches. Above all else, it is important to avoid over-the-counter remedies like Tylenol. . [sic] they will block your body’s ability to clear the virus and contribute to a lengthening of your illness and symptoms. . [sic] or worse- contribute to an autoimmune disease.” [from your webpage https:\u002F\u002Fsodapharmlife.com\u002F2021\u002F08\u002F31\u002Fmy-recommendations-for-managing-covid-at-home\u002F]\u003C\u002Fp>\n\n\u003Cp>• \u003Cstrong>“Which Cough Do You Cough. . . and How Do You Make It Stop? . . .\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>WET UNPRODUCTIVE COUGH OR DRY BARKING\u002FPAINFUL . . .\u003C\u002Fp>\n\n\u003Cp>With COVID, my observation is that the mucus produced is especially ‘sticky.’ . . . It is critical that you follow my recommendations in the Managing COVID at Home post until this cough is resolved. Get up and move! Hydrate like it’s your job, steam, drink expectorant teas and get that mucus out of your lungs! . . .\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Useful Aides: . . .\u003C\u002Fem>\u003Cbr>\n\u003Cbr>\n• Cold and Congestion Tea . . .\u003C\u002Fp>\n\n\u003Cp>\u003Cem>General Recommendations . . .\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>2. A natural mentholated salve, like our Vapor Balm, can be applied at night. . . .\u003Cbr>\n3. An old-fashioned mustard plaster. . . . This is by far one of my favorite weapons in my arsenal against an unproductive cough.” [from your webpage https:\u002F\u002Fsodapharmlife.com\u002F2021\u002F10\u002F13\u002Fwhich-cough-do-you-cough-and-how-do-you-make-itstop\u002F]\u003C\u002Fp>\n\n\u003Cp>• \u003Cstrong>“Mullein Leaves are Cryptonite [sic] to Congestion . . .\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>A Bit About The Healing Aspects of Mullein . . .\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>I formulated my Cold and Congestion Tea with dried mullein leaf because it is so effective at moving out mucus while also being gentle to the lungs. This is especially important right now as so many are trying to recover from COVID. It’s funny to me that I scheme to avoid touching the plant in its fresh or dried form. As irritating as it is on my hands and arms it is that soothing to my lungs.” [from your webpage https:\u002F\u002Fsodapharmlife.com\u002F2021\u002F08\u002F31\u002Fmullein-leaves-are-cryptonite-tocongestion\u002F]\u003C\u002Fp>\n\n\u003Cp>• “Get your cold and flu pack - everything you need for cold\u002Fflu or COVID management at home in one click . . . https:\u002F\u002Fsodapharmlife.com\u002Fproduct\u002Fcold-flu-covid-pack\u002F Don’t just wait until you’re bad enough to go to the ER!! Get better instead!” [from the November 8, 2021 posts on both your Instagram webpage at https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCWB7bIqrdbG\u002F and your Facebook webpage at https:\u002F\u002Fwww.facebook.com\u002Fsodapharmlife\u002F]\u003C\u002Fp>\n\n\u003Cp>Your website, https:\u002F\u002Fsodapharmlife.com\u002F, also includes various “Category” tags such as “Covid” that link to the “Cold\u002FFlu\u002FCOVID Pack” and “Mustard Plaster” products and provide evidence of the products’ intended uses.\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the product identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\u003C\u002Fp>\n\n\u003Cp>Sincerely,&nbsp;\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donald D. Ashley\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Serena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDawn Combs\n\nSoda Pharm\n\n16671 Burns Road\n\nMarysville, OH 43040\n\nUnited States\n\nccombs@mockingbirdmeadows.com\n\ndcombs@mockingbirdmeadows.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nDate: March 10, 2022\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fsodapharmlife.com\u002F on February 7, 2022, and March 8, 2022, respectively. We also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002Fsodapharmlife\u002F and https:\u002F\u002Fwww.instagram.com\u002Fsodapharmlife\u002F, where you direct consumers to your website, https:\u002F\u002Fsodapharmlife.com\u002F, to purchase your products. The FDA has observed that your website offers the “Cold\u002FFlu\u002FCOVID Pack,” “Cold and Congestion Loose Leaf Tea,” “Goldenseal Extract,” “Cool Down Loose Leaf Tea,” “Resistance Extract,” “Ache Ease Herbal Drink Syrup,” “Pain Release Extract,” “Headache Blend Extract,” “Vapor Balm,” and the “Mustard Plaster” products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your website and your social media websites that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n• “Practical Advice For Managing Covid-19 at Home\n\nOver the past week, I’ve had a number of calls, emails and texts from people who are sick and need advice while managing covid at home. Some have tested positive for some form of COVID-19. It has come to a point that I have said or written some version of the same thing so many times that I thought I would just make a formal post. . . .\n\nCongestion . . .\n\nFor congestion, you want an expectorant. This is why I created our Cold and Congestion Tea . . . it is filled with plants that aid the body in expelling mucus, but does so without being an irritant to the delicate mucous membranes in the lung. . . .\n\nInfection\n\nIt is important to get ahead of infection if you are managing covid at home. My favorite remedy here is our Goldenseal Tincture. Goldenseal has a special affinity for our mucous membranes and is what I reach for when an antibiotic is needed. . . .\n\nFever . . .\n\nIf you are managing covid at home and have a threatening fever that is climbing into the danger zone or if you have a very high fever that is sustained for more than a day, it is good to interfere. This is where cold cloths on the forehead, lukewarm baths, or our Cool Down Tea can be of benefit. . . .\n\nThis happens a lot in people who have compromised immune systems . . . particularly in those who as children were given OTC fever medicine. For these folks I have a tincture called Resistance, that is specific for people fighting off a flu-like illness with an unproductive fever mechanism. . . .\n\nHeadache, Body Aches\n\nAnything that is anti-inflammatory is helpful here. We use our Ache Ease syrup for aches and pains and our Pain Release Tincture or our Headache Tincture to help those who are struggling with pain and\u002For headaches. Above all else, it is important to avoid over-the-counter remedies like Tylenol. . [sic] they will block your body’s ability to clear the virus and contribute to a lengthening of your illness and symptoms. . [sic] or worse- contribute to an autoimmune disease.” [from your webpage https:\u002F\u002Fsodapharmlife.com\u002F2021\u002F08\u002F31\u002Fmy-recommendations-for-managing-covid-at-home\u002F]\n\n• “Which Cough Do You Cough. . . and How Do You Make It Stop? . . .\n\nWET UNPRODUCTIVE COUGH OR DRY BARKING\u002FPAINFUL . . .\n\nWith COVID, my observation is that the mucus produced is especially ‘sticky.’ . . . It is critical that you follow my recommendations in the Managing COVID at Home post until this cough is resolved. Get up and move! Hydrate like it’s your job, steam, drink expectorant teas and get that mucus out of your lungs! . . .\n\nUseful Aides: . . .\n\n• Cold and Congestion Tea . . .\n\nGeneral Recommendations . . .\n\n2. A natural mentholated salve, like our Vapor Balm, can be applied at night. . . .\n\n3. An old-fashioned mustard plaster. . . . This is by far one of my favorite weapons in my arsenal against an unproductive cough.” [from your webpage https:\u002F\u002Fsodapharmlife.com\u002F2021\u002F10\u002F13\u002Fwhich-cough-do-you-cough-and-how-do-you-make-itstop\u002F]\n\n• “Mullein Leaves are Cryptonite [sic] to Congestion . . .\n\nA Bit About The Healing Aspects of Mullein . . .\n\nI formulated my Cold and Congestion Tea with dried mullein leaf because it is so effective at moving out mucus while also being gentle to the lungs. This is especially important right now as so many are trying to recover from COVID. It’s funny to me that I scheme to avoid touching the plant in its fresh or dried form. As irritating as it is on my hands and arms it is that soothing to my lungs.” [from your webpage https:\u002F\u002Fsodapharmlife.com\u002F2021\u002F08\u002F31\u002Fmullein-leaves-are-cryptonite-tocongestion\u002F]\n\n• “Get your cold and flu pack - everything you need for cold\u002Fflu or COVID management at home in one click . . . https:\u002F\u002Fsodapharmlife.com\u002Fproduct\u002Fcold-flu-covid-pack\u002F Don’t just wait until you’re bad enough to go to the ER!! Get better instead!” [from the November 8, 2021 posts on both your Instagram webpage at https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCWB7bIqrdbG\u002F and your Facebook webpage at https:\u002F\u002Fwww.facebook.com\u002Fsodapharmlife\u002F]\n\nYour website, https:\u002F\u002Fsodapharmlife.com\u002F, also includes various “Category” tags such as “Covid” that link to the “Cold\u002FFlu\u002FCOVID Pack” and “Mustard Plaster” products and provide evidence of the products’ intended uses.\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the product identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n_____________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Soda Pharm","soda-pharm-626261-03102022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsoda-pharm-626261-03102022","2026-10-26T08:10:00.989198+00:00","2022-03-11","626261","Dawn Combs","2026-08-20T02:06:57.123+00:00","2022-03-10",{"id":91,"raw":92,"subject":99,"body_html":100,"body_text":101,"firm_name":102,"letter_id":103,"created_at":104,"fei_number":19,"letter_url":105,"updated_at":106,"action_type":22,"case_status":107,"posted_date":108,"marcs_cms_no":109,"product_type":110,"closeout_date":111,"issuing_office":96,"recipient_name":112,"body_fetched_at":113,"delivery_method":114,"recipient_title":19,"reference_number":19,"action_taken_date":115,"medical_device_id":19,"response_letter_date":19},3151,[93,94,95,96,97,13,98,13],"\u003Ctime datetime=\"2021-09-09T14:50:00Z\">09\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-07T04:00:00Z\">09\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Far-rahman-pharm-llc-614578-09072021\">Ar-Rahman Pharm LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Unapproved New Drugs\u002FMisbranded ","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Far-rahman-pharm-llc-614578-03152022\">\u003Ctime datetime=\"2022-03-21T04:00:00Z\">03\u002F21\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Abdur‐Rahmaan Felder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Ar-Rahman Pharm LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14625 Baltimore Ave., Suite 885\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Laurel\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>20707\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>RE: 614578\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Abdur‐Rahmaan Felder:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fwww.ar‐rahmahpharm.com\u002F in August 2021 and has determined that you take orders there for your Diabetes Support product. In addition, FDA reviewed your social media websites, https:\u002F\u002Fwww.instagram.com\u002Farrahmahpharm\u002F, and https:\u002F\u002Fwww.facebook.com\u002FArRahmahPharm which directs consumers to your website https:\u002F\u002Fwww.ar‐rahmahpharm.com\u002F to purchase your product. You are also advised that the Federal Trade Commission reviewed your websites in August 2021.\u003C\u002Fp>\n\n\u003Cp>The claims on your website and social media websites establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your product is intended for use as a drug include:\u003C\u002Fp>\n\n\u003Cp>• “DIABETES SUPPORT (your product name) . . . Diabetes is caused when the body either resists insulin or does not produce enough; either of which can lead to unbalanced blood glucose levels. Our diabetes support formula assists in keeping blood sugar at an optimum level. ..... Diabetes Support helps to balance blood glucose levels.”\u003Cbr>\n• “May help balance Blood Sugar Levels”\u003Cbr>\n\u003Cbr>\nOn your social media Instagram page:\u003C\u002Fp>\n\n\u003Cp>• “Herbs such as those in our Diabetes support formula have been scientifically shown to support healthy blood sugar levels.”\u003Cbr>\n• “Provide supplemental nutrients to the pancreas for balancing insulin and glucagon.\"\u003Cbr>\n• “Our diabetes support formula assists in keeping blood sugar at an optimum level. This wonderful blend . . . makes blood sugar management easier. With nutrient dense herbs . . . Diabetes Support helps to balance blood glucose levels.\"\u003C\u002Fp>\n\n\u003Cp>On your social media Facebook page:\u003C\u002Fp>\n\n\u003Cp>• \"Our diabetes support formula assists in keeping blood sugar at an optimum level. This wonderful blend . . . makes blood sugar management easier. With nutrient dense herbs . . . Diabetes Support helps to balance blood glucose levels.”\u003Cbr>\n• “May help balance Blood Sugar Levels\"\u003C\u002Fp>\n\n\u003Cp>Your Diabetes Support product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product Diabetes Support is intended for treatment of one or more diseases that, with certain exceptions not applicable here, are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, your Diabetes Support product fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all‐inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003Cbr>\n\u003Cbr>\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply to the above violations should be directed to Rob Genzel Jr. with the FDA via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> In addition, the Federal Trade Commission has determined that it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess a reasonable basis consisting of competent and reliable scientific evidence, including, when appropriate, well‐controlled human clinical studies, substantiating that the claims are true at the time they are made. POM Wonderful LLC, 155 F.T.C. 1, 60‐61, (2013), aff’d in relevant part, 777 F.3d 478 (D.C. Cir. 2015); Daniel Chapter One, FTC Dkt. No. 9239, 2009 WL 5160000 at *16‐19 (F.T.C. Dec. 24, 2009), aff’d, 405 Fed. Appx.505 (D.C. Cir. 2010); Removatron Int'l Corp., 111 F.T.C. 206, 297‐99 (1988), aff’d, 884 F.2d 1489, 1496 (1st Cir. 1989); see also, FTC v. Direct Mktg. Concepts, 569 F. Supp. 2d 285, 300, 303 (D. Mass. 2008), aff’d, 624 F.3d 1 (1st Cir. 2010); FTC v. Nat'l Urological Group, Inc., 645 F. Supp. 2d 1167, 1190, 1202 (N.D. Ga. 2008), aff’d, 356 Fed. Appx. 358 (11th Cir. 2009); FTC v. Natural Solution, Inc., No. CV 06‐6112‐JFW, 2007‐2 Trade Cas. (CCH) P75,866, 2007 U.S. Dist. LEXIS 60783, at *11‐12 (C.D. Cal. Aug. 7, 2007). More generally, to make or exaggerate such claims, whether directly or indirectly, through the use of a product name, website name, metatags, or other means, without rigorous scientific evidence sufficient to substantiate the claims, violates the FTC Act. See Daniel Chapter One, WL 5160000 at *17‐19.\u003C\u002Fp>\n\n\u003Cp>The FTC is concerned that one or more of the efficacy claims cited above may not be substantiated by competent and reliable scientific evidence. Notice is hereby given that you must cease and desist from making any claim that a product and prevent, treat, or cure diabetes without competent and reliable scientific evidence consisting of well‐controlled human clinical studies substantiating that the claims are true. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction or Administrative Cease and Desist Order. In addition, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of a disease may be subject to a civil penalty of up to $43,792 per violation pursuant to Section 5(m)(1)(B) of the FTC Act, 15 U.S.C. § 45(m)(1)(B), and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b).\u003C\u002Fp>\n\n\u003Cp>With regard to the advertising claims discussed above, please notify Richard Cleland of the FTC via electronic mail at rcleland@ftc.gov within fifteen (15) working days of receipt of this letter of the specific actions you have taken to address FTC's concerns.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nGlenn Bass\u003Cbr>\nActing\u003Cbr>\nDeputy Director\u003Cbr>\nOffice of Compliance Center for Food Safety\u003Cbr>\n&nbsp; &nbsp; and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nSerena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nAbdur‐Rahmaan Felder\n\nAr-Rahman Pharm LLC\n\n14625 Baltimore Ave., Suite 885\n\nLaurel, MD 20707\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nRE: 614578\n\nDear Mr. Abdur‐Rahmaan Felder:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fwww.ar‐rahmahpharm.com\u002F in August 2021 and has determined that you take orders there for your Diabetes Support product. In addition, FDA reviewed your social media websites, https:\u002F\u002Fwww.instagram.com\u002Farrahmahpharm\u002F, and https:\u002F\u002Fwww.facebook.com\u002FArRahmahPharm which directs consumers to your website https:\u002F\u002Fwww.ar‐rahmahpharm.com\u002F to purchase your product. You are also advised that the Federal Trade Commission reviewed your websites in August 2021.\n\nThe claims on your website and social media websites establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your product is intended for use as a drug include:\n\n• “DIABETES SUPPORT (your product name) . . . Diabetes is caused when the body either resists insulin or does not produce enough; either of which can lead to unbalanced blood glucose levels. Our diabetes support formula assists in keeping blood sugar at an optimum level. ..... Diabetes Support helps to balance blood glucose levels.”\n\n• “May help balance Blood Sugar Levels”\n\nOn your social media Instagram page:\n\n• “Herbs such as those in our Diabetes support formula have been scientifically shown to support healthy blood sugar levels.”\n\n• “Provide supplemental nutrients to the pancreas for balancing insulin and glucagon.\"\n\n• “Our diabetes support formula assists in keeping blood sugar at an optimum level. This wonderful blend . . . makes blood sugar management easier. With nutrient dense herbs . . . Diabetes Support helps to balance blood glucose levels.\"\n\nOn your social media Facebook page:\n\n• \"Our diabetes support formula assists in keeping blood sugar at an optimum level. This wonderful blend . . . makes blood sugar management easier. With nutrient dense herbs . . . Diabetes Support helps to balance blood glucose levels.”\n\n• “May help balance Blood Sugar Levels\"\n\nYour Diabetes Support product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product Diabetes Support is intended for treatment of one or more diseases that, with certain exceptions not applicable here, are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, your Diabetes Support product fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all‐inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply to the above violations should be directed to Rob Genzel Jr. with the FDA via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nFTC Cease and Desist Demand: In addition, the Federal Trade Commission has determined that it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess a reasonable basis consisting of competent and reliable scientific evidence, including, when appropriate, well‐controlled human clinical studies, substantiating that the claims are true at the time they are made. POM Wonderful LLC, 155 F.T.C. 1, 60‐61, (2013), aff’d in relevant part, 777 F.3d 478 (D.C. Cir. 2015); Daniel Chapter One, FTC Dkt. No. 9239, 2009 WL 5160000 at *16‐19 (F.T.C. Dec. 24, 2009), aff’d, 405 Fed. Appx.505 (D.C. Cir. 2010); Removatron Int'l Corp., 111 F.T.C. 206, 297‐99 (1988), aff’d, 884 F.2d 1489, 1496 (1st Cir. 1989); see also, FTC v. Direct Mktg. Concepts, 569 F. Supp. 2d 285, 300, 303 (D. Mass. 2008), aff’d, 624 F.3d 1 (1st Cir. 2010); FTC v. Nat'l Urological Group, Inc., 645 F. Supp. 2d 1167, 1190, 1202 (N.D. Ga. 2008), aff’d, 356 Fed. Appx. 358 (11th Cir. 2009); FTC v. Natural Solution, Inc., No. CV 06‐6112‐JFW, 2007‐2 Trade Cas. (CCH) P75,866, 2007 U.S. Dist. LEXIS 60783, at *11‐12 (C.D. Cal. Aug. 7, 2007). More generally, to make or exaggerate such claims, whether directly or indirectly, through the use of a product name, website name, metatags, or other means, without rigorous scientific evidence sufficient to substantiate the claims, violates the FTC Act. See Daniel Chapter One, WL 5160000 at *17‐19.\n\nThe FTC is concerned that one or more of the efficacy claims cited above may not be substantiated by competent and reliable scientific evidence. Notice is hereby given that you must cease and desist from making any claim that a product and prevent, treat, or cure diabetes without competent and reliable scientific evidence consisting of well‐controlled human clinical studies substantiating that the claims are true. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction or Administrative Cease and Desist Order. In addition, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of a disease may be subject to a civil penalty of up to $43,792 per violation pursuant to Section 5(m)(1)(B) of the FTC Act, 15 U.S.C. § 45(m)(1)(B), and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b).\n\nWith regard to the advertising claims discussed above, please notify Richard Cleland of the FTC via electronic mail at rcleland@ftc.gov within fifteen (15) working days of receipt of this letter of the specific actions you have taken to address FTC's concerns.\n\nSincerely,\n\n\u002FS\u002F\n\nGlenn Bass\n\nActing\n\nDeputy Director\n\nOffice of Compliance Center for Food Safety\n\nand Applied Nutrition\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission","Ar-Rahman Pharm LLC","ar-rahman-pharm-llc-614578-09072021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Far-rahman-pharm-llc-614578-09072021","2026-10-26T08:07:57.188185+00:00","Closed Out","2021-09-09","614578","Dietary Supplements","2022-03-21","Abdur‐Rahmaan Felder","2026-08-20T02:36:30.414+00:00","United Parcel Service","2021-09-07",{"id":117,"raw":118,"subject":122,"body_html":123,"body_text":124,"firm_name":125,"letter_id":126,"created_at":127,"fei_number":19,"letter_url":128,"updated_at":129,"action_type":22,"case_status":23,"posted_date":130,"marcs_cms_no":131,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":132,"body_fetched_at":133,"delivery_method":134,"recipient_title":19,"reference_number":135,"action_taken_date":136,"medical_device_id":19,"response_letter_date":19},21669,[119,120,121,36,122,13,13,13],"\u003Ctime datetime=\"2026-10-13T04:00:00Z\">10\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-02T04:00:00Z\">10\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhanlim-pharm-co-ltd-734782-10022026\">Hanlim Pharm Co., Ltd.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-03\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jungjin Kim\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Hanlim Pharm Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Seocho-Daero, 52-Gil 42\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Seongdong-gu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Seoul\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 2, 2026\u003C\u002Fp>\u003Cp>WARNING LETTER\u003Cbr>Reference number: 320-27-03\u003C\u002Fp>\u003Cp>To Mr. Jungjin Kim:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were observed and documented during an inspection of your drug manufacturing facility, Hanlim Pharm Co., Ltd., FDA Establishment Identifier (FEI) 3004886113, at 2-27 Yeongmun-ro, Yonginsi Ceoin-gu, Gyeonggi-do, from April 16 to April 24, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your May 15, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Poor Aseptic Practices and Cleanroom Behavior\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You manufacture sterile, \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products (including \u003Cstrong>(b)(4)\u003C\u002Fstrong>). We observed poor aseptic practices during set-up and filling operations including, but not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>Operators repeatedly broke first air by reaching their arms, torsos, and heads over open sterile tubes, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and open \u003Cstrong>(b)(4)\u003C\u002Fstrong> during \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions.\u003C\u002Fli>\u003Cli>Operators used \u003Cstrong>(b)(4)\u003C\u002Fstrong> directly over open bottles, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and caps.\u003C\u002Fli>\u003Cli>An operator was observed working in the Grade A area of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> line wearing a visibly stained gown.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cem>Inadequate Smoke Studies\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Dynamic airflow visualization (smoke) studies demonstrated that airflow patterns failed to adequately protect the aseptic processing line, including exposed sterile product and product contact equipment, from significant contamination hazards.\u003C\u002Fp>\u003Cp>For example, your dynamic smoke studies did not demonstrate unidirectional airflow protection of the production line when barrier \u003Cstrong>(b)(4)\u003C\u002Fstrong> were open. The studies showed air moving at a sharp angle upward toward return vents, leaving critical areas of your aseptic processing lines unprotected throughout the period in which the \u003Cstrong>(b)(4)\u003C\u002Fstrong> are opened. This fundamental design flaw enables the entrainment of lower-quality air from the surrounding lower-classified (Class 10,000\u002FISO 7) cleanroom into the Class 100 (ISO 5) aseptic processing line, posing a severe risk to product sterility.\u003C\u002Fp>\u003Cp>We also observed other design flaws in your production equipment that led to poor ergonomics and deficient aseptic practices that compromised unidirectional airflow.\u003C\u002Fp>\u003Cp>In addition, smoke studies were incomplete, as they failed to sufficiently evaluate airflow directionality during critical aseptic processing activities.\u003C\u002Fp>\u003Cp>In your response, you state you will assess and redesign your \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line \u003Cstrong>(b)(4)\u003C\u002Fstrong> to address deficiencies noted by FDA, and you will perform smoke studies on the newly redesigned line. Additionally, you state you will conduct extensive classroom and hands-on training, along with qualification to improve aseptic operator behavior.\u003C\u002Fp>\u003Cp>We acknowledge your commitment to redesigning the \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution line, and your decision to decommission your \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution lines.\u003C\u002Fp>\u003Cp>Your response is inadequate. It lacks a comprehensive program to effectively monitor personnel practices during commercial production, which is especially concerning given our past inspectional findings of poor aseptic behavior.\u003C\u002Fp>\u003Cp>Further, your response failed to provide sufficient plans to improve your airflow visualization program. Notably, your response lacked adequate provisions to improve quality assurance oversight, and ensure thorough and objective evaluation of future airflow unidirectionality studies by qualified subject matter experts.\u003C\u002Fp>\u003Cp>Your aseptic manufacturing processes should be designed, and operations executed, to prevent contamination hazards to your sterile product. Flaws in the design of cleanrooms and aseptic processing lines, or improper execution of aseptic operations can promote influx of contamination into the critical processing area.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures, including but not limited to an independent assessment of the following with accompanying corrective action and preventive action (CAPA):\u003Cbr>o Suitability of actual practices based on extensive retrospective review and prospective observation of aseptic processing operations.\u003Cbr>o Deficiencies in production management oversight, and identification of specific improvements to ensure effective and routine supervisory oversight for all batches.\u003Cbr>o Frequency and depth of quality unit (QU) oversight (e.g., audit, ad hoc, daily interactions) of aseptic processing and its support operations.\u003Cbr>o Adequacy of written procedures and operational ergonomics.\u003Cbr>o The assessment should also evaluate how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\u003Cli>An independent, comprehensive evaluation of airflow unidirectionality in your aseptic processing operations. Ensure smoke studies are conducted under dynamic conditions with thorough and complete evaluations of aseptic processing line airflow unidirectionality, including the impact of aseptic interventions and dynamic interactions with the surrounding cleanroom. Conduct these smoke studies after you remediate your aseptic operation and using proper practices (e.g., neutrally buoyant media) to appropriately visualize airflow.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups (21 CFR 211.42(c)), and your firm failed to establish and follow adequate control procedures to monitor the output and to validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product (21 CFR 211.110(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Equipment Cleaning and Sterilization\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your aseptic processing operation is inadequately designed to prevent contamination of your sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products.\u003C\u002Fp>\u003Cp>For example, you did not appropriately sterilize critical container-closure contact surfaces, such as the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, bowl, track and \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment, as well as the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, bowl, track, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment. Instead, you wipe these surfaces with sporicidal disinfectants.\u003C\u002Fp>\u003Cp>To ensure sterility, it is imperative that only sterilized equipment comes into direct contact with the sterile formulation, containers, and closures.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Environmental Monitoring\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also failed to ensure adequate environmental monitoring (EM) of classified areas used for aseptic production of sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products.\u003C\u002Fp>\u003Cp>The EM program used to monitor critical areas was deficient. You failed to demonstrate that the locations and frequencies established for viable air sampling, surface monitoring, and non-viable particulate sampling were adequately justified and sufficient to promptly detect contamination risks. For example, sampling was not adequate to evaluate the environment in proximity to containers and closures, nor on the surfaces of barriers facing your ISO 5 (Grade A) spaces.\u003C\u002Fp>\u003Cp>Because you had not established a sufficient EM program, you lacked evidence of daily environmental control that is foundational to assuring sterility of aseptically processed products.\u003C\u002Fp>\u003Cp>A vigilant, ongoing personnel and environmental monitoring program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Visual Inspection Program\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your visual inspection program for sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products was deficient. Your firm failed to routinely categorize defects as part of your visual inspection program. In addition, you did not establish appropriate acceptance criteria. Notably, your process has experienced significant defect rates.\u003C\u002Fp>\u003Cp>It is important that visible particulate contamination is appropriately evaluated. When categorizing visible particles, extrinsic or foreign matter should receive special attention, as it may indicate possible insanitary or microbial contamination. Sterile manufacturing operations should be designed to prevent foreign contaminants, and such contamination should trigger a thorough investigation and appropriate CAPA.\u003C\u002Fp>\u003Cp>In your response, you state you will assess your \u003Cstrong>(b)(4)\u003C\u002Fstrong> filling line and improve its design. You state you will also revise cleaning and disinfection procedures, and conduct an EM risk assessment and subsequent EM performance qualification. Additionally, your response commits to improvements in visual inspection equipment, with better categorization of rejects and established acceptance criteria.\u003C\u002Fp>\u003Cp>Your response is inadequate. It fails to systematically address the need for robust aseptic processing operations and collection of more meaningful data to support aseptic operational control. It also lacks details describing how you will ensure use of sterilizable equipment in the future and conduct EM with sufficient frequency at locations where significant activity or exposure occurs during aseptic production. Additionally, you failed to provide the details of your improved visual inspection program, including how you will ensure thorough investigations, when appropriate.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\u003Cbr>o All human interactions within the ISO 5 area (e.g., risk reduction or elimination of \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions wherever possible)\u003Cbr>o Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\u003Cbr>o Air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\u003Cbr>o Facility layout\u003Cbr>o Personnel Flow and Material Flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers)\u003Cbr>o Disinfection practices and procedures\u003Cbr>o Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of \u003Cstrong>(b)(4)\u003C\u002Fstrong> your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fli>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Include the following as part of the assessment and CAPA plan:\u003Cbr>o A detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning, disinfection, and sterilization\u003Cbr>o A list of improvements, with an explanation how each will enhance cleaning and disinfection effectiveness\u003Cbr>o Improved ongoing verification of proper cleaning and disinfection execution\u003Cbr>o And, any other needed remediations\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and remediation plan for your drug product visual inspection program to ensure compliance with CGMP. The assessment and remediation should include, but not be limited to, the following:\u003Cbr>o Implement enhancements to your 100% visible particulate inspection practices, including defining critical, major, and minor defects and establish associated individual defect limits.\u003Cbr>o Ensure adequate methods, equipment, and personnel qualifications to reproducibly detect visible particulates, include particulates which historically have been found in your operation.\u003Cbr>o Conduct rigorous qualification studies to ensure your \u003Cstrong>(b)(4)\u003C\u002Fstrong> visible particulate inspection systems consistently and reproducibly detect the variety of visible particulates encountered in your drug products.\u003Cbr>o For drug products that are difficult to inspect (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> containers), implement destructive testing and other advanced technologies (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) as appropriate, with statistically significant sample sizes to test for defects.\u003Cbr>o Incorporate product-specific knowledge, process experience, deviation investigation analysis, complaint data, recall data, and quality risk management to improve the visual inspection program.\u003Cbr>o Associated remediations to your visual inspection program, including newly established written procedures, equipment, and methods. Include a summary of the review and recommendations made by your independent consultant.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to establish an adequate QU with the responsibilities and authority to oversee the manufacture of drug products. For example, you failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Adherence to a stability program that supports the drug products’ expiration dating (21 CFR 211.166(a)).\u003C\u002Fli>\u003Cli>Contemporaneous documentation of EM and personnel monitoring sampling data in laboratory records (21 CFR 211.194(a)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous (ALCOA) records throughout your operation.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority, independence, and resources to effectively function that includes, but is not limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for independent QU oversight throughout your operations to ensure satisfactory procedures and adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003Cbr>o Also, describe how executive management will support robust quality assurance at your firm, including but not limited to timely provision of resources that enable proactive detection and resolution of emerging manufacturing\u002Fquality issues to assure a continuing state of control\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your QU is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA guidances: \u003Cem>Q8(R2) Pharmaceutical Development\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload, \u003Cem>Q9(R1) Quality Risk Management\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload and \u003Cem>Q10 Pharmaceutical Quality System\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Ceased and Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment to suspend production of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Drugs at this facility for the U.S. market and to cease production of all other \u003Cstrong>(b)(4)\u003C\u002Fstrong> solutions.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. If you resume CGMP activities, you are responsible for resolving all deficiencies and systemic\u003Cbr>flaws to ensure your firm is capable of ongoing CGMP compliance. In addition, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>1 \u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPA, before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Repeats Violation at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In a previous warning letter (WL 320-19-01), FDA cited similar CGMP violations. You proposed specific remediations for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Guidance on Aseptic Processing\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Hanlim Pharm Co., Ltd. at 2-27 Yeongmun-ro, Yonginsi Ceoin-gu, Gyeonggi-do into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Identify your written response with FEI 3004886113 and ATTN: Compliance officer Philip Kreiter in the letter.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc: Registered U.S. Agent\u003Cbr>Toscano Consulting Group, Inc\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>_____________________\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-03\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jungjin Kim\n\nRecipient Title\n\nChairman\n\nHanlim Pharm Co., Ltd.\n\nSeocho-Daero, 52-Gil 42\n\nSeongdong-gu\n\nSeoul\n\nSouth Korea\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 2, 2026\nWARNING LETTER\nReference number: 320-27-03\nTo Mr. Jungjin Kim:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nFDA Inspection\nViolations were observed and documented during an inspection of your drug manufacturing facility, Hanlim Pharm Co., Ltd., FDA Establishment Identifier (FEI) 3004886113, at 2-27 Yeongmun-ro, Yonginsi Ceoin-gu, Gyeonggi-do, from April 16 to April 24, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your May 15, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nPoor Aseptic Practices and Cleanroom Behavior\nYou manufacture sterile, (b)(4) drug products (including (b)(4)). We observed poor aseptic practices during set-up and filling operations including, but not limited to:\nOperators repeatedly broke first air by reaching their arms, torsos, and heads over open sterile tubes, (b)(4), and open (b)(4) during (b)(4) interventions.\nOperators used (b)(4) directly over open bottles, (b)(4), and caps.\nAn operator was observed working in the Grade A area of the (b)(4) line wearing a visibly stained gown.\nInadequate Smoke Studies\nDynamic airflow visualization (smoke) studies demonstrated that airflow patterns failed to adequately protect the aseptic processing line, including exposed sterile product and product contact equipment, from significant contamination hazards.\nFor example, your dynamic smoke studies did not demonstrate unidirectional airflow protection of the production line when barrier (b)(4) were open. The studies showed air moving at a sharp angle upward toward return vents, leaving critical areas of your aseptic processing lines unprotected throughout the period in which the (b)(4) are opened. This fundamental design flaw enables the entrainment of lower-quality air from the surrounding lower-classified (Class 10,000\u002FISO 7) cleanroom into the Class 100 (ISO 5) aseptic processing line, posing a severe risk to product sterility.\nWe also observed other design flaws in your production equipment that led to poor ergonomics and deficient aseptic practices that compromised unidirectional airflow.\nIn addition, smoke studies were incomplete, as they failed to sufficiently evaluate airflow directionality during critical aseptic processing activities.\nIn your response, you state you will assess and redesign your (b)(4) filling line (b)(4) to address deficiencies noted by FDA, and you will perform smoke studies on the newly redesigned line. Additionally, you state you will conduct extensive classroom and hands-on training, along with qualification to improve aseptic operator behavior.\nWe acknowledge your commitment to redesigning the (b)(4) solution line, and your decision to decommission your (b)(4) solution lines.\nYour response is inadequate. It lacks a comprehensive program to effectively monitor personnel practices during commercial production, which is especially concerning given our past inspectional findings of poor aseptic behavior.\nFurther, your response failed to provide sufficient plans to improve your airflow visualization program. Notably, your response lacked adequate provisions to improve quality assurance oversight, and ensure thorough and objective evaluation of future airflow unidirectionality studies by qualified subject matter experts.\nYour aseptic manufacturing processes should be designed, and operations executed, to prevent contamination hazards to your sterile product. Flaws in the design of cleanrooms and aseptic processing lines, or improper execution of aseptic operations can promote influx of contamination into the critical processing area.\nIn response to this letter, provide:\nYour systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures, including but not limited to an independent assessment of the following with accompanying corrective action and preventive action (CAPA):\no Suitability of actual practices based on extensive retrospective review and prospective observation of aseptic processing operations.\no Deficiencies in production management oversight, and identification of specific improvements to ensure effective and routine supervisory oversight for all batches.\no Frequency and depth of quality unit (QU) oversight (e.g., audit, ad hoc, daily interactions) of aseptic processing and its support operations.\no Adequacy of written procedures and operational ergonomics.\no The assessment should also evaluate how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\nAn independent, comprehensive evaluation of airflow unidirectionality in your aseptic processing operations. Ensure smoke studies are conducted under dynamic conditions with thorough and complete evaluations of aseptic processing line airflow unidirectionality, including the impact of aseptic interventions and dynamic interactions with the surrounding cleanroom. Conduct these smoke studies after you remediate your aseptic operation and using proper practices (e.g., neutrally buoyant media) to appropriately visualize airflow.\n2. Your firm failed to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups (21 CFR 211.42(c)), and your firm failed to establish and follow adequate control procedures to monitor the output and to validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product (21 CFR 211.110(a)).\nInadequate Equipment Cleaning and Sterilization\nYour aseptic processing operation is inadequately designed to prevent contamination of your sterile (b)(4) drug products.\nFor example, you did not appropriately sterilize critical container-closure contact surfaces, such as the (b)(4), bowl, track and (b)(4) equipment, as well as the (b)(4), bowl, track, and (b)(4) equipment. Instead, you wipe these surfaces with sporicidal disinfectants.\nTo ensure sterility, it is imperative that only sterilized equipment comes into direct contact with the sterile formulation, containers, and closures.\nInadequate Environmental Monitoring\nYou also failed to ensure adequate environmental monitoring (EM) of classified areas used for aseptic production of sterile (b)(4) drug products.\nThe EM program used to monitor critical areas was deficient. You failed to demonstrate that the locations and frequencies established for viable air sampling, surface monitoring, and non-viable particulate sampling were adequately justified and sufficient to promptly detect contamination risks. For example, sampling was not adequate to evaluate the environment in proximity to containers and closures, nor on the surfaces of barriers facing your ISO 5 (Grade A) spaces.\nBecause you had not established a sufficient EM program, you lacked evidence of daily environmental control that is foundational to assuring sterility of aseptically processed products.\nA vigilant, ongoing personnel and environmental monitoring program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\nInadequate Visual Inspection Program\nYour visual inspection program for sterile (b)(4) drug products was deficient. Your firm failed to routinely categorize defects as part of your visual inspection program. In addition, you did not establish appropriate acceptance criteria. Notably, your process has experienced significant defect rates.\nIt is important that visible particulate contamination is appropriately evaluated. When categorizing visible particles, extrinsic or foreign matter should receive special attention, as it may indicate possible insanitary or microbial contamination. Sterile manufacturing operations should be designed to prevent foreign contaminants, and such contamination should trigger a thorough investigation and appropriate CAPA.\nIn your response, you state you will assess your (b)(4) filling line and improve its design. You state you will also revise cleaning and disinfection procedures, and conduct an EM risk assessment and subsequent EM performance qualification. Additionally, your response commits to improvements in visual inspection equipment, with better categorization of rejects and established acceptance criteria.\nYour response is inadequate. It fails to systematically address the need for robust aseptic processing operations and collection of more meaningful data to support aseptic operational control. It also lacks details describing how you will ensure use of sterilizable equipment in the future and conduct EM with sufficient frequency at locations where significant activity or exposure occurs during aseptic production. Additionally, you failed to provide the details of your improved visual inspection program, including how you will ensure thorough investigations, when appropriate.\nIn response to this letter, provide:\nA comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\no All human interactions within the ISO 5 area (e.g., risk reduction or elimination of (b)(4) interventions wherever possible)\no Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\no Air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\no Facility layout\no Personnel Flow and Material Flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers)\no Disinfection practices and procedures\no Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of (b)(4) your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\nA CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Include the following as part of the assessment and CAPA plan:\no A detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning, disinfection, and sterilization\no A list of improvements, with an explanation how each will enhance cleaning and disinfection effectiveness\no Improved ongoing verification of proper cleaning and disinfection execution\no And, any other needed remediations\nA comprehensive, independent assessment and remediation plan for your drug product visual inspection program to ensure compliance with CGMP. The assessment and remediation should include, but not be limited to, the following:\no Implement enhancements to your 100% visible particulate inspection practices, including defining critical, major, and minor defects and establish associated individual defect limits.\no Ensure adequate methods, equipment, and personnel qualifications to reproducibly detect visible particulates, include particulates which historically have been found in your operation.\no Conduct rigorous qualification studies to ensure your (b)(4) visible particulate inspection systems consistently and reproducibly detect the variety of visible particulates encountered in your drug products.\no For drug products that are difficult to inspect (e.g., (b)(4) containers), implement destructive testing and other advanced technologies (e.g., (b)(4)) as appropriate, with statistically significant sample sizes to test for defects.\no Incorporate product-specific knowledge, process experience, deviation investigation analysis, complaint data, recall data, and quality risk management to improve the visual inspection program.\no Associated remediations to your visual inspection program, including newly established written procedures, equipment, and methods. Include a summary of the review and recommendations made by your independent consultant.\n3. Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour firm failed to establish an adequate QU with the responsibilities and authority to oversee the manufacture of drug products. For example, you failed to ensure:\nAdherence to a stability program that supports the drug products’ expiration dating (21 CFR 211.166(a)).\nContemporaneous documentation of EM and personnel monitoring sampling data in laboratory records (21 CFR 211.194(a)).\nIn response to this letter, provide:\nA comprehensive assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous (ALCOA) records throughout your operation.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority, independence, and resources to effectively function that includes, but is not limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for independent QU oversight throughout your operations to ensure satisfactory procedures and adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\no Also, describe how executive management will support robust quality assurance at your firm, including but not limited to timely provision of resources that enable proactive detection and resolution of emerging manufacturing\u002Fquality issues to assure a continuing state of control\nIneffective Quality System\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your QU is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nYour firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA guidances: Q8(R2) Pharmaceutical Development at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload, Q9(R1) Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\nDrug Production Ceased and Suspended\nWe acknowledge your commitment to suspend production of (b)(4) Drugs at this facility for the U.S. market and to cease production of all other (b)(4) solutions.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. If you resume CGMP activities, you are responsible for resolving all deficiencies and systemic\nflaws to ensure your firm is capable of ongoing CGMP compliance. In addition, based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPA, before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nIn your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\nRepeats Violation at Facility\nIn a previous warning letter (WL 320-19-01), FDA cited similar CGMP violations. You proposed specific remediations for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nAdditional Guidance on Aseptic Processing\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nConclusion\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Hanlim Pharm Co., Ltd. at 2-27 Yeongmun-ro, Yonginsi Ceoin-gu, Gyeonggi-do into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter2. Identify your written response with FEI 3004886113 and ATTN: Compliance officer Philip Kreiter in the letter.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc: Registered U.S. Agent\nToscano Consulting Group, Inc\n(b)(4)\n_____________________\n1 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\n2 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Hanlim Pharm Co., Ltd.","hanlim-pharm-co-ltd-734782-10022026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhanlim-pharm-co-ltd-734782-10022026","2026-11-17T01:02:03.701861+00:00","2026-10-13","734782","Mr. Jungjin Kim","2026-10-14T12:31:42.364+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","320-27-03","2026-10-02",{"id":138,"raw":139,"subject":144,"body_html":145,"body_text":146,"firm_name":147,"letter_id":148,"created_at":42,"fei_number":19,"letter_url":149,"updated_at":150,"action_type":22,"case_status":23,"posted_date":151,"marcs_cms_no":152,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":19,"body_fetched_at":153,"delivery_method":134,"recipient_title":19,"reference_number":19,"action_taken_date":154,"medical_device_id":19,"response_letter_date":19},306,[140,141,142,36,143,13,13,13],"\u003Ctime datetime=\"2026-03-03T05:00:00Z\">03\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-20T05:00:00Z\">02\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpharmazee-721473-02202026\">PharmaZee\u003C\u002Fa>","False &amp; Misleading Claims\u002FMisbranded (Telehealth)","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>PharmaZee\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5940 S Rainbow Blvd Ste 400\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89118\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@pharmazee.co\"> support@pharmazee.co \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 20, 2026\u003C\u002Fp>\u003Cp>PharmaZee:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fpharmazee.co, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The compounded semaglutide and tirzepatide products displayed on your website identify “PharmaZee” on the pictured label, suggesting PharmaZee is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, the representations on your website that PharmaZee is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“clinically proven medications”\u003C\u002Fli>\u003Cli>“proven prescription medications”\u003C\u002Fli>\u003Cli>“Same active ingredient as Ozempic® and Wegovy®”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\u003C\u002Fp>\u003Cp>1) Identifying the entities that produce the compounded products offered on your website;\u003C\u002Fp>\u003Cp>2) Providing a representative sample of labeling for such products; and\u003C\u002Fp>\u003Cp>3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Matthew J. Lash\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> \u003Cem>See also\u003C\u002Fem> 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nPharmaZee\n\n5940 S Rainbow Blvd Ste 400\n\nLas Vegas, NV 89118\n\nUnited States\n\nsupport@pharmazee.co\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFebruary 20, 2026\nPharmaZee:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fpharmazee.co, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe compounded semaglutide and tirzepatide products displayed on your website identify “PharmaZee” on the pictured label, suggesting PharmaZee is the compounder of those drugs when in fact it is not.2 Accordingly, the representations on your website that PharmaZee is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nAdditionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“clinically proven medications”\n“proven prescription medications”\n“Same active ingredient as Ozempic® and Wegovy®”\nCompounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\nFor the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\nYou should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\n1) Identifying the entities that produce the compounded products offered on your website;\n2) Providing a representative sample of labeling for such products; and\n3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n______________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].","PharmaZee","pharmazee-721473-02202026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpharmazee-721473-02202026","2026-10-26T08:09:41.545408+00:00","2026-03-03","721473","2026-08-19T04:55:35.458+00:00","2026-02-20",{"id":156,"raw":157,"subject":161,"body_html":162,"body_text":163,"firm_name":164,"letter_id":165,"created_at":82,"fei_number":19,"letter_url":166,"updated_at":167,"action_type":22,"case_status":23,"posted_date":168,"marcs_cms_no":169,"product_type":47,"closeout_date":19,"issuing_office":76,"recipient_name":170,"body_fetched_at":171,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":172,"medical_device_id":19,"response_letter_date":19},2940,[158,159,160,76,161,13,13,13],"\u003Ctime datetime=\"2022-01-04T15:00:00Z\">01\u002F04\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-01-03T05:00:00Z\">01\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famcyte-pharma-inc-623474-01032022\">Amcyte Pharma, Inc.\u003C\u002Fa>","Unapproved and Misbranded Product Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gustavo Mahler\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Amcyte Pharma, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5400 Carillon Point\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kirkland\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98004\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@nasitrol.com\"> info@nasitrol.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: January 3, 2022\u003C\u002Fp>\n\n\u003Cp>RE: Unapproved and Misbranded Product Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fnasitrol.com\u002F on December 20, 2021. The FDA has observed that your website offers Nasitrol for sale in the United States and that this product is intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, this product is an unapproved new drug sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website, https:\u002F\u002Fnasitrol.com\u002Fscience\u002F, that establish the intended use of your product and misleadingly represents it as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“\u003Cstrong>In vitro study of Iota carrageenan in SARS-CoV-2\u003C\u002Fstrong> . . . This study performed at the University of Tennessee provides evidence of the inhibitory effect of Iota Carrageenan on the propagation of SARS-CoV-2 in a call [sic] based assay.”\u003C\u002Fli>\n\t\u003Cli>“\u003Cstrong>A Nasitrol clinical trial ICU hospital personnel exposed to SARS-CoV-2\u003C\u002Fstrong> . . . An independent, double-blinded, placebo controlled multicenter clinical trial providing evidence of the protective effect of Nasitrol in doctors and nurses highly exposed to SARS-CoV-2 (personnel dedicated to the COVID-19 ICU) during a period of one month.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donald D. Ashley\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nGustavo Mahler\n\nAmcyte Pharma, Inc.\n\n5400 Carillon Point\n\nKirkland, WA 98004\n\nUnited States\n\ninfo@nasitrol.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nDate: January 3, 2022\n\nRE: Unapproved and Misbranded Product Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fnasitrol.com\u002F on December 20, 2021. The FDA has observed that your website offers Nasitrol for sale in the United States and that this product is intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, this product is an unapproved new drug sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your website, https:\u002F\u002Fnasitrol.com\u002Fscience\u002F, that establish the intended use of your product and misleadingly represents it as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“In vitro study of Iota carrageenan in SARS-CoV-2 . . . This study performed at the University of Tennessee provides evidence of the inhibitory effect of Iota Carrageenan on the propagation of SARS-CoV-2 in a call [sic] based assay.”\n\n“A Nasitrol clinical trial ICU hospital personnel exposed to SARS-CoV-2 . . . An independent, double-blinded, placebo controlled multicenter clinical trial providing evidence of the protective effect of Nasitrol in doctors and nurses highly exposed to SARS-CoV-2 (personnel dedicated to the COVID-19 ICU) during a period of one month.”\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n__________________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Amcyte Pharma, Inc.","amcyte-pharma-inc-623474-01032022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famcyte-pharma-inc-623474-01032022","2026-10-26T08:07:54.496715+00:00","2022-01-04","623474","Gustavo Mahler","2026-08-20T02:17:31.407+00:00","2022-01-03",{"id":174,"raw":175,"subject":179,"body_html":180,"body_text":181,"firm_name":182,"letter_id":183,"created_at":18,"fei_number":19,"letter_url":184,"updated_at":185,"action_type":22,"case_status":23,"posted_date":186,"marcs_cms_no":187,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":188,"body_fetched_at":189,"delivery_method":190,"recipient_title":19,"reference_number":19,"action_taken_date":191,"medical_device_id":19,"response_letter_date":19},983,[176,177,178,36,179,13,13,13],"\u003Ctime datetime=\"2025-03-25T04:00:00Z\">03\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-05T05:00:00Z\">03\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fannovex-pharma-inc-698115-03052025\">Annovex Pharma, Inc.\u003C\u002Fa>","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Adedayo Akinbi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Annovex Pharma, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7403 Lockport PI, Suite C-D\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lorton\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>22079\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>WL # 698115\u003C\u002Fp>\u003Cp>March 5, 2025\u003C\u002Fp>\u003Cp>\u003Cbr>Dear Dr. Akinbi:\u003C\u002Fp>\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> on October 14, 2021, and most recently on November 22, 2024. From August 26, 2024, to September 6, 2024, FDA investigators inspected your facility, Annovex Pharma, Inc. located at 7403 Lockport PI, Suite C-D, Lorton, VA 22079. During the inspection, the investigators noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing drug products which put patients at risk.\u003C\u002Fp>\u003Cp>FDA issued a Form FDA 483 to your facility on September 6, 2024. FDA acknowledges receipt of your facility’s response, dated September 25, 2024, October 24, 2024, November 27, 2024, and December 27, 2024. Based on this inspection, it appears you produced drugs that violate the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>A. Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\u003Cp>For a compounded drug product to qualify for the exemptions under section 503B, it must be compounded in an outsourcing facility that is in compliance with the registration and reporting requirements in section 503B(b), including the requirement to submit a report to FDA upon initially registering as an outsourcing facility, once in June of each year, and once in December of each year identifying the drug products compounded during the previous 6-month period (section 503B(b)(2) of the FDCA [21 U.S.C. §353b(b)(2)]) and the requirement to submit adverse event reports to FDA “in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations)” (section 503B(a)(1), (b)(5) of the FDCA [21 U.S.C. § 353b(a)(1), (b)(5)]).\u003C\u002Fp>\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503B\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the inspection, FDA investigators noted that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigators noted:\u003C\u002Fp>\u003Cp>1. Your facility failed to submit a report to FDA in June 2024 identifying the drug products that you compounded during the previous 6-month period, including Heparin 4 units\u002FmL in 0.9% Sodium Chloride \u003Cstrong>(b)(4)\u003C\u002Fstrong> IV bag, Phenylephrine 100 mcg\u002Fml in 0.9% Sodium Chloride Solution 10ml syringe, and Phenylephrine HCl 25 mg in 0.9% Sodium Chloride 250 mL Bag.\u003C\u002Fp>\u003Cp>2. Your facility did not submit adverse event reports to FDA in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations).\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Specifically, your facility’s procedures for reporting adverse events are inadequate. For example, your documented procedures for reporting adverse events (1) do not include a definition of what constitutes a “serious” and “unexpected” adverse event (21 CFR 310.305(b)); (2) do not include a requirement to report each adverse drug experience received or otherwise obtained that is both serious and unexpected as soon as possible, but in no case later than 15 calendar days of initial receipt of the information (21 CFR 310.305(c)(1)(i)); (3) do not include a requirement to promptly investigate and submit a follow-up report regarding a serious, unexpected adverse event within 15 calendar days of receipt of new information or as requested by FDA (21 CFR 310.305(c)(2)); (4) do not include a requirement that the firm investigate four data elements when an adverse event report is received – Identifiable Patient, Identifiable Reporter, Suspect Drug Product, Serious Adverse Event (21 CFR 310.305(d)); and (5) do not provide that adverse events should be reported utilizing FDA’s Safety Reporting Portal (SRP) or Electronic Submission Gateway (ESG) (21 CFR 310.305(e)).\u003C\u002Fp>\u003Cp>Because your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\u003C\u002Fp>\u003Cp>Specific violations are described below.\u003C\u002Fp>\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\u003C\u002Fp>\u003Cp>1. Your media fills were not performed under the most challenging or stressful conditions. In addition, your firm continued to produce and distribute drug products intended to be sterile despite positive growth being identified in 10% of filled units during your January 2024 media fill. Your firm failed to investigate the positive growth and discarded all units that showed signs of microbial contamination. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\u003C\u002Fp>\u003Cp>2. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\u003C\u002Fp>\u003Cp>FDA investigators also noted CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\u003C\u002Fp>\u003Cp>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fp>\u003Cp>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fp>\u003Cp>3. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fp>\u003Cp>4. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fp>\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\u003C\u002Fp>\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not have any FDA-approved applications on file for drug products that you compound.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\u003Cp>\u003Cstrong>Failure to Report Drugs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As noted above, your facility failed to submit a report to FDA in June 2024 identifying the drug products that you compounded during the previous 6-month period (section 503B(b)(2) of the FDCA). The failure to report drugs by an entity that is registered with FDA in accordance with section 503B(b) is a prohibited act under section 301(ccc)(3) of the FDCA [21 U.S.C. § 331(ccc)(3)].\u003C\u002Fp>\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your facility’s responses to the Form FDA 483.\u003C\u002Fp>\u003Cp>Some of your corrective actions appear adequate; however, we cannot fully evaluate the adequacy of the following corrective actions due to lack of adequate supporting documentation: Regarding your smoke studies, we acknowledge your commitments, including your plan to perform updated dynamic smoke studies during your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom certification; however, you have not provided sufficient supporting documentation for our review, such as your smoke study protocol.\u003C\u002Fp>\u003Cp>Some of your corrective actions appear deficient:\u003C\u002Fp>\u003Cp>1. Regarding your media fills, we acknowledge your commitments going forward and the revised procedures provided in your responses. However, we remain concerned with your firm’s failure to investigate the positive growth observed during your January 2024 media fill simulation. Any contaminated unit should be considered objectionable and investigated. The investigation should survey the possible causes of contamination and should assess the impact of products produced since the last successful media fill.\u003C\u002Fp>\u003Cp>In addition, your responses do not include data to adequately demonstrate a consistent ability to maintain aseptic operating conditions. During your latest media fill simulation, conducted in July 2024, you did not incubate all \u003Cstrong>(b)(4)\u003C\u002Fstrong> units, but instead only incubated \u003Cstrong>(b)(4)\u003C\u002Fstrong> randomly selected units. Your firm has provided no evidence that you have successfully performed additional media fill runs to ensure your aseptic processing operation is validated and your firm continues to produce via aseptic processing and distribute drug products intended to be sterile.\u003C\u002Fp>\u003Cp>2. Regarding your firm’s failure to provide our investigators with your 2023 media fill records due to technical issues, you provided a new procedure, SOP-0261 Retention of Records, which details document retention requirements; however, this procedure does not specify how and where documents will be retained or how these retained documents will be controlled. We acknowledge your statement that you have purchased a dedicated secure server system and that you have hired a validation consult to complete installation, operational, and performance qualification; however, you have not provided details on how you are currently retaining and securing documents while waiting for the server to be qualified. Complete and accurate records are necessary to ensure that manufacturing processes are consistently followed and reproducible. Additionally, incomplete manufacturing records deprive you of the ability to reliably conduct batch record review, adequately investigate deviations and batch failures, and to ensure a continued state of validation processes.\u003C\u002Fp>\u003Cp>3. Your firm provided several updated written procedures with your responses; however, they appear to be in draft form as the approval signature manifests are incomplete. Therefore, the effective date of these revised procedures cannot be verified.\u003C\u002Fp>\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\u003C\u002Fp>\u003Cp>Regarding issues related to the conditions of section 503B of the FDCA, some of your corrective actions appear adequate: You state that you are “implementing improved tracking and reporting systems to ensure that all compounded products are accurately and timely reported in future submissions.”\u003C\u002Fp>\u003Cp>In addition, regarding issues related to the conditions of section 503B of the FDCA, some of your corrective actions appear deficient: Your revised procedures for reporting adverse event reporting do not adequately address adverse event reporting. For example, your revised procedures do not include a requirement to promptly investigate and submit a follow-up report regarding a serious, unexpected adverse event within 15 calendar days of receipt of new information or as requested by FDA.\u003C\u002Fp>\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\u003C\u002Fp>\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>Your response and any questions regarding the contents of this letter should be sent to compoundinginspections@fda.hhs.gov. In your response, refer to the Warning Letter Number above (# 698115) and include a subject line that clearly identifies the submission as a Response to Warning Letter.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>F. Gail Bormel, JD, RPh\u003Cbr>Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> For more information, see, FDA’s guidance, “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” which can be found at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM434188.pdf.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> The specific products made by your firm are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nAdedayo Akinbi\n\nRecipient Title\n\nFounder and CEO\n\nAnnovex Pharma, Inc.\n\n7403 Lockport PI, Suite C-D\n\nLorton, VA 22079\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nWL # 698115\nMarch 5, 2025\n\nDear Dr. Akinbi:\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on October 14, 2021, and most recently on November 22, 2024. From August 26, 2024, to September 6, 2024, FDA investigators inspected your facility, Annovex Pharma, Inc. located at 7403 Lockport PI, Suite C-D, Lorton, VA 22079. During the inspection, the investigators noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing drug products which put patients at risk.\nFDA issued a Form FDA 483 to your facility on September 6, 2024. FDA acknowledges receipt of your facility’s response, dated September 25, 2024, October 24, 2024, November 27, 2024, and December 27, 2024. Based on this inspection, it appears you produced drugs that violate the FDCA.\nA. Compounded Drug Products under the FDCA\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.2\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\nFor a compounded drug product to qualify for the exemptions under section 503B, it must be compounded in an outsourcing facility that is in compliance with the registration and reporting requirements in section 503B(b), including the requirement to submit a report to FDA upon initially registering as an outsourcing facility, once in June of each year, and once in December of each year identifying the drug products compounded during the previous 6-month period (section 503B(b)(2) of the FDCA [21 U.S.C. §353b(b)(2)]) and the requirement to submit adverse event reports to FDA “in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations)” (section 503B(a)(1), (b)(5) of the FDCA [21 U.S.C. § 353b(a)(1), (b)(5)]).\nB. Failure to Meet the Conditions of Section 503B\nDuring the inspection, FDA investigators noted that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigators noted:\n1. Your facility failed to submit a report to FDA in June 2024 identifying the drug products that you compounded during the previous 6-month period, including Heparin 4 units\u002FmL in 0.9% Sodium Chloride (b)(4) IV bag, Phenylephrine 100 mcg\u002Fml in 0.9% Sodium Chloride Solution 10ml syringe, and Phenylephrine HCl 25 mg in 0.9% Sodium Chloride 250 mL Bag.\n2. Your facility did not submit adverse event reports to FDA in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations).3 Specifically, your facility’s procedures for reporting adverse events are inadequate. For example, your documented procedures for reporting adverse events (1) do not include a definition of what constitutes a “serious” and “unexpected” adverse event (21 CFR 310.305(b)); (2) do not include a requirement to report each adverse drug experience received or otherwise obtained that is both serious and unexpected as soon as possible, but in no case later than 15 calendar days of initial receipt of the information (21 CFR 310.305(c)(1)(i)); (3) do not include a requirement to promptly investigate and submit a follow-up report regarding a serious, unexpected adverse event within 15 calendar days of receipt of new information or as requested by FDA (21 CFR 310.305(c)(2)); (4) do not include a requirement that the firm investigate four data elements when an adverse event report is received – Identifiable Patient, Identifiable Reporter, Suspect Drug Product, Serious Adverse Event (21 CFR 310.305(d)); and (5) do not provide that adverse events should be reported utilizing FDA’s Safety Reporting Portal (SRP) or Electronic Submission Gateway (ESG) (21 CFR 310.305(e)).\nBecause your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\nSpecific violations are described below.\nC. Violations of the FDCA\nAdulterated Drug Products\nFDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\n1. Your media fills were not performed under the most challenging or stressful conditions. In addition, your firm continued to produce and distribute drug products intended to be sterile despite positive growth being identified in 10% of filled units during your January 2024 media fill. Your firm failed to investigate the positive growth and discarded all units that showed signs of microbial contamination. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\n2. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\nFDA investigators also noted CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n3. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\n4. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\nUnapproved New Drug Products\nYou do not have any FDA-approved applications on file for drug products that you compound.4 Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\nMisbranded Drug Products\nYou compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.5 The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\nFailure to Report Drugs\nAs noted above, your facility failed to submit a report to FDA in June 2024 identifying the drug products that you compounded during the previous 6-month period (section 503B(b)(2) of the FDCA). The failure to report drugs by an entity that is registered with FDA in accordance with section 503B(b) is a prohibited act under section 301(ccc)(3) of the FDCA [21 U.S.C. § 331(ccc)(3)].\nD. Corrective Actions\nWe have reviewed your facility’s responses to the Form FDA 483.\nSome of your corrective actions appear adequate; however, we cannot fully evaluate the adequacy of the following corrective actions due to lack of adequate supporting documentation: Regarding your smoke studies, we acknowledge your commitments, including your plan to perform updated dynamic smoke studies during your (b)(4) cleanroom certification; however, you have not provided sufficient supporting documentation for our review, such as your smoke study protocol.\nSome of your corrective actions appear deficient:\n1. Regarding your media fills, we acknowledge your commitments going forward and the revised procedures provided in your responses. However, we remain concerned with your firm’s failure to investigate the positive growth observed during your January 2024 media fill simulation. Any contaminated unit should be considered objectionable and investigated. The investigation should survey the possible causes of contamination and should assess the impact of products produced since the last successful media fill.\nIn addition, your responses do not include data to adequately demonstrate a consistent ability to maintain aseptic operating conditions. During your latest media fill simulation, conducted in July 2024, you did not incubate all (b)(4) units, but instead only incubated (b)(4) randomly selected units. Your firm has provided no evidence that you have successfully performed additional media fill runs to ensure your aseptic processing operation is validated and your firm continues to produce via aseptic processing and distribute drug products intended to be sterile.\n2. Regarding your firm’s failure to provide our investigators with your 2023 media fill records due to technical issues, you provided a new procedure, SOP-0261 Retention of Records, which details document retention requirements; however, this procedure does not specify how and where documents will be retained or how these retained documents will be controlled. We acknowledge your statement that you have purchased a dedicated secure server system and that you have hired a validation consult to complete installation, operational, and performance qualification; however, you have not provided details on how you are currently retaining and securing documents while waiting for the server to be qualified. Complete and accurate records are necessary to ensure that manufacturing processes are consistently followed and reproducible. Additionally, incomplete manufacturing records deprive you of the ability to reliably conduct batch record review, adequately investigate deviations and batch failures, and to ensure a continued state of validation processes.\n3. Your firm provided several updated written procedures with your responses; however, they appear to be in draft form as the approval signature manifests are incomplete. Therefore, the effective date of these revised procedures cannot be verified.\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\nRegarding issues related to the conditions of section 503B of the FDCA, some of your corrective actions appear adequate: You state that you are “implementing improved tracking and reporting systems to ensure that all compounded products are accurately and timely reported in future submissions.”\nIn addition, regarding issues related to the conditions of section 503B of the FDCA, some of your corrective actions appear deficient: Your revised procedures for reporting adverse event reporting do not adequately address adverse event reporting. For example, your revised procedures do not include a requirement to promptly investigate and submit a follow-up report regarding a serious, unexpected adverse event within 15 calendar days of receipt of new information or as requested by FDA.\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\nE. Conclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nYour response and any questions regarding the contents of this letter should be sent to compoundinginspections@fda.hhs.gov. In your response, refer to the Warning Letter Number above (# 698115) and include a subject line that clearly identifies the submission as a Response to Warning Letter.\nSincerely,\n\u002FS\u002F\nF. Gail Bormel, JD, RPh\nDirector\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n____________________\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\n3 For more information, see, FDA’s guidance, “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” which can be found at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM434188.pdf.\n4 The specific products made by your firm are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n5 Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).","Annovex Pharma, Inc.","annovex-pharma-inc-698115-03052025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fannovex-pharma-inc-698115-03052025","2026-10-26T08:07:56.122195+00:00","2025-03-25","698115","Adedayo Akinbi","2026-08-19T16:54:42.607+00:00","VIA Electronic Mail","2025-03-05",{"id":193,"raw":194,"subject":199,"body_html":200,"body_text":201,"firm_name":202,"letter_id":203,"created_at":204,"fei_number":19,"letter_url":205,"updated_at":206,"action_type":22,"case_status":23,"posted_date":207,"marcs_cms_no":208,"product_type":47,"closeout_date":19,"issuing_office":76,"recipient_name":209,"body_fetched_at":210,"delivery_method":211,"recipient_title":19,"reference_number":19,"action_taken_date":212,"medical_device_id":19,"response_letter_date":19},1949,[195,196,197,76,198,13,13,13],"\u003Ctime datetime=\"2023-08-08T13:20:00Z\">08\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-03T04:00:00Z\">08\u002F03\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsangleaf-pharm-co-ltd-663495-08032023\">Sangleaf Pharm., Co. Ltd.\u003C\u002Fa>","Failure to Provide Information\u003Cbr \u002F>\r\n","Failure to Provide Information","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Doo Hyun Yang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Sangleaf Pharm., Co. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>DOGOKRO1GIL14\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Seoul\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>06253\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hanil9900@hanmail.net\"> hanil9900@hanmail.net\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-30\u003C\u002Fp>\n\n\u003Cp>August 3, 2023\u003C\u002Fp>\n\n\u003Cp>Reference FEI 3012845410\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Doo Hyun Yang:\u003C\u002Fp>\n\n\u003Cp>Your firm was registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products, including toothpaste for children. Ingredients of the drugs registered as manufactured at your firm include ingredients susceptible to Diethylene Glycol (DEG) and Ethylene Glycol (EG) substitution. A review of import records showed multiple shipments of drug products into the United States which declared Sangleaf Pharm., Co., Ltd., as the drug manufacturer. On December 14, 2022, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. This request went unanswered. A second request was sent via e-mail on January 11, 2023, followed by an attempted contact by telephone with your registered U.S. Agent on January 26, 2023, regarding this matter. The Agency sent a follow-up written request for such records and other information on January 27, 2023. Delivery to you was confirmed by the shipper, but you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\u003C\u002Fp>\n\n\u003Cp>It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the current good manufacturing practice (CGMP) requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\u003C\u002Fp>\n\n\u003Cp>Until FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at Sangleaf Pharm., Co., Ltd., 4 Sagimakgol-ro, 62 Beon-gil, Jungwon-gu, Seongnam Gyeonggi, 13210 South Korea, into the United States that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\n\n\u003Cp>FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-79 on March 30, 2023.\u003C\u002Fp>\n\n\u003Cp>After you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI #3012845410 and ATTN: Matthew R. Dionne, Pharm.D, Compliance Officer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research, FDA\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered U.S. Agent:\u003Cbr>\nOnbix Corp. U.S.\u003Cbr>\nonbixUS@gmail.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Doo Hyun Yang\n\nSangleaf Pharm., Co. Ltd.\n\nDOGOKRO1GIL14\n\nSeoul\n\n06253\n\nSouth Korea\n\nhanil9900@hanmail.net\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-30\n\nAugust 3, 2023\n\nReference FEI 3012845410\n\nDear Mr. Doo Hyun Yang:\n\nYour firm was registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products, including toothpaste for children. Ingredients of the drugs registered as manufactured at your firm include ingredients susceptible to Diethylene Glycol (DEG) and Ethylene Glycol (EG) substitution. A review of import records showed multiple shipments of drug products into the United States which declared Sangleaf Pharm., Co., Ltd., as the drug manufacturer. On December 14, 2022, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. This request went unanswered. A second request was sent via e-mail on January 11, 2023, followed by an attempted contact by telephone with your registered U.S. Agent on January 26, 2023, regarding this matter. The Agency sent a follow-up written request for such records and other information on January 27, 2023. Delivery to you was confirmed by the shipper, but you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\n\nIt is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the current good manufacturing practice (CGMP) requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nBecause your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\n\nUntil FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at Sangleaf Pharm., Co., Ltd., 4 Sagimakgol-ro, 62 Beon-gil, Jungwon-gu, Seongnam Gyeonggi, 13210 South Korea, into the United States that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\n\nFDA placed all drugs and drug products manufactured by your firm on Import Alert 66-79 on March 30, 2023.\n\nAfter you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI #3012845410 and ATTN: Matthew R. Dionne, Pharm.D, Compliance Officer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research, FDA\n\nCC:\n\nRegistered U.S. Agent:\n\nOnbix Corp. U.S.\n\nonbixUS@gmail.com","Sangleaf Pharm., Co. Ltd.","sangleaf-pharm-co-ltd-663495-08032023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsangleaf-pharm-co-ltd-663495-08032023","2026-10-26T08:09:53.47207+00:00","2023-08-08","663495","Mr. Doo Hyun Yang","2026-08-20T00:48:58.934+00:00","VIA UPS","2023-08-03",{"id":214,"raw":215,"subject":179,"body_html":219,"body_text":220,"firm_name":221,"letter_id":222,"created_at":42,"fei_number":19,"letter_url":223,"updated_at":224,"action_type":22,"case_status":23,"posted_date":225,"marcs_cms_no":226,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":227,"body_fetched_at":228,"delivery_method":229,"recipient_title":19,"reference_number":19,"action_taken_date":230,"medical_device_id":19,"response_letter_date":19},449,[216,217,218,36,179,13,13,13],"\u003Ctime datetime=\"2025-12-02T05:00:00Z\">12\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-10T04:00:00Z\">10\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpq-pharmacy-llc-715795-10102025\">PQ Pharmacy, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Hale N. Dimetry\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>PQ Pharmacy, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>15215 Technology Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brooksville\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>34604-0690\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>WL # 715795\u003C\u002Fp>\u003Cp>October 10, 2025\u003Cbr>\u003Cbr>Dear Mr. Dimetry:\u003C\u002Fp>\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> on October 29, 2020, and most recently on November 26, 2024. From March 25, 2025, to April 4, 2025, an FDA investigator inspected your facility, PQ Pharmacy, LLC, located at 15215 Technology Drive, Brooksville, FL 34604. During the inspection, the investigator noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\u003Cp>FDA issued a Form FDA 483 to your facility on April 4, 2025. FDA acknowledges receipt of your facility’s response, dated April 7, 2025. Based on this inspection, it appears you produced drugs that violate the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>A. Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\u003Cp>In addition, for a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]).\u003C\u002Fp>\u003Cp>Furthermore, for a compounded drug product to qualify for the exemptions under section 503B, it must be compounded in an outsourcing facility that is in compliance with the registration and reporting requirements in section 503B(b), including the requirement to submit adverse event reports to FDA “in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations)” (section 503B(a)(1), (b)(5) of the FDCA [21 U.S.C. § 353b(a)(1), (b)(5)]).\u003C\u002Fp>\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503B\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the inspection, the FDA investigator collected evidence indicating that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigator collected evidence indicating that:\u003Cbr>1. Some of your facility’s drug products, such as Prednisolone\u002FMoxifloxacin HCl\u002FBromfenac PF Sterile Ophthalmic Solution and Prednisolone\u002FMoxifloxacin HCl PF Sterile Ophthalmic Solution, did not include the established name of the drug.\u003C\u002Fp>\u003Cp>2. Your facility did not submit adverse event reports to FDA in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, CFR (or any successor regulations).3 Specifically, your facility’s procedures for reporting adverse events are inadequate. For example, your documented procedures for reporting adverse events do not include the following information in the definition of what constitutes a “serious” adverse event: “Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse drug experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.” (21 CFR 310.305(b)).\u003C\u002Fp>\u003Cp>Because your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\u003C\u002Fp>\u003Cp>Specific violations are described below.\u003C\u002Fp>\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that:\u003C\u002Fp>\u003Cp>1. An operator rested their arms on the work surface of the hood during aseptic production. This practice may introduce contamination into the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> work area.\u003C\u002Fp>\u003Cp>2. Operators conducted aseptic manipulations in an area where the movement of “first air” in the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> area was disrupted by operator manipulations, including the failure to limit unnecessary movement and make mindful, slow, deliberate movements within the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> laminar flow hoods and within the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom suite.\u003C\u002Fp>\u003Cp>3. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\u003C\u002Fp>\u003Cp>The FDA investigator also noted CGMP violations at your facility that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\u003C\u002Fp>\u003Cp>1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fp>\u003Cp>2. Your firm failed to follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fp>\u003Cp>3. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fp>\u003Cp>4. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fp>\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\u003C\u002Fp>\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not have any FDA-approved applications on file for drug products that you compound.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)], a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your facility’s response to the Form FDA 483. Some of your corrective actions appear adequate; however, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\u003C\u002Fp>\u003Cp>1. You did not provide scientific justification for the selection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> intensity to conduct visual inspection for all sterile products.\u003C\u002Fp>\u003Cp>2. You did not provide training records and personnel qualification records for procedure S203005.3 Qualification of Personnel for Particulate and Defect Inspection Activities.\u003C\u002Fp>\u003Cp>Some of your corrective actions appear deficient:\u003C\u002Fp>\u003Cp>1. Regarding your failure to conduct hold time studies, we note that you have provided methods, such as media fill runs, to mitigate certain risks; however, these measures alone are insufficient. A hold time study remains necessary to evaluate container closures of the bulk holding material, testing of the bulk material being held prior to further processing, potential risk associated with sterility, contamination, product degradation, adsorption, or absorption. Furthermore, you failed to establish adequate written procedures for production and process controls, including but not limited to the following:\u003C\u002Fp>\u003Cp>a. Hold time studies to justify your \u003Cstrong>(b)(4)\u003C\u002Fstrong>-day holding of bulk product.\u003C\u002Fp>\u003Cp>b. Hold time studies to include the impact of an additional \u003Cstrong>(b)(4)\u003C\u002Fstrong> step, particularly in cases where such steps are used to extend the bulk hold period beyond the initial \u003Cstrong>(b)(4)\u003C\u002Fstrong>-days.\u003C\u002Fp>\u003Cp>c. Process validation, to include your \u003Cstrong>(b)(4)\u003C\u002Fstrong> step following detection of particulates or to provide a scientific study justifying this step. Moreover, you failed to define when an investigation is warranted in the event a product requires \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example, your standard operating procedures do not mandate a root cause investigation in cases of \u003Cstrong>(b)(4)\u003C\u002Fstrong> failure or particulate observation beyond initiating a deviation. Additionally, your classification of deviations, such as “Critical Deviation,” does not include the definition for \u003Cstrong>(b)(4)\u003C\u002Fstrong> resulting from \u003Cstrong>(b)(4)\u003C\u002Fstrong> failures \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>2. Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up. More specifically, you failed to expand your investigations into other products using the same lots of affected material (i.e. bulk bags, syringes, or \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Although you state that a review was conducted, the deviation report does not include a list of the specific lots that were assessed. Relying solely on trending data is not sufficient to justify the scope of an investigation.\u003C\u002Fp>\u003Cp>a. Regarding the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the bulk solution bag, your response fails to clarify whether your \u003Cstrong>(b)(4)\u003C\u002Fstrong> process has been validated for repeat \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedures. While your firm has identified the likely root cause of deviation DEV2024072 as intrinsic to the interior of the bulk bag, your response does not demonstrate that you have conducted adequate analysis beyond verifying expiration dates. Furthermore, there is no evidence that you examined other products manufactured using the same lot of bulk bags that produced the contaminated material, nor did you conduct additional review of retained samples that could provide valuable insight into the scope of this issue. Moreover, you did not investigate the integrity of the bags’ material nor conduct further investigation including communicating with the manufacturer. In addition, particulate testing appears to have been conducted only after the repeated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which raises concerns that the nature and extent of the contamination were not being appropriately characterized.\u003C\u002Fp>\u003Cp>b. Regarding your failure to follow-up on the root cause determination of DEV2024075, numerous critical deficiencies remain unaddressed and require comprehensive corrective and preventative actions. Your investigation does not include an adequate root cause analysis as you failed to review other products using the same lot of syringes, conduct any review of retained samples, or provide identification and characterization of the particulates to determine how they differed from the 19 rejects identified during 100% visual inspection. Additionally, your response does not address whether you investigated the integrity of the syringes themselves or notified the syringe manufacturer or distributor of this potential component-related issue.\u003C\u002Fp>\u003Cp>c. You failed to follow-up your root cause determination of DEV2023007 related to the sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, you did not conduct process validation for the change involving the flushing and discarding of the first \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> mL of product (depending on the product). You also conducted no further investigation into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> issue, including communication with the manufacturer.\u003C\u002Fp>\u003Cp>d. Your conclusion that post-bulk fill contamination was addressed through \u003Cstrong>(b)(4)\u003C\u002Fstrong> does not identify the original source of the contamination.\u003C\u002Fp>\u003Cp>Additionally, you provided no assessment or strategy to prevent further \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination from reoccurring.\u003C\u002Fp>\u003Cp>e. You did not provide a risk analysis of the products produced during the observed poor aseptic practices, nor was this analysis extended to other drug products produced on the same days. Disposition was also not provided for the following products, including whether they were released or distributed:\u003C\u002Fp>\u003Cdiv>\u003Ctable>\u003Ctbody>\u003Ctr>\u003Ctd>\u003Cstrong>Product\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Lot number\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Production date\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>Prednisolone Sodium Phosphate\u002FMoxifloxacin HCl\u002FBromfenac PF\u003C\u002Ftd>\u003Ctd>PMB032025NFG\u003C\u002Ftd>\u003Ctd>3\u002F26\u002F2025\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>Prednisolone Sodium Phosphate\u002FMoxifloxacin HCl\u002FBromfenac PF\u003C\u002Ftd>\u003Ctd>PMB032025NFG1 (5.6mL)\u003C\u002Ftd>\u003Ctd>3\u002F28\u002F2025\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>Prednisolone Sodium Phosphate\u002FMoxifloxacin HCl\u002FBromfenac PF\u003C\u002Ftd>\u003Ctd>PMB032025EO1 (8.6mL)\u003C\u002Ftd>\u003Ctd>3\u002F28\u002F2025\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>Semaglutide 5mg vials\u003C\u002Ftd>\u003Ctd>SEM032525JP\u003C\u002Ftd>\u003Ctd>3\u002F28\u002F2025\u003C\u002Ftd>\u003C\u002Ftr>\u003C\u002Ftbody>\u003C\u002Ftable>\u003Cp>3. Your smoke studies remain inadequate to demonstrate proper unidirectional airflow within the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> area. While we acknowledge that your smoke studies now include dynamic studies mimicking the operations of capping and crimping, these studies reveal airflow deficiencies that could compromise aseptic operations. Specifically, video 4 \u003Cstrong>(b)(4)\u003C\u002Fstrong> Static shows from time 0:59 to 1:37 the smoke arching past multiple rows of vials as it exits the front of the hood, indicating disrupted laminar flow that could transport contaminants across the work surface. Additionally, multiple objects such as the sampling plates and the sampler, are placed in front of the ventilation at the back of the hood, creating physical barriers that disrupt the intended unidirectional airflow pattern.\u003C\u002Fp>\u003C\u002Fdiv>\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. \u003Cem>See\u003C\u002Fem> section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\u003C\u002Fp>\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\u003C\u002Fp>\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>All correspondence should refer to the Warning Letter Number above (# 715795) and include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>F. Gail Bormel, JD, RPh\u003Cbr>Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> For more information, see, FDA’s guidance, “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” which can be found at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM434188.pdf.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> The specific products made by your firm are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nHale N. Dimetry\n\nRecipient Title\n\nPresident\n\nPQ Pharmacy, LLC\n\n15215 Technology Drive\n\nBrooksville, FL 34604-0690\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nWL # 715795\nOctober 10, 2025\n\nDear Mr. Dimetry:\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on October 29, 2020, and most recently on November 26, 2024. From March 25, 2025, to April 4, 2025, an FDA investigator inspected your facility, PQ Pharmacy, LLC, located at 15215 Technology Drive, Brooksville, FL 34604. During the inspection, the investigator noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\nFDA issued a Form FDA 483 to your facility on April 4, 2025. FDA acknowledges receipt of your facility’s response, dated April 7, 2025. Based on this inspection, it appears you produced drugs that violate the FDCA.\nA. Compounded Drug Products under the FDCA\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.2\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\nIn addition, for a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]).\nFurthermore, for a compounded drug product to qualify for the exemptions under section 503B, it must be compounded in an outsourcing facility that is in compliance with the registration and reporting requirements in section 503B(b), including the requirement to submit adverse event reports to FDA “in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations)” (section 503B(a)(1), (b)(5) of the FDCA [21 U.S.C. § 353b(a)(1), (b)(5)]).\nB. Failure to Meet the Conditions of Section 503B\nDuring the inspection, the FDA investigator collected evidence indicating that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigator collected evidence indicating that:\n1. Some of your facility’s drug products, such as Prednisolone\u002FMoxifloxacin HCl\u002FBromfenac PF Sterile Ophthalmic Solution and Prednisolone\u002FMoxifloxacin HCl PF Sterile Ophthalmic Solution, did not include the established name of the drug.\n2. Your facility did not submit adverse event reports to FDA in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, CFR (or any successor regulations).3 Specifically, your facility’s procedures for reporting adverse events are inadequate. For example, your documented procedures for reporting adverse events do not include the following information in the definition of what constitutes a “serious” adverse event: “Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse drug experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.” (21 CFR 310.305(b)).\nBecause your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\nSpecific violations are described below.\nC. Violations of the FDCA\nAdulterated Drug Products\nThe FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that:\n1. An operator rested their arms on the work surface of the hood during aseptic production. This practice may introduce contamination into the ISO (b)(4) work area.\n2. Operators conducted aseptic manipulations in an area where the movement of “first air” in the ISO (b)(4) area was disrupted by operator manipulations, including the failure to limit unnecessary movement and make mindful, slow, deliberate movements within the ISO (b)(4) laminar flow hoods and within the ISO (b)(4) cleanroom suite.\n3. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO (b)(4) area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\nThe FDA investigator also noted CGMP violations at your facility that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\n1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n2. Your firm failed to follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n3. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\n4. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\nUnapproved New Drug Products\nYou do not have any FDA-approved applications on file for drug products that you compound.4 Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)], a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\nMisbranded Drug Products\nYou compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.5 The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\nD. Corrective Actions\nWe have reviewed your facility’s response to the Form FDA 483. Some of your corrective actions appear adequate; however, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\n1. You did not provide scientific justification for the selection of (b)(4) intensity to conduct visual inspection for all sterile products.\n2. You did not provide training records and personnel qualification records for procedure S203005.3 Qualification of Personnel for Particulate and Defect Inspection Activities.\nSome of your corrective actions appear deficient:\n1. Regarding your failure to conduct hold time studies, we note that you have provided methods, such as media fill runs, to mitigate certain risks; however, these measures alone are insufficient. A hold time study remains necessary to evaluate container closures of the bulk holding material, testing of the bulk material being held prior to further processing, potential risk associated with sterility, contamination, product degradation, adsorption, or absorption. Furthermore, you failed to establish adequate written procedures for production and process controls, including but not limited to the following:\na. Hold time studies to justify your (b)(4)-day holding of bulk product.\nb. Hold time studies to include the impact of an additional (b)(4) step, particularly in cases where such steps are used to extend the bulk hold period beyond the initial (b)(4)-days.\nc. Process validation, to include your (b)(4) step following detection of particulates or to provide a scientific study justifying this step. Moreover, you failed to define when an investigation is warranted in the event a product requires (b)(4). For example, your standard operating procedures do not mandate a root cause investigation in cases of (b)(4) failure or particulate observation beyond initiating a deviation. Additionally, your classification of deviations, such as “Critical Deviation,” does not include the definition for (b)(4) resulting from (b)(4) failures (b)(4).\n2. Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up. More specifically, you failed to expand your investigations into other products using the same lots of affected material (i.e. bulk bags, syringes, or (b)(4)). Although you state that a review was conducted, the deviation report does not include a list of the specific lots that were assessed. Relying solely on trending data is not sufficient to justify the scope of an investigation.\na. Regarding the (b)(4) of the bulk solution bag, your response fails to clarify whether your (b)(4) process has been validated for repeat (b)(4) procedures. While your firm has identified the likely root cause of deviation DEV2024072 as intrinsic to the interior of the bulk bag, your response does not demonstrate that you have conducted adequate analysis beyond verifying expiration dates. Furthermore, there is no evidence that you examined other products manufactured using the same lot of bulk bags that produced the contaminated material, nor did you conduct additional review of retained samples that could provide valuable insight into the scope of this issue. Moreover, you did not investigate the integrity of the bags’ material nor conduct further investigation including communicating with the manufacturer. In addition, particulate testing appears to have been conducted only after the repeated (b)(4), which raises concerns that the nature and extent of the contamination were not being appropriately characterized.\nb. Regarding your failure to follow-up on the root cause determination of DEV2024075, numerous critical deficiencies remain unaddressed and require comprehensive corrective and preventative actions. Your investigation does not include an adequate root cause analysis as you failed to review other products using the same lot of syringes, conduct any review of retained samples, or provide identification and characterization of the particulates to determine how they differed from the 19 rejects identified during 100% visual inspection. Additionally, your response does not address whether you investigated the integrity of the syringes themselves or notified the syringe manufacturer or distributor of this potential component-related issue.\nc. You failed to follow-up your root cause determination of DEV2023007 related to the sterile (b)(4). Additionally, you did not conduct process validation for the change involving the flushing and discarding of the first (b)(4) or (b)(4) mL of product (depending on the product). You also conducted no further investigation into the (b)(4) issue, including communication with the manufacturer.\nd. Your conclusion that post-bulk fill contamination was addressed through (b)(4) does not identify the original source of the contamination.\nAdditionally, you provided no assessment or strategy to prevent further (b)(4) contamination from reoccurring.\ne. You did not provide a risk analysis of the products produced during the observed poor aseptic practices, nor was this analysis extended to other drug products produced on the same days. Disposition was also not provided for the following products, including whether they were released or distributed:\nProductLot numberProduction date\nPrednisolone Sodium Phosphate\u002FMoxifloxacin HCl\u002FBromfenac PFPMB032025NFG3\u002F26\u002F2025\nPrednisolone Sodium Phosphate\u002FMoxifloxacin HCl\u002FBromfenac PFPMB032025NFG1 (5.6mL)3\u002F28\u002F2025\nPrednisolone Sodium Phosphate\u002FMoxifloxacin HCl\u002FBromfenac PFPMB032025EO1 (8.6mL)3\u002F28\u002F2025\nSemaglutide 5mg vialsSEM032525JP3\u002F28\u002F2025\n3. Your smoke studies remain inadequate to demonstrate proper unidirectional airflow within the ISO (b)(4) area. While we acknowledge that your smoke studies now include dynamic studies mimicking the operations of capping and crimping, these studies reveal airflow deficiencies that could compromise aseptic operations. Specifically, video 4 (b)(4) Static shows from time 0:59 to 1:37 the smoke arching past multiple rows of vials as it exits the front of the hood, indicating disrupted laminar flow that could transport contaminants across the work surface. Additionally, multiple objects such as the sampling plates and the sampler, are placed in front of the ventilation at the back of the hood, creating physical barriers that disrupt the intended unidirectional airflow pattern.\n\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\nE. Conclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nAll correspondence should refer to the Warning Letter Number above (# 715795) and include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nF. Gail Bormel, JD, RPh\nDirector\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n________________________\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\n3 For more information, see, FDA’s guidance, “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” which can be found at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM434188.pdf.\n4 The specific products made by your firm are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n5 Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).","PQ Pharmacy, LLC","pq-pharmacy-llc-715795-10102025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpq-pharmacy-llc-715795-10102025","2026-10-26T08:09:43.271938+00:00","2025-12-02","715795","Hale N. Dimetry","2026-08-19T12:25:32.021+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","2025-10-10",{"id":232,"raw":233,"subject":99,"body_html":237,"body_text":238,"firm_name":239,"letter_id":240,"created_at":241,"fei_number":19,"letter_url":242,"updated_at":243,"action_type":22,"case_status":23,"posted_date":244,"marcs_cms_no":245,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":19,"body_fetched_at":246,"delivery_method":247,"recipient_title":19,"reference_number":19,"action_taken_date":248,"medical_device_id":19,"response_letter_date":19},1021,[234,235,236,36,99,13,13,13],"\u003Ctime datetime=\"2025-03-11T04:00:00Z\">03\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-03T05:00:00Z\">03\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffox-pharma-llc-699225-03032025\">Fox Pharma LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Fox Pharma LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2401 Frankford Ave, Ste 4B\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Philadelphia\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>19125\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@foxpharma.us\"> info@foxpharma.us\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 3, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>RE: 699225\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Fox Pharma LLC:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Ffoxpharma.us in January 2025 and has observed that your website offers various injectable lipolytic products, such as “LemonBottle Ampoule Solution,” “Lipo Lab PPC Solution (brown vial),” “Lipo Lab PPC Solution,” “Lipo Vela,” “Lipo Lab V-Line,” “Kabelline,” and “Super V-Line Sol,” for sale in the United States. We have also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002Ffoxpharma.us\u002F and https:\u002F\u002Fwww.instagram.com\u002Ffoxpharma_us\u002F. Your social media websites direct consumers to your https:\u002F\u002Ffoxpharma.us website to purchase your products. As described below, your injectable lipolytic products including “LemonBottle Ampoule Solution,” “Lipo Lab PPC Solution (brown vial),” “Lipo Lab PPC Solution,” “Lipo Vela,” “Lipo Lab V-Line,” “Kabelline,” and “Super V-Line Sol” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.\u003C\u002Fp>\u003Cp>Your products are drugs as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims observed on your websites that establish the intended use of your products as drugs for human use include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>LemonBottle Ampoule Solution\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On your webpage https:\u002F\u002Ffoxpharma.us\u002Fproducts\u002Flemon-bottle:\u003Cbr>􀁸 “[F]or fat decomposition to increase metabolism of fat cells and accelerate it.”\u003Cbr>􀁸 “[M]etabolic activation effect of Riboflavin separate and send out the fat cell fast lipase activity and inflammation relief”\u003Cbr>􀁸 “[A]ctivation of fat metabolism”\u003C\u002Fp>\u003Cp>On a May 16, 2024, post on your Facebook and Instagram social media websites at https:\u002F\u002Fwww.facebook.com\u002Ffoxpharma.us\u002F and https:\u002F\u002Fwww.instagram.com\u002Ffoxpharma_us\u002F:\u003Cbr>􀁸 “Lecithin destroys and transports unnecessary fat cells”\u003Cbr>􀁸 “Bromelain (Ananas Sativus (Pineapple)) helps to break down fat and remove inflammation”\u003Cbr>􀁸 “[I]f you [sic] uncomfortable with liposuction[,] diet does not help”\u003Cbr>􀁸 “[I]f you want to lose weight quickly in a short time”\u003C\u002Fp>\u003Cp>\u003Cu>Lipo Lab PPC Solution (brown vial)\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On your webpage https:\u002F\u002Ffoxpharma.us\u002Fproducts\u002Flipo-lab-10x10ml-brown-vial:\u003Cbr>􀁸 “Lipo Lab is one of the safest and most effective fat-dissolving products in existence today. It offers fast subcutaneous fat removal.”\u003Cbr>􀁸 “It fights obesity in two main ways - by speeding up metabolism and melting the fat tissues in a natural and health-friendly manner.”\u003Cbr>􀁸 “[R]emove[s] cellulite.”\u003C\u002Fp>\u003Cp>\u003Cu>Lipo Lab PPC Solution\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On your webpage https:\u002F\u002Ffoxpharma.us\u002Fproducts\u002Flipolab-ppc-10-ml-10-vials:\u003Cbr>􀁸 “With the combination of the best PPC ingredients and PLLA and PDRN, LipoLine products will reduce fat and, at the same time, increase the skin's own collagen production and elasticity, creating a resilient body line.”\u003Cbr>􀁸 “PPC(PhosphatidylCholine) [sic] spotlighted as the latest solution to obesity”\u003Cbr>􀁸 “Reduces the storage of fat layer”\u003C\u002Fp>\u003Cp>\u003Cu>Lipo Vela\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On your webpage https:\u002F\u002Ffoxpharma.us\u002Fproducts\u002Flipo-vela-10x10ml:\u003Cbr>􀁸 “Effective &amp; Safe Lipolisys [sic] Solution”\u003Cbr>􀁸 “Combined with Sodium Deoxycholate, L-carnitine and Vitamin B12, which further accelerates lipolysis, it promotes the metabolism of fat cells and dissolves lipolysis safely and effectively.”\u003Cbr>􀁸 “It contains cell growth factors, collagen promotion, and skin antioxidants that help to prevent wrinkles and maintain elasticity during the lipolysis process.”\u003Cbr>􀁸 “LIPOLISYS [sic] ACCELERATOR[:] Effective ingredients to promote the dissolution of fat cells, Energy metabolism and activation”\u003C\u002Fp>\u003Cp>\u003Cu>Lipo Lab V-Line\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On your webpage https:\u002F\u002Ffoxpharma.us\u002Fproducts\u002Flipo-lab-v-line-5x10ml:\u003Cbr>􀁸 “Lipo Lab V-line is a premium-class lipolytic for the elimination of excessive fat tissue and non-surgical face contouring.”\u003Cbr>􀁸 “Facial fat reduction”\u003C\u002Fp>\u003Cp>On a February 9, 2024, post on your Facebook social media website https:\u002F\u002Fwww.facebook.com\u002Freel\u002F6887553201356719:\u003Cbr>􀁸 “Skin cell activation”\u003Cbr>􀁸 “Your insecurity about your saggy skin and uneven face shape will be solved with a few treatment sessions with this fat-reducing injectable.”\u003C\u002Fp>\u003Cp>\u003Cu>Kabelline\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On your webpage https:\u002F\u002Ffoxpharma.us\u002Fproducts\u002Fkabelline-box-5x8ml:\u003Cbr>􀁸 “Kabelline destroys fat cells in the chin area, which results in a noticeable and satisfactory reduction of redundant fat cells.”\u003Cbr>􀁸 “Once these adipocytes (fat cells) are destroyed, these cells no longer can store and accumulate fat.”\u003Cbr>􀁸 “Deoxycholic acid aids in the breakdown of fat and its absorption; it is a naturally occurring body molecule.”\u003Cbr>􀁸 “Non-invasive treatment to destroy fat cells without the use of surgeries”\u003C\u002Fp>\u003Cp>\u003Cu>Super V-Line Sol\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On your webpage https:\u002F\u002Ffoxpharma.us\u002Fproducts\u002Fsuper-v-line-sol-5x10ml:\u003Cbr>􀁸 “[A] safe and efficient lipolytic solution that specifically targets facial fat deposits.”\u003Cbr>􀁸 “It contains a lipolytic complex composed of natural ingredients that help reduce excessive facial fat and age-related changes in facial contour.”\u003Cbr>􀁸 “Reduces facial fat deposits”\u003Cbr>􀁸 “[R]emoves cellulite”\u003Cbr>􀁸 “More effective and accessible than traditional liposuction surgery”\u003C\u002Fp>\u003Cp>Your “LemonBottle Ampoule Solution,” “Lipo Lab PPC Solution (brown vial),” “Lipo Lab PPC Solution,” “Lipo Vela,” “Lipo Lab V-Line,” “Kabelline,” and “Super V-Line Sol” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov. Please include your firm name and the unique identifier “699225” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nFox Pharma LLC\n\n2401 Frankford Ave, Ste 4B\n\nPhiladelphia, PA 19125\n\nUnited States\n\ninfo@foxpharma.us\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nMarch 3, 2025\nRE: 699225\nDear Fox Pharma LLC:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Ffoxpharma.us in January 2025 and has observed that your website offers various injectable lipolytic products, such as “LemonBottle Ampoule Solution,” “Lipo Lab PPC Solution (brown vial),” “Lipo Lab PPC Solution,” “Lipo Vela,” “Lipo Lab V-Line,” “Kabelline,” and “Super V-Line Sol,” for sale in the United States. We have also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002Ffoxpharma.us\u002F and https:\u002F\u002Fwww.instagram.com\u002Ffoxpharma_us\u002F. Your social media websites direct consumers to your https:\u002F\u002Ffoxpharma.us website to purchase your products. As described below, your injectable lipolytic products including “LemonBottle Ampoule Solution,” “Lipo Lab PPC Solution (brown vial),” “Lipo Lab PPC Solution,” “Lipo Vela,” “Lipo Lab V-Line,” “Kabelline,” and “Super V-Line Sol” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d).\nThese products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.\nYour products are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended to prevent, treat, or cure disease conditions and\u002For affect the structure or function of the body. Examples of claims observed on your websites that establish the intended use of your products as drugs for human use include, but may not be limited to, the following:\nLemonBottle Ampoule Solution\nOn your webpage https:\u002F\u002Ffoxpharma.us\u002Fproducts\u002Flemon-bottle:\n􀁸 “[F]or fat decomposition to increase metabolism of fat cells and accelerate it.”\n􀁸 “[M]etabolic activation effect of Riboflavin separate and send out the fat cell fast lipase activity and inflammation relief”\n􀁸 “[A]ctivation of fat metabolism”\nOn a May 16, 2024, post on your Facebook and Instagram social media websites at https:\u002F\u002Fwww.facebook.com\u002Ffoxpharma.us\u002F and https:\u002F\u002Fwww.instagram.com\u002Ffoxpharma_us\u002F:\n􀁸 “Lecithin destroys and transports unnecessary fat cells”\n􀁸 “Bromelain (Ananas Sativus (Pineapple)) helps to break down fat and remove inflammation”\n􀁸 “[I]f you [sic] uncomfortable with liposuction[,] diet does not help”\n􀁸 “[I]f you want to lose weight quickly in a short time”\nLipo Lab PPC Solution (brown vial)\nOn your webpage https:\u002F\u002Ffoxpharma.us\u002Fproducts\u002Flipo-lab-10x10ml-brown-vial:\n􀁸 “Lipo Lab is one of the safest and most effective fat-dissolving products in existence today. It offers fast subcutaneous fat removal.”\n􀁸 “It fights obesity in two main ways - by speeding up metabolism and melting the fat tissues in a natural and health-friendly manner.”\n􀁸 “[R]emove[s] cellulite.”\nLipo Lab PPC Solution\nOn your webpage https:\u002F\u002Ffoxpharma.us\u002Fproducts\u002Flipolab-ppc-10-ml-10-vials:\n􀁸 “With the combination of the best PPC ingredients and PLLA and PDRN, LipoLine products will reduce fat and, at the same time, increase the skin's own collagen production and elasticity, creating a resilient body line.”\n􀁸 “PPC(PhosphatidylCholine) [sic] spotlighted as the latest solution to obesity”\n􀁸 “Reduces the storage of fat layer”\nLipo Vela\nOn your webpage https:\u002F\u002Ffoxpharma.us\u002Fproducts\u002Flipo-vela-10x10ml:\n􀁸 “Effective & Safe Lipolisys [sic] Solution”\n􀁸 “Combined with Sodium Deoxycholate, L-carnitine and Vitamin B12, which further accelerates lipolysis, it promotes the metabolism of fat cells and dissolves lipolysis safely and effectively.”\n􀁸 “It contains cell growth factors, collagen promotion, and skin antioxidants that help to prevent wrinkles and maintain elasticity during the lipolysis process.”\n􀁸 “LIPOLISYS [sic] ACCELERATOR[:] Effective ingredients to promote the dissolution of fat cells, Energy metabolism and activation”\nLipo Lab V-Line\nOn your webpage https:\u002F\u002Ffoxpharma.us\u002Fproducts\u002Flipo-lab-v-line-5x10ml:\n􀁸 “Lipo Lab V-line is a premium-class lipolytic for the elimination of excessive fat tissue and non-surgical face contouring.”\n􀁸 “Facial fat reduction”\nOn a February 9, 2024, post on your Facebook social media website https:\u002F\u002Fwww.facebook.com\u002Freel\u002F6887553201356719:\n􀁸 “Skin cell activation”\n􀁸 “Your insecurity about your saggy skin and uneven face shape will be solved with a few treatment sessions with this fat-reducing injectable.”\nKabelline\nOn your webpage https:\u002F\u002Ffoxpharma.us\u002Fproducts\u002Fkabelline-box-5x8ml:\n􀁸 “Kabelline destroys fat cells in the chin area, which results in a noticeable and satisfactory reduction of redundant fat cells.”\n􀁸 “Once these adipocytes (fat cells) are destroyed, these cells no longer can store and accumulate fat.”\n􀁸 “Deoxycholic acid aids in the breakdown of fat and its absorption; it is a naturally occurring body molecule.”\n􀁸 “Non-invasive treatment to destroy fat cells without the use of surgeries”\nSuper V-Line Sol\nOn your webpage https:\u002F\u002Ffoxpharma.us\u002Fproducts\u002Fsuper-v-line-sol-5x10ml:\n􀁸 “[A] safe and efficient lipolytic solution that specifically targets facial fat deposits.”\n􀁸 “It contains a lipolytic complex composed of natural ingredients that help reduce excessive facial fat and age-related changes in facial contour.”\n􀁸 “Reduces facial fat deposits”\n􀁸 “[R]emoves cellulite”\n􀁸 “More effective and accessible than traditional liposuction surgery”\nYour “LemonBottle Ampoule Solution,” “Lipo Lab PPC Solution (brown vial),” “Lipo Lab PPC Solution,” “Lipo Vela,” “Lipo Lab V-Line,” “Kabelline,” and “Super V-Line Sol” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov. Please include your firm name and the unique identifier “699225” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration","Fox Pharma LLC","fox-pharma-llc-699225-03032025","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ffox-pharma-llc-699225-03032025","2026-10-26T08:08:43.002077+00:00","2025-03-11","699225","2026-08-19T16:58:30.227+00:00","Via Email","2025-03-03",{"id":250,"raw":251,"subject":255,"body_html":256,"body_text":257,"firm_name":258,"letter_id":259,"created_at":18,"fei_number":19,"letter_url":260,"updated_at":261,"action_type":22,"case_status":23,"posted_date":262,"marcs_cms_no":263,"product_type":264,"closeout_date":19,"issuing_office":36,"recipient_name":265,"body_fetched_at":266,"delivery_method":247,"recipient_title":19,"reference_number":19,"action_taken_date":267,"medical_device_id":19,"response_letter_date":19},781,[252,253,254,36,255,13,13,13],"\u003Ctime datetime=\"2025-07-15T04:00:00Z\">07\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-09T04:00:00Z\">07\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthea-pharma-inc-712416-07092025\">Thea Pharma, Inc.\u003C\u002Fa>","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Susan K. Benton\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Thea Pharma, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>303 Wyman Street, Suite 205\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Waltham\u003C\u002Fspan>, \u003Cspan>MA\u003C\u002Fspan> \u003Cspan>02451\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>July 9, 2025\u003C\u002Fp>\u003Cp>RE: 712416\u003C\u002Fp>\u003Cp>Dear Ms. Benton:\u003C\u002Fp>\u003Cp>This letter is to advise you that on August 29, 2024 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including on your website at the internet address www.ivizia.com and your Amazon storefront at https:\u002F\u002Fwww.amazon.com\u002FiVIZIA-Lubricant-Preservative-Free-Moisturizing-Friendly\u002Fdp\u002FB09TD27BR5?th=1 where your IVIZIA sterile lubricant eye drops product is available for purchase in the United States without a prescription.\u003C\u002Fp>\u003Cp>Based on our review, your IVIZIA sterile lubricant eye drops product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act,) 21 U.S.C. 355(a) and 331(d). In addition, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your IVIZIA sterile lubricant eye drops is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples of claims from the product labeling and your website that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>IVIZIA sterile lubricant eye drops\u003C\u002Fu>\u003Cbr>“\u003Cstrong>Use\u003C\u002Fstrong> 􀆒 For use as a lubricant to prevent further irritation or to relieve dryness of the eye” [from the Drug Facts panel on product carton labeling]\u003C\u002Fp>\u003Cp>“iVIZIA for Dry Eyes . . . made with hydrating polymers, sodium hyaluronate, and trehalose, iVIZIA’s unique multi-moisturizing formula improves eye comfort during computer work . . .” [from your website https:\u002F\u002Fwww.ivizia.com\u002F]\u003C\u002Fp>\u003Cp>“Instant and long-lasting relief of dry eye symptoms for up to 8 hours…UNIQUE FORMULA…POVIDONE (active ingredient) …A hydrating polymer that significantly decreases dry eye discomfort…. made with revitalizing hyaluronic acid and trehalose…HYALURONIC ACID “HA” (inactive)…one of the most water-loving molecules…described as “nature’s moisturizer”. It can bind 1000 times its weight in water… TREHALOSE (inactive)… synthetized by plants such as the Rose of Jericho…can survive extreme dehydration thanks to trehalose.”[from your website under Product-Dry Eye Drops https:\u002F\u002Fwww.ivizia.com\u002Fivizia-dry-eye-drops\u002F (last visited December 2024)]\u003C\u002Fp>\u003Cp>“Scientifically formulated to moisturize and lubricate dry eyes…Hyaluronic Acid (enhancer)…can hold 1000x its weight in moisture…Trehalose (enhancer)…works with hyaluronic acid to resist drying longer.” [from the website directly linked from IVIZIA.com product page which direct consumers to purchase IVIZIA sterile lubricant eye drops without a prescription under the “BUY NOW” button https:\u002F\u002Fwww.amazon.com\u002FiVIZIALubricant-Preservative-Free-Moisturizing-Friendly\u002Fdp\u002FB09TCZRG1K?ref_=ast_sto_dp (last visited December 2024]\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above evidence of intended use, your IVIZIA sterile lubricant eye drops product is intended for use as an ophthalmic demulcent (lubricant) drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for your IVIZIA sterile lubricant eye drops drug product.\u003C\u002Fp>\u003Cp>Your drug product is marketed as an ophthalmic demulcent drug product and is subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which generally governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, such as your IVIZIA sterile lubricant eye drops, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here Over-the-Counter (OTC) monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (hereinafter M018).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, your IVIZIA sterile lubricant eye drops drug product does not conform to the conditions specified in M018 for the reasons described below.\u003C\u002Fp>\u003Cp>Your IVIZIA sterile lubricant eye drops is a demulcent product formulated with several active ingredients that are not permitted for OTC monograph ophthalmic demulcent drug products. Specifically, according to your products labeling, your IVIZIA sterile lubricant eye drops is formulated with the active ingredients hyaluronic acid and trehalose.\u003C\u002Fp>\u003Cp>However, hyaluronic acid and trehalose are not active ingredients permitted for ophthalmic demulcent drug products under M018. 21. We note that, although you identify these ingredients as inactive ingredients on the product label, statements on your website show that they are active ingredients because they are intended to furnish pharmacological activity for the treatment of a disease or condition\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Example of these statements include, “made with hydrating polymers, sodium hyaluronate, and trehalose, iVIZIA’s unique multi-moisturizing formula improves eye comfort during computer work . . .” Furthermore, claims such as “can hold 1000x its weight in moisture” and “nature’s moisturizer,” are associated with the ingredient hyaluronic acid and claims such as “can survive extreme dehydration thanks to trehalose,” and “works with hyaluronic acid to resist drying longer” are associated with the ingredient trehalose. Thus, these ingredients are active ingredients and, because they are not active ingredients permitted under M018.12, your IVIZIA sterile lubricant eye drops product does not conform with the conditions for lawful marketing of an OTC ophthalmic demulcent drug product as set forth in M018.\u003C\u002Fp>\u003Cp>Thus, your IVIZIA sterile lubricant eye drops product does not comply with the applicable conditions specified in M018 and has not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug. The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, your IVIZIA sterile lubricant eye drops is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov. Please include your firm name and the unique identifier “712416” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling\u003Cbr>Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\u003Cp>cc: Chrysoula Koukoutsis, Director, Global Regulatory Affairs, Vice President of Regulatory Affairs\u003C\u002Fp>\u003Cp>___________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M018 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000023, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 201.66(b)(2), which defines an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that IVISIA lubricant eye drops product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nSusan K. Benton\n\nRecipient Title\n\nPresident\n\nThea Pharma, Inc.\n\n303 Wyman Street, Suite 205\n\nWaltham, MA 02451\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nJuly 9, 2025\nRE: 712416\nDear Ms. Benton:\nThis letter is to advise you that on August 29, 2024 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including on your website at the internet address www.ivizia.com and your Amazon storefront at https:\u002F\u002Fwww.amazon.com\u002FiVIZIA-Lubricant-Preservative-Free-Moisturizing-Friendly\u002Fdp\u002FB09TD27BR5?th=1 where your IVIZIA sterile lubricant eye drops product is available for purchase in the United States without a prescription.\nBased on our review, your IVIZIA sterile lubricant eye drops product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act,) 21 U.S.C. 355(a) and 331(d). In addition, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\nYour IVIZIA sterile lubricant eye drops is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\nExamples of claims from the product labeling and your website that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\nIVIZIA sterile lubricant eye drops\n“Use 􀆒 For use as a lubricant to prevent further irritation or to relieve dryness of the eye” [from the Drug Facts panel on product carton labeling]\n“iVIZIA for Dry Eyes . . . made with hydrating polymers, sodium hyaluronate, and trehalose, iVIZIA’s unique multi-moisturizing formula improves eye comfort during computer work . . .” [from your website https:\u002F\u002Fwww.ivizia.com\u002F]\n“Instant and long-lasting relief of dry eye symptoms for up to 8 hours…UNIQUE FORMULA…POVIDONE (active ingredient) …A hydrating polymer that significantly decreases dry eye discomfort…. made with revitalizing hyaluronic acid and trehalose…HYALURONIC ACID “HA” (inactive)…one of the most water-loving molecules…described as “nature’s moisturizer”. It can bind 1000 times its weight in water… TREHALOSE (inactive)… synthetized by plants such as the Rose of Jericho…can survive extreme dehydration thanks to trehalose.”[from your website under Product-Dry Eye Drops https:\u002F\u002Fwww.ivizia.com\u002Fivizia-dry-eye-drops\u002F (last visited December 2024)]\n“Scientifically formulated to moisturize and lubricate dry eyes…Hyaluronic Acid (enhancer)…can hold 1000x its weight in moisture…Trehalose (enhancer)…works with hyaluronic acid to resist drying longer.” [from the website directly linked from IVIZIA.com product page which direct consumers to purchase IVIZIA sterile lubricant eye drops without a prescription under the “BUY NOW” button https:\u002F\u002Fwww.amazon.com\u002FiVIZIALubricant-Preservative-Free-Moisturizing-Friendly\u002Fdp\u002FB09TCZRG1K?ref_=ast_sto_dp (last visited December 2024]\nUnapproved New Drug Violations\nBased on the above evidence of intended use, your IVIZIA sterile lubricant eye drops product is intended for use as an ophthalmic demulcent (lubricant) drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for your IVIZIA sterile lubricant eye drops drug product.\nYour drug product is marketed as an ophthalmic demulcent drug product and is subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which generally governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, such as your IVIZIA sterile lubricant eye drops, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here Over-the-Counter (OTC) monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (hereinafter M018).1 However, your IVIZIA sterile lubricant eye drops drug product does not conform to the conditions specified in M018 for the reasons described below.\nYour IVIZIA sterile lubricant eye drops is a demulcent product formulated with several active ingredients that are not permitted for OTC monograph ophthalmic demulcent drug products. Specifically, according to your products labeling, your IVIZIA sterile lubricant eye drops is formulated with the active ingredients hyaluronic acid and trehalose.\nHowever, hyaluronic acid and trehalose are not active ingredients permitted for ophthalmic demulcent drug products under M018. 21. We note that, although you identify these ingredients as inactive ingredients on the product label, statements on your website show that they are active ingredients because they are intended to furnish pharmacological activity for the treatment of a disease or condition2. Example of these statements include, “made with hydrating polymers, sodium hyaluronate, and trehalose, iVIZIA’s unique multi-moisturizing formula improves eye comfort during computer work . . .” Furthermore, claims such as “can hold 1000x its weight in moisture” and “nature’s moisturizer,” are associated with the ingredient hyaluronic acid and claims such as “can survive extreme dehydration thanks to trehalose,” and “works with hyaluronic acid to resist drying longer” are associated with the ingredient trehalose. Thus, these ingredients are active ingredients and, because they are not active ingredients permitted under M018.12, your IVIZIA sterile lubricant eye drops product does not conform with the conditions for lawful marketing of an OTC ophthalmic demulcent drug product as set forth in M018.\nThus, your IVIZIA sterile lubricant eye drops product does not comply with the applicable conditions specified in M018 and has not otherwise been found GRASE.3 Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug. The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, your IVIZIA sterile lubricant eye drops is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov. Please include your firm name and the unique identifier “712416” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling\nCompliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\ncc: Chrysoula Koukoutsis, Director, Global Regulatory Affairs, Vice President of Regulatory Affairs\n___________________________\n1 M018 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000023, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\n2 See 21 CFR 201.66(b)(2), which defines an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.”\n3 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that IVISIA lubricant eye drops product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).","Thea Pharma, Inc.","thea-pharma-inc-712416-07092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthea-pharma-inc-712416-07092025","2026-10-26T08:10:11.070796+00:00","2025-07-15","712416","Drugs Over-the-Counter Drugs","Susan K. Benton","2026-08-19T16:36:32.641+00:00","2025-07-09",{"id":269,"raw":270,"subject":179,"body_html":276,"body_text":277,"firm_name":278,"letter_id":279,"created_at":204,"fei_number":19,"letter_url":280,"updated_at":281,"action_type":22,"case_status":23,"posted_date":282,"marcs_cms_no":283,"product_type":47,"closeout_date":19,"issuing_office":284,"recipient_name":285,"body_fetched_at":286,"delivery_method":229,"recipient_title":19,"reference_number":19,"action_taken_date":287,"medical_device_id":19,"response_letter_date":19},1605,[271,272,273,274,275,13,13,13],"\u003Ctime datetime=\"2024-02-13T14:20:00Z\">02\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-01-26T05:00:00Z\">01\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fquva-pharma-inc-675685-01262024\">QuVa Pharma, Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations I ","Compounding Pharmacy\u002FAdulterated Drug Products ","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Stuart Hinchen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>QuVa Pharma, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3 Sugar Creek Center Blvd, Suite 250\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sugar Land\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77478\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:stuart.hinchen@quvapharma.com\"> stuart.hinchen@quvapharma.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nWL # 675685\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 26, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hinchen:\u003C\u002Fp>\n\n\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> on September 15, 2017, and most recently on December 14, 2023. From August 16, 2022, to October 14, 2022, FDA investigators inspected your facility, QuVa Pharma, Inc., located at 519 State Route 173, Bloomsbury, NJ 08804. During the inspection, the investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your facility on October 14, 2022. FDA acknowledges receipt of your facility’s response, dated November 4, 2022, as well as your subsequent correspondence. FDA also acknowledges that, on September 20, 2022, your facility initiated a voluntary recall of oxytocin 30 Units\u002F500 mL (0.06 Units\u002FmL) added to 0.9% Sodium Chloride, Injection for IV Use, Lot # 30027403, due to incorrect product formulation. Based on this inspection, it appears you produced drugs that violate the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed:\u003C\u002Fp>\n\n\u003Col>\n\t\u003Cli>You did not perform adequate product evaluation and take appropriate corrective actions after mold was recovered on operator glove finger plate samples taken after aseptic operations within the ISO 5 area.\u003C\u002Fli>\n\t\u003Cli>&nbsp;An operator placing their upper left side of their body into the ISO 5 hood within the syringe filler. In addition, another operator was observed placing their sleeves, chest, and forehead under the ISO 5 hood.\u003C\u002Fli>\n\u003C\u002Fol>\n\n\u003Cp>FDA investigators also noted CGMP violations at your facility, that caused your drug product(s) to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\u003C\u002Fp>\n\n\u003Col>\n\t\u003Cli>Your firm failed to follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fli>\n\t\u003Cli>Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fli>\n\t\u003Cli>Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fli>\n\t\u003Cli>Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they are purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fli>\n\t\u003Cli>Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fli>\n\u003C\u002Fol>\n\n\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\u003C\u002Fp>\n\n\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your facility’s responses to the Form FDA 483. We acknowledge your recall of oxytocin 30 Units\u002F500 mL (0.06 Units\u002FmL) added to 0.9% Sodium Chloride, Injection for IV Use, Lot # 30027403, due to incorrect product formulation, on September 20, 2022.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your facility’s responses to the Form FDA 483. Some of your corrective actions appear adequate; however, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\u003C\u002Fp>\n\n\u003Col>\n\t\u003Cli>Regarding observation 5B(i), you note personnel monitoring (PM) sampling of the forearm added in NJ-SOP-SA-0010 “Environmental Monitoring \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;Filler”, section 5.2.5.1.1 states “\u003Cstrong>(b)(4)\u003C\u002Fstrong> samples to be taken representing \u003Cstrong>(b)(4)\u003C\u002Fstrong> locations and conditions at the conclusion of filling operations. Selected sample locations include...samples of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Your firm has not provided documentation of environmental monitoring (EM) results in these locations to demonstrate current controls are adequate.\u003C\u002Fli>\n\t\u003Cli>In your response to observation 3, your firm performed a document change request CR-15631 to update NJ-SOP-QA-0011, “Performing Acceptable Quality Limit Inspections”, to remove the reference to ‘excessive liquid in the ribs’ as a minor defect. Your firm’s response lacks justification and supporting documentation for the rationale to remove “Excessive Liquid Between Plunger Ribs (Over \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the rib)” as a minor defect. Also, your response failed to provide an example of a master batch record to show where operators are to identify and record defects related to leaking syringes. In addition, your firm did not provide sufficient information regarding the training provided to your employees, instead your firm provided a signed sheet.\u003C\u002Fli>\n\t\u003Cli>In your response to observation 4A, you provided updated procedures that require user login with \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you failed to provide the attachments with these updated procedures, trained personnel, batch records, and associated test slip as documentation that individual logins are now implemented. Also, in your response to observation 4B, you failed to provide the change control record, including the current active user list for the shared file, and employee training records.\u003C\u002Fli>\n\u003C\u002Fol>\n\n\u003Cp>Some of your corrective actions appear deficient:\u003C\u002Fp>\n\n\u003Cp>1. Specifically, in your firm’s response to observation 1A, the action level for microbial recovery in ISO 5 on the surface or glove remains \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU for surface and personnel fingertip samples, per updated SOP COR-POL-SA-0001, “Environmental\u002FPersonnel Monitoring Master Plan”, Table 3. In addition, 5.1.7.6.3 states, “Recoveries for ISO 5 Surface and\u002For Personnel Monitoring samples wherein recovery of \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU\u002Fplate is observed and an action limit \u003Cstrong>(b)(4)\u003C\u002Fstrong> will require the completion of an ISO 5 Low Level Recovery Report. The report will document \u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\n\n\u003Cp>Any microbial contamination in the ISO 5 area is considered an insanitary condition and is a serious concern. Upon recovery, your firm should immediately assess the impact on drug products produced. This assessment should include a thorough evaluation of how contamination could have entered this critical area, and over what period of time the contamination could have existed, as well as drug products that remain on the market that could be affected. Your response failed to ensure a thorough investigation will be performed for any microbial recovery in the ISO 5 environment (e.g., air, surface, and glove) regardless of organism type.\u003C\u002Fp>\n\n\u003Cp>2. In your response to observation 1D, your firm created an SOP to ensure an incident report is initiated in response to work orders when appropriate. However, your firm’s documentation supporting your retrospective investigations was lacking or unclear. Specifically, regarding IR-08345 for WO-005406, it is unclear if the ISO 5 hood pressure gauge is checked prior to starting the batch. However, your investigation report notes the batch record states to make sure the hood is “on” and “working”. Your procedure, NJ-SOP-SA-0008, was not provided to show the requirement to “report any atypical findings such as loss of pressure or damage to PEC,” prior to starting the batch, therefore it was unclear whether the product impact assessment covered an adequate timeframe. It is also not clear whether smoke studies were performed as part of your hood recertification when the impeller was replaced, as no documentation was provided of such. In addition, regarding IR-08346\u002FDEV-01847 for suspected drug splash in the ISO 5 hood, WO-005828 noted on July 23, 2022, that personnel took off the screen to inspect the HEPA filter, and found a 1 inch by half inch light brown stain in the center section. WO-005828 further notes that the stainless grate was cleaned, and a sign was put on the hood to say out of service. WO-005828 does not appear to align with your firm’s IR-08346\u002FDEV-01847 investigation which states when the filter was examined in September 2022, no residue was observed, and no further action was required. From the information provided, it is unclear whether your firm performed adequate investigations.\u003C\u002Fp>\n\n\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. See 21 CFR 210.1(b), 21 CFR 200.10(b).\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter #675685 and include FEI #3013931875.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact CAPT Liatte Closs, Compliance Officer, at Liatte.Closs@fda.hhs.gov and courtesy copy ORAPHARM1_Responses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Stuart Hinchen\n\nRecipient Title\n\nCEO\n\nQuVa Pharma, Inc.\n\n3 Sugar Creek Center Blvd, Suite 250\n\nSugar Land, TX 77478\n\nUnited States\n\nstuart.hinchen@quvapharma.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nWL # 675685\n\nJanuary 26, 2024\n\nDear Mr. Hinchen:\n\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on September 15, 2017, and most recently on December 14, 2023. From August 16, 2022, to October 14, 2022, FDA investigators inspected your facility, QuVa Pharma, Inc., located at 519 State Route 173, Bloomsbury, NJ 08804. During the inspection, the investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\n\nFDA issued a Form FDA 483 to your facility on October 14, 2022. FDA acknowledges receipt of your facility’s response, dated November 4, 2022, as well as your subsequent correspondence. FDA also acknowledges that, on September 20, 2022, your facility initiated a voluntary recall of oxytocin 30 Units\u002F500 mL (0.06 Units\u002FmL) added to 0.9% Sodium Chloride, Injection for IV Use, Lot # 30027403, due to incorrect product formulation. Based on this inspection, it appears you produced drugs that violate the FDCA.\n\nA. Compounded Drug Products under the FDCA\n\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.2\n\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\n\nB. Violations of the FDCA\n\nAdulterated Drug Products\n\nFDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed:\n\nYou did not perform adequate product evaluation and take appropriate corrective actions after mold was recovered on operator glove finger plate samples taken after aseptic operations within the ISO 5 area.\n\nAn operator placing their upper left side of their body into the ISO 5 hood within the syringe filler. In addition, another operator was observed placing their sleeves, chest, and forehead under the ISO 5 hood.\n\nFDA investigators also noted CGMP violations at your facility, that caused your drug product(s) to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\n\nYour firm failed to follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nYour firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\n\nYour firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they are purport or are represented to possess (21 CFR 211.100(a)).\n\nYour firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\n\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\n\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nC. Corrective Actions\n\nWe have reviewed your facility’s responses to the Form FDA 483. We acknowledge your recall of oxytocin 30 Units\u002F500 mL (0.06 Units\u002FmL) added to 0.9% Sodium Chloride, Injection for IV Use, Lot # 30027403, due to incorrect product formulation, on September 20, 2022.\n\nWe have reviewed your facility’s responses to the Form FDA 483. Some of your corrective actions appear adequate; however, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\n\nRegarding observation 5B(i), you note personnel monitoring (PM) sampling of the forearm added in NJ-SOP-SA-0010 “Environmental Monitoring (b)(4) Filler”, section 5.2.5.1.1 states “(b)(4) samples to be taken representing (b)(4) locations and conditions at the conclusion of filling operations. Selected sample locations include...samples of the (b)(4).” Your firm has not provided documentation of environmental monitoring (EM) results in these locations to demonstrate current controls are adequate.\n\nIn your response to observation 3, your firm performed a document change request CR-15631 to update NJ-SOP-QA-0011, “Performing Acceptable Quality Limit Inspections”, to remove the reference to ‘excessive liquid in the ribs’ as a minor defect. Your firm’s response lacks justification and supporting documentation for the rationale to remove “Excessive Liquid Between Plunger Ribs (Over (b)(4) of the rib)” as a minor defect. Also, your response failed to provide an example of a master batch record to show where operators are to identify and record defects related to leaking syringes. In addition, your firm did not provide sufficient information regarding the training provided to your employees, instead your firm provided a signed sheet.\n\nIn your response to observation 4A, you provided updated procedures that require user login with (b)(4). However, you failed to provide the attachments with these updated procedures, trained personnel, batch records, and associated test slip as documentation that individual logins are now implemented. Also, in your response to observation 4B, you failed to provide the change control record, including the current active user list for the shared file, and employee training records.\n\nSome of your corrective actions appear deficient:\n\n1. Specifically, in your firm’s response to observation 1A, the action level for microbial recovery in ISO 5 on the surface or glove remains (b)(4) CFU for surface and personnel fingertip samples, per updated SOP COR-POL-SA-0001, “Environmental\u002FPersonnel Monitoring Master Plan”, Table 3. In addition, 5.1.7.6.3 states, “Recoveries for ISO 5 Surface and\u002For Personnel Monitoring samples wherein recovery of (b)(4) CFU\u002Fplate is observed and an action limit (b)(4) will require the completion of an ISO 5 Low Level Recovery Report. The report will document (b)(4).”\n\nAny microbial contamination in the ISO 5 area is considered an insanitary condition and is a serious concern. Upon recovery, your firm should immediately assess the impact on drug products produced. This assessment should include a thorough evaluation of how contamination could have entered this critical area, and over what period of time the contamination could have existed, as well as drug products that remain on the market that could be affected. Your response failed to ensure a thorough investigation will be performed for any microbial recovery in the ISO 5 environment (e.g., air, surface, and glove) regardless of organism type.\n\n2. In your response to observation 1D, your firm created an SOP to ensure an incident report is initiated in response to work orders when appropriate. However, your firm’s documentation supporting your retrospective investigations was lacking or unclear. Specifically, regarding IR-08345 for WO-005406, it is unclear if the ISO 5 hood pressure gauge is checked prior to starting the batch. However, your investigation report notes the batch record states to make sure the hood is “on” and “working”. Your procedure, NJ-SOP-SA-0008, was not provided to show the requirement to “report any atypical findings such as loss of pressure or damage to PEC,” prior to starting the batch, therefore it was unclear whether the product impact assessment covered an adequate timeframe. It is also not clear whether smoke studies were performed as part of your hood recertification when the impeller was replaced, as no documentation was provided of such. In addition, regarding IR-08346\u002FDEV-01847 for suspected drug splash in the ISO 5 hood, WO-005828 noted on July 23, 2022, that personnel took off the screen to inspect the HEPA filter, and found a 1 inch by half inch light brown stain in the center section. WO-005828 further notes that the stainless grate was cleaned, and a sign was put on the hood to say out of service. WO-005828 does not appear to align with your firm’s IR-08346\u002FDEV-01847 investigation which states when the filter was examined in September 2022, no residue was observed, and no further action was required. From the information provided, it is unclear whether your firm performed adequate investigations.\n\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. See 21 CFR 210.1(b), 21 CFR 200.10(b).\n\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\n\nD. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\n\nSend your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter #675685 and include FEI #3013931875.\n\nIf you have questions regarding the contents of this letter, please contact CAPT Liatte Closs, Compliance Officer, at Liatte.Closs@fda.hhs.gov and courtesy copy ORAPHARM1_Responses@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations\n\n__________________________\n\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\n\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.","QuVa Pharma, Inc.","quva-pharma-inc-675685-01262024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fquva-pharma-inc-675685-01262024","2026-10-26T08:09:46.281002+00:00","2024-02-13","675685","Division of Pharmaceutical Quality Operations I","Mr. Stuart Hinchen","2026-08-20T00:18:48.779+00:00","2024-01-26",{"id":289,"raw":290,"subject":77,"body_html":294,"body_text":295,"firm_name":296,"letter_id":297,"created_at":298,"fei_number":19,"letter_url":299,"updated_at":300,"action_type":22,"case_status":23,"posted_date":301,"marcs_cms_no":302,"product_type":47,"closeout_date":19,"issuing_office":76,"recipient_name":303,"body_fetched_at":304,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":305,"medical_device_id":19,"response_letter_date":19},2267,[291,292,293,76,77,13,13,13],"\u003Ctime datetime=\"2023-01-06T15:00:00Z\">01\u002F06\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-05T05:00:00Z\">01\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpharmacanna-647390-01052023\">PharmaCanna\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Johnny H. Meier\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>PharmaCanna\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2615 State Road 7 Suite B530\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wellington\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33414\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@pharmacanna.us\"> info@pharmacanna.us\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 647390\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: January 5, 2023\u003Cbr>\n\u003Cbr>\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fwww.pharmacanna.com on November 30, 2022, and January 3, 2023, respectively. We also reviewed your Facebook and YouTube social media websites at https:\u002F\u002Fwww.facebook.com\u002Fpharmacanna and https:\u002F\u002Fwww.youtube.com\u002F@pharmacannacbdbypharmacist543, where you direct consumers to your website, https:\u002F\u002Fwww.pharmacanna.com to purchase your cannabinoid products, including the CBDefense 2000 product. The FDA has observed that your website offers the CBDefense 2000 product for sale in the United States and that this product is intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, this product is an unapproved new drug sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website and social media that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CBDefense 2000 - Virus Protective Formula . . . This revolutionary virus fighting product contains the two cannabinoids, CBDa &amp; CBGa, that has been shown through a published study to keep covid from infecting human cells. These two acidic hemp molecules assist in blocking the ability of the virus to attach to human cells.” [From your product webpage https:\u002F\u002Fwww.pharmacanna.com\u002Fproducts\u002Fcbdefense-2000]\u003C\u002Fli>\n\t\u003Cli>“COVID prevention with CBD? Canada study shows it's possible. Might be time to start a daily dose of PharmaCanna's all-natural pharmaceutical grade CBD products…. USE CODE: COV19” [from a May 15, 2020, post on your Facebook social media webpage https:\u002F\u002Fwww.facebook.com\u002Fpharmacanna]\u003C\u002Fli>\n\t\u003Cli>“ATTN: PHARMACY OWNERS RE: COVID&nbsp; If you are dealing with patients looking for covid vaccines, covid tests, and anything related to anti-covid, then PharmaCanna may have the revolutionary product for your patients. We introduce CBDefense 2000 with 1000mg of CBD\u002FCBDA and 1000mg of CBG\u002FCBGA. . . . From the recently published study. . . : ‘Two cannabinoids with the highest affinities for the spike protein, cannabidiolic acid (CBDA) and cannabigerolic acid (CBGA), were confirmed to block infection of human epithelial cells by a pseudovirus expressing the spike protein. More importantly, both CBDA and CBGA block infection of the original live SARS-CoV-2 virus and variants of concern, including the B.1.1.7 and B.1.351.’” [from a February 3, 2022, post on your Facebook social media webpage https:\u002F\u002Fwww.facebook.com\u002Fpharmacanna]\u003C\u002Fli>\n\t\u003Cli>“Our CBDefense 2000, anti-covid formula, is Now Available. . . Use Code: DEFENSE” [from a March 9, 2022, post on your Facebook social media webpage https:\u002F\u002Fwww.facebook.com\u002Fpharmacanna]\u003C\u002Fli>\n\t\u003Cli>“[S]o we’ve announced recently about our CBDefense which is the that [sic] contains the two active ingredients that’s in that product is the acidic version of cbd and cbg which would be cbda and cbga and those are two ingredients according to a published study that came out of Oregon state university that has shown that those two cannabinoids are attaching to the protein spikes or I should say the spike proteins of covid so basically not allowing covid to infect human cells so we’re super excited.” [From a March 10, 2022, video titled “PharmaCanna Phamily Update #3 - FREE CBD for a Year,” posted on your YouTube social media website https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=UPMOp8zlljU]\u003C\u002Fli>\n\t\u003Cli>“[F]or those of you out there that are interested in uh just boosting your covid fighting uh properties in your body uh we’ll be doing CBDefense at 30 percent off using the code defense so [it will] be DEFENSE.” [From a March 10, 2022, video titled “PharmaCanna Phamily Update #3 - FREE CBD for a Year,” posted on your YouTube social media website https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=UPMOp8zlljU]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You should take immediate action to address this matter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours,&nbsp;\u003C\u002Fstrong>\u003Cstrong>please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand: \u003C\u002Fstrong>In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the product identified above. Thus, any coronavirus-related prevention or treatment claims regarding such product are not supported by competent and reliable scientific evidence. You must immediately cease and desist making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Serena Viswanathan, Associate Director of the FTC’s Division of Advertising Practices, at sviswanathan@ftc.gov certifying that you have ceased making unsubstantiated claims for the product identified above. If you have any questions regarding compliance with the FTC Act, please contact Ms. Viswanathan at 202-326-3244.\u003C\u002Fp>\n\n\u003Cp>Sincerely,&nbsp;\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nActing Director&nbsp;\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Serena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJohnny H. Meier\n\nPharmaCanna\n\n2615 State Road 7 Suite B530\n\nWellington, FL 33414\n\nUnited States\n\ninfo@pharmacanna.us\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nRE: 647390\n\nDate: January 5, 2023\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fwww.pharmacanna.com on November 30, 2022, and January 3, 2023, respectively. We also reviewed your Facebook and YouTube social media websites at https:\u002F\u002Fwww.facebook.com\u002Fpharmacanna and https:\u002F\u002Fwww.youtube.com\u002F@pharmacannacbdbypharmacist543, where you direct consumers to your website, https:\u002F\u002Fwww.pharmacanna.com to purchase your cannabinoid products, including the CBDefense 2000 product. The FDA has observed that your website offers the CBDefense 2000 product for sale in the United States and that this product is intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, this product is an unapproved new drug sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your website and social media that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“CBDefense 2000 - Virus Protective Formula . . . This revolutionary virus fighting product contains the two cannabinoids, CBDa & CBGa, that has been shown through a published study to keep covid from infecting human cells. These two acidic hemp molecules assist in blocking the ability of the virus to attach to human cells.” [From your product webpage https:\u002F\u002Fwww.pharmacanna.com\u002Fproducts\u002Fcbdefense-2000]\n\n“COVID prevention with CBD? Canada study shows it's possible. Might be time to start a daily dose of PharmaCanna's all-natural pharmaceutical grade CBD products…. USE CODE: COV19” [from a May 15, 2020, post on your Facebook social media webpage https:\u002F\u002Fwww.facebook.com\u002Fpharmacanna]\n\n“ATTN: PHARMACY OWNERS RE: COVID If you are dealing with patients looking for covid vaccines, covid tests, and anything related to anti-covid, then PharmaCanna may have the revolutionary product for your patients. We introduce CBDefense 2000 with 1000mg of CBD\u002FCBDA and 1000mg of CBG\u002FCBGA. . . . From the recently published study. . . : ‘Two cannabinoids with the highest affinities for the spike protein, cannabidiolic acid (CBDA) and cannabigerolic acid (CBGA), were confirmed to block infection of human epithelial cells by a pseudovirus expressing the spike protein. More importantly, both CBDA and CBGA block infection of the original live SARS-CoV-2 virus and variants of concern, including the B.1.1.7 and B.1.351.’” [from a February 3, 2022, post on your Facebook social media webpage https:\u002F\u002Fwww.facebook.com\u002Fpharmacanna]\n\n“Our CBDefense 2000, anti-covid formula, is Now Available. . . Use Code: DEFENSE” [from a March 9, 2022, post on your Facebook social media webpage https:\u002F\u002Fwww.facebook.com\u002Fpharmacanna]\n\n“[S]o we’ve announced recently about our CBDefense which is the that [sic] contains the two active ingredients that’s in that product is the acidic version of cbd and cbg which would be cbda and cbga and those are two ingredients according to a published study that came out of Oregon state university that has shown that those two cannabinoids are attaching to the protein spikes or I should say the spike proteins of covid so basically not allowing covid to infect human cells so we’re super excited.” [From a March 10, 2022, video titled “PharmaCanna Phamily Update #3 - FREE CBD for a Year,” posted on your YouTube social media website https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=UPMOp8zlljU]\n\n“[F]or those of you out there that are interested in uh just boosting your covid fighting uh properties in your body uh we’ll be doing CBDefense at 30 percent off using the code defense so [it will] be DEFENSE.” [From a March 10, 2022, video titled “PharmaCanna Phamily Update #3 - FREE CBD for a Year,” posted on your YouTube social media website https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=UPMOp8zlljU]\n\nYou should take immediate action to address this matter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the product identified above. Thus, any coronavirus-related prevention or treatment claims regarding such product are not supported by competent and reliable scientific evidence. You must immediately cease and desist making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Serena Viswanathan, Associate Director of the FTC’s Division of Advertising Practices, at sviswanathan@ftc.gov certifying that you have ceased making unsubstantiated claims for the product identified above. If you have any questions regarding compliance with the FTC Act, please contact Ms. Viswanathan at 202-326-3244.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nActing Director\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n________________________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","PharmaCanna","pharmacanna-647390-01052023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpharmacanna-647390-01052023","2026-10-26T08:09:41.116692+00:00","2023-01-06","647390","Johnny H. Meier","2026-08-20T01:20:17.106+00:00","2023-01-05",{"id":307,"raw":308,"subject":122,"body_html":313,"body_text":314,"firm_name":315,"letter_id":316,"created_at":204,"fei_number":19,"letter_url":317,"updated_at":318,"action_type":22,"case_status":107,"posted_date":319,"marcs_cms_no":320,"product_type":47,"closeout_date":321,"issuing_office":76,"recipient_name":322,"body_fetched_at":323,"delivery_method":247,"recipient_title":19,"reference_number":324,"action_taken_date":325,"medical_device_id":19,"response_letter_date":19},1516,[309,310,311,76,122,13,312,13],"\u003Ctime datetime=\"2024-04-16T13:20:00Z\">04\u002F16\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-08T04:00:00Z\">04\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnatco-pharma-limited-672564-04082024\">Natco Pharma Limited\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnatco-pharma-limited-672564-09252025\">\u003Ctime datetime=\"2025-09-29T04:00:00Z\">09\u002F29\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-24-32\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Rajeev Nannapaneni\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice Chairman and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Natco Pharma Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Natco House Road No: 2, Banjara Hills\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hyderabad\u003C\u002Fspan> \u003Cspan>500034\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-32\u003C\u002Fp>\n\n\u003Cp>April 8, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Nannapaneni:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Natco Pharma Limited, FEI 3004540906, at Kothur Village Rangareddy, Telangana, India, from October 9 to 18, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your November 8, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your cleaning procedure for your non-dedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment is inadequate. Our investigators observed residue inside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and throughout the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of two non-dedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, identified as VS\u002F034 and T\u002F020, and labeled as “cleaned.” You confirmed the presence of multiple active pharmaceutical ingredients (APIs) with values higher than your allowable limit when you sampled and tested these residues. You swabbed similar areas of other \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment and also identified residues of various API throughout the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In your response, you state a potential cause for API residues found in \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment is due to higher \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Further, your assessment concluded \u003Cstrong>(b)(4)\u003C\u002Fstrong> tablets manufactured in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> VS\u002F034 are not contaminated with other API residues. Additionally, your response mentions that in August 2022, you implemented a \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning process to clean the \u003Cstrong>(b)(4)\u003C\u002Fstrong> upstream of your \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, this cleaning process was implemented for only 3 of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in drug production.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Cross-contamination is not uniform, and your testing of control samples and placebo batches failed to scientifically prove that your products are free of contaminants from your visibly dirty equipment. You do not sufficiently address contamination recovered from product contact surfaces, and you fail to acknowledge that other locations and other sampling may reveal high levels of contamination. Your reserve sample testing alone is insufficient to determine the scope of the cross-contamination issue and mitigate risks associated with it. A failure to adequately clean \u003Cstrong>(b)(4)\u003C\u002Fstrong> units may lead to cross-contamination between drug products.\u003C\u002Fp>\n\n\u003Cp>You do not provide interim control of equipment cleaning for the remaining \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to manufacture your drug products. You have not submitted your finished drug products test results to determine the impact of cross-contamination observed during the inspection.\u003C\u002Fp>\n\n\u003Cp>Your response also fails to address the presence of unknown peaks obtained from swab samples collected from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an expanded assessment to determine whether cross-contaminated product batches may have been released for distribution. The assessment should identify any inadequacies in cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\n\t\u003Cli>A corrective action and preventive action (CAPA) plan, based on the retrospective assessment, includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o In addition to this holistic remediation, provide specific CAPA activities that are being undertaken to effectively remediate the conditions that caused the specific cross-contamination incidents discussed above. Provide an independent review by your consultant that determines the effectiveness of your CAPA, including but not limited to:\u003Cbr>\n\u003Cbr>\n A list of all enhancements to cleaning and maintenance procedures including specific frequencies and locations to be cleaned in all relevant equipment (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003Cbr>\n Identify any other sources of cross contamination other than \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\n Determine the adequacy of your analytical methodology to identify residual carryover.\u003Cbr>\n Your investigations into the unknown (unidentified) peaks detected in your reserve samples.\u003Cbr>\n Supporting evidence to demonstrate that the challenges identified during your study, such as interference of product matrix and co-eluting peaks, were adequately resolved.\u003Cbr>\n Adequacy of scope of the investigation and its related CAPA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s investigations into unexplained discrepancies were inadequate. Your quality unit (QU) failed to thoroughly investigate all finished product batches and components associated with unexplained discrepancies. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your investigation related to missing batch record pages for \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg powder batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> lacked evidence to support your conclusion. \u003Cstrong>(b)(4)\u003C\u002Fstrong> critical manufacturing steps were recorded 25 days after production. You concluded that the most probable cause was the inattention of your manufacturing operators.\u003C\u002Fli>\n\t\u003Cli>Your firm initiated an investigation due to missing sample weight balance printouts of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tablets batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You changed the sample weight 22 days after analysis. You concluded that the most probable cause was analyst error.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You concluded your investigations without a root cause determination supported by evidence or initiating CAPA.\u003C\u002Fp>\n\n\u003Cp>The inspection also documented questionable practices regarding the disposition and destruction of CGMP records by employees.\u003C\u002Fp>\n\n\u003Cp>In your response, you commit to conduct a review of all investigations from January 2021 to the end of 2023. Your response also indicates you hired a third-party consultant to perform an assessment of your documentation system.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. Your response does not include the protocol followed and lacks a comprehensive assessment into the type and extent of records destroyed.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, discrepancies, failure, and records management system. Provide a detailed action plan to remediate your quality system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance unit oversight, and written procedures. Address how your firm will ensure that all phases of investigations are conducted appropriately.\u003C\u002Fli>\n\t\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether staff possesses proper investigation competencies, effectively conducts root cause analysis, and assures CAPA effectiveness. Also, determine whether your quality system ensures you regularly review investigation trends, implement improvements to the CAPA program when needed, ensure appropriate quality unit decision rights, and receive full executive management that promotes timely lifecycle manufacturing improvements.\u003C\u002Fli>\n\t\u003Cli>Submit a full report of the holistic assessment for the inadequacy of investigations and lacking CGMP documentation control for all batches produced from January 2021 until the end of 2023 intended for the U.S. market.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to temporarily suspend production of all drugs manufactured on all dedicated and non-dedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment for the U.S. market while you remediate the CGMP violations.\u003C\u002Fp>\n\n\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Natco Pharma Limited at Kothur Village Rangareddy, India into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004540906 and ATTN: Rafael E. Arroyo.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-24-32\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Rajeev Nannapaneni\n\nRecipient Title\n\nVice Chairman and CEO\n\nNatco Pharma Limited\n\nNatco House Road No: 2, Banjara Hills\n\nHyderabad 500034\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWarning Letter 320-24-32\n\nApril 8, 2024\n\nDear Mr. Nannapaneni:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Natco Pharma Limited, FEI 3004540906, at Kothur Village Rangareddy, Telangana, India, from October 9 to 18, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your November 8, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\n\nYour cleaning procedure for your non-dedicated (b)(4) equipment is inadequate. Our investigators observed residue inside the (b)(4) and throughout the (b)(4) of two non-dedicated (b)(4), identified as VS\u002F034 and T\u002F020, and labeled as “cleaned.” You confirmed the presence of multiple active pharmaceutical ingredients (APIs) with values higher than your allowable limit when you sampled and tested these residues. You swabbed similar areas of other (b)(4) equipment and also identified residues of various API throughout the (b)(4).\n\nIn your response, you state a potential cause for API residues found in (b)(4) equipment is due to higher (b)(4). Further, your assessment concluded (b)(4) tablets manufactured in the (b)(4) VS\u002F034 are not contaminated with other API residues. Additionally, your response mentions that in August 2022, you implemented a (b)(4) cleaning process to clean the (b)(4) upstream of your (b)(4). However, this cleaning process was implemented for only 3 of the (b)(4) used in drug production.\n\nYour response is inadequate. Cross-contamination is not uniform, and your testing of control samples and placebo batches failed to scientifically prove that your products are free of contaminants from your visibly dirty equipment. You do not sufficiently address contamination recovered from product contact surfaces, and you fail to acknowledge that other locations and other sampling may reveal high levels of contamination. Your reserve sample testing alone is insufficient to determine the scope of the cross-contamination issue and mitigate risks associated with it. A failure to adequately clean (b)(4) units may lead to cross-contamination between drug products.\n\nYou do not provide interim control of equipment cleaning for the remaining (b)(4) used to manufacture your drug products. You have not submitted your finished drug products test results to determine the impact of cross-contamination observed during the inspection.\n\nYour response also fails to address the presence of unknown peaks obtained from swab samples collected from the (b)(4) of (b)(4).\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an expanded assessment to determine whether cross-contaminated product batches may have been released for distribution. The assessment should identify any inadequacies in cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\nA corrective action and preventive action (CAPA) plan, based on the retrospective assessment, includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\no In addition to this holistic remediation, provide specific CAPA activities that are being undertaken to effectively remediate the conditions that caused the specific cross-contamination incidents discussed above. Provide an independent review by your consultant that determines the effectiveness of your CAPA, including but not limited to:\n\n A list of all enhancements to cleaning and maintenance procedures including specific frequencies and locations to be cleaned in all relevant equipment (e.g., (b)(4)).\n\n Identify any other sources of cross contamination other than (b)(4) equipment, (b)(4) and (b)(4).\n\n Determine the adequacy of your analytical methodology to identify residual carryover.\n\n Your investigations into the unknown (unidentified) peaks detected in your reserve samples.\n\n Supporting evidence to demonstrate that the challenges identified during your study, such as interference of product matrix and co-eluting peaks, were adequately resolved.\n\n Adequacy of scope of the investigation and its related CAPA.\n\n2. Your firm failed to thoroughly investigate any discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour firm’s investigations into unexplained discrepancies were inadequate. Your quality unit (QU) failed to thoroughly investigate all finished product batches and components associated with unexplained discrepancies. For example:\n\nYour investigation related to missing batch record pages for (b)(4) mg powder batch (b)(4) lacked evidence to support your conclusion. (b)(4) critical manufacturing steps were recorded 25 days after production. You concluded that the most probable cause was the inattention of your manufacturing operators.\n\nYour firm initiated an investigation due to missing sample weight balance printouts of (b)(4) Tablets batch (b)(4). You changed the sample weight 22 days after analysis. You concluded that the most probable cause was analyst error.\n\nYou concluded your investigations without a root cause determination supported by evidence or initiating CAPA.\n\nThe inspection also documented questionable practices regarding the disposition and destruction of CGMP records by employees.\n\nIn your response, you commit to conduct a review of all investigations from January 2021 to the end of 2023. Your response also indicates you hired a third-party consultant to perform an assessment of your documentation system.\n\nYour response is inadequate. Your response does not include the protocol followed and lacks a comprehensive assessment into the type and extent of records destroyed.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, discrepancies, failure, and records management system. Provide a detailed action plan to remediate your quality system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance unit oversight, and written procedures. Address how your firm will ensure that all phases of investigations are conducted appropriately.\n\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether staff possesses proper investigation competencies, effectively conducts root cause analysis, and assures CAPA effectiveness. Also, determine whether your quality system ensures you regularly review investigation trends, implement improvements to the CAPA program when needed, ensure appropriate quality unit decision rights, and receive full executive management that promotes timely lifecycle manufacturing improvements.\n\nSubmit a full report of the holistic assessment for the inadequacy of investigations and lacking CGMP documentation control for all batches produced from January 2021 until the end of 2023 intended for the U.S. market.\n\nDrug Production Suspended\n\nWe acknowledge your commitment to temporarily suspend production of all drugs manufactured on all dedicated and non-dedicated (b)(4) equipment for the U.S. market while you remediate the CGMP violations.\n\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Natco Pharma Limited at Kothur Village Rangareddy, India into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004540906 and ATTN: Rafael E. Arroyo.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n______________________\n\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Natco Pharma Limited","natco-pharma-limited-672564-04082024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnatco-pharma-limited-672564-04082024","2026-10-26T08:09:30.012432+00:00","2024-04-16","672564","2025-09-29","Mr. Rajeev Nannapaneni","2026-08-20T00:10:53.869+00:00","320-24-32","2024-04-08",{"id":327,"raw":328,"subject":99,"body_html":331,"body_text":332,"firm_name":333,"letter_id":334,"created_at":104,"fei_number":19,"letter_url":335,"updated_at":336,"action_type":22,"case_status":107,"posted_date":108,"marcs_cms_no":337,"product_type":110,"closeout_date":338,"issuing_office":96,"recipient_name":339,"body_fetched_at":340,"delivery_method":341,"recipient_title":19,"reference_number":19,"action_taken_date":115,"medical_device_id":19,"response_letter_date":19},3144,[93,94,329,96,97,13,330,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpharmaganics-llc-614576-09072021\">Pharmaganics LLC\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpharmaganics-llc-614576-01122022\">\u003Ctime datetime=\"2022-12-18T05:00:00Z\">12\u002F18\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tom Redmond III\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Pharmaganics LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8475 Parley Lake Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Waconia\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55387\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@diabetesdoctor.com\"> info@diabetesdoctor.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>RE: 614576\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Tom Redmond III:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.diabetesdoctor.com, in August 2021 and has determined that you take orders there for your “Diabetes Doctor Pre-Diabetes” and “Diabetes Doctor Blood Sugar 24 Hour” products. We have also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002Fnaturaldiabetesdoctor and https:\u002F\u002Fwww.instagram.com\u002Fdiabetesdoctor\u002F, which direct consumers to your website www.diabetesdoctor.com to purchase your products. Additionally, we reviewed products listings and seller profile on your Walmart webpage on https:\u002F\u002Fwww.walmart.com\u002F, and your product listings and seller profile on your Amazon storefront on https:\u002F\u002Fwww.Amazon.com, both which you operate under the name, “Diabetes Doctor”. You are also advised that the Federal Trade Commission reviewed your websites in August 2021.\u003C\u002Fp>\n\n\u003Cp>The claims on your website, social media webpages, Amazon storefront, and Walmart webpage establish that your products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>On your “Diabetes Doctor Pre-Diabetes” product page on your website:\u003Cbr>\n• “Fights Insulin Resistance”\u003Cbr>\n• “Maintain healthy function of vital diabetes organs”\u003Cbr>\n• “Curcumin\u002FTurmeric [ingredient in product]…In a research study of people with pre- diabetes, taking curcumin for 9-months significantly reduced the number of prediabetic individuals who eventually developed Type 2 diabetes. Curcumin treatment appeared to support healthy function of β-cells, the insulin producing cells of the pancreas.”\u003Cbr>\n• “Magnesium [ingredient in product]...Research shows that a 100 mg\u002Fday increase in magnesium intake is associated with a 15% risk reduction for developing type 2 diabetes…”\u003Cbr>\n• “Vitamin D3 [ingredient in product] Clinical research has demonstrated that in people without diabetes, increasing blood levels of vitamin D is associated with a lower risk of developing type 2 diabetes. Our formula uses the activated form of Vitamin D (D3).”\u003C\u002Fp>\n\n\u003Cp>On your “Diabetes Doctor Blood Sugar 24 Hour” product page on your website:\u003Cbr>\n• “Studies have shown cassia cinnamon [ingredient in product] at high doses can reduce fasting blood sugars by 25mg\u002FdL\u003Cbr>\n• “Milk Thistle [ingredient in product] … has been clinically proven to fight resistance for significant benefits on blood sugar health”\u003Cbr>\n&nbsp; o “Lower fasting blood sugars by 11%”\u003Cbr>\n&nbsp; o “Lower insulin needs by 14%”\u003Cbr>\n&nbsp; o “Lower HbA1C by 1.5%”\u003Cbr>\n&nbsp; o “Lower abnormal liver enzymes in patients with non-alcoholic fatty liver disease”\u003Cbr>\n&nbsp; o “Lower protein in the urine (marker of kidney damage) in patients with diabetic kidney disease”\u003Cbr>\n• “Bilberry [ingredient in product] …shown improved retinal (eye) circulatory health in adults with diabetic retinopathy after 6 months”\u003Cbr>\n• “Banaba [ingredient in product] acts as a natural insulin sensitizer to support healthy blood sugar and A1C . …[B]anaba can reduce blood sugars by 30%, and A1C by 0.65%”\u003C\u002Fp>\n\n\u003Cp>On your social media Facebook page:\u003Cbr>\n• “Research shows that cinnamon [ingredient in product] does NOT work to lower blood sugars….. unless used at doses of 500-1000 mg\u002Fday! Blood Sugar 24 Hour Support includes Cinnamon at the right dose (750 mg\u002Fday)” [August 4, 2020]\u003Cbr>\n• In the comments an individual asks, “Can this be taken as a diabetes preventative?” and Diabetes Doctor responds with “Check out our products for Pre Diabetes https:\u002F\u002Fdiabetesdoctor.com\u002Fcollections\u002Fpre-diabetes” [August 4, 2020]\u003Cbr>\n\u003Cbr>\nOn your social media Instagram page:\u003Cbr>\n• “[C]omprehensive product that is designed to help you meet your daily diabetes needs from blood sugar control to diabetes specific organ health …. help that insulin function better and cut through insulin resistance …” [March 5, 2021]\u003C\u002Fp>\n\n\u003Cp>On your Amazon.com storefront product page for your “Diabetes Doctor Pre-Diabetes” product:\u003Cbr>\n• “Diabetes Doctor Early Defense – Pre-Diabetes and Diabetes Support … Stabilize Blood Sugar Levels”\u003Cbr>\n• PROMOTES GOOD HEALTH: “Early Defense is specially designed to support your prediabetes needs.”\u003Cbr>\n• “ESSENTIAL NUTRIENTS: Early Defense contains a blend of key ingredients like Magnesium and Vitamin D3 [ingredients in the product] that are critical in diabetes health.”\u003C\u002Fp>\n\n\u003Cp>On your Amazon.com storefront product page for your “Diabetes Doctor Blood Sugar 24 Hour” product:\u003Cbr>\n• “Diabetes Doctor Daily Support – 7 in 1 Blend for Daily Diabetes Needs and High Blood Sugar Regulation - Target Insulin Resistance and Sensitivity, Organ Health …”\u003Cbr>\n• “REVOLUTIONARY BLEND AND HIGH DOSES: … natural ingredients needed for daily Diabetes support and blood sugar regulation”\u003Cbr>\n• “COMBAT INSULATION RESISTANCE: Diabetes Doctor's powerful blend of Cinnamon, Banaba, Magnesium, and Chromium helps promote healthy insulin function …”\u003C\u002Fp>\n\n\u003Cp>On your Walmart.com product listing page for “Diabetes Doctor Blood Sugar 24 Hour”:\u003Cbr>\n• “Take control of your diabetes naturally with the help of Blood Sugar 24 hour Supplement by Diabetes Doctor. Help maintain healthy blood sugar levels …which helps your body’s natural insulin work better.”\u003Cbr>\n• “This product is not only a multivitamin but has been specifically designed to target the root cause of high blood sugar and Type 2 diabetes”\u003C\u002Fp>\n\n\u003Cp>Your “Diabetes Doctor Pre-Diabetes” and “Diabetes Doctor Blood Sugar 24 Hour” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product “Diabetes Doctor Pre-Diabetes” and “Diabetes Doctor Blood Sugar 24 Hour” products are intended for treatment of one or more diseases that, with certain exceptions not applicable here, are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, your “Diabetes Doctor Pre-Diabetes” and “Diabetes Doctor Blood Sugar 24 Hour” products fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply to the above violations should be directed to Aaron Dotson with the FDA via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> In addition, the Federal Trade Commission has determined that it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess a reasonable basis consisting of competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. POM Wonderful LLC, 155 F.T.C. 1, 60-61, (2013), aff’d in relevant part, 777 F.3d 478 (D.C. Cir. 2015); Daniel Chapter One, FTC Dkt. No. 9239, 2009 WL 5160000 at *16-19 (F.T.C. Dec. 24, 2009), aff’d, 405 Fed. Appx.505 (D.C. Cir. 2010); Removatron Int'l Corp., 111 F.T.C. 206, 297-99 (1988), aff’d, 884 F.2d 1489, 1496 (1st Cir. 1989); see also, FTC v. Direct Mktg. Concepts, 569 F. Supp. 2d 285, 300, 303 (D. Mass. 2008), aff’d, 624 F.3d 1 (1st Cir. 2010); FTC v. Nat'l Urological Group, Inc., 645 F. Supp. 2d 1167, 1190, 1202 (N.D. Ga. 2008), aff’d, 356 Fed. Appx. 358 (11th Cir. 2009); FTC v. Natural Solution, Inc., No. CV 06-6112-JFW, 2007-2 Trade Cas. (CCH) P75,866, 2007 U.S. Dist. LEXIS 60783, at *11-12 (C.D. Cal. Aug. 7, 2007). More generally, to make or exaggerate such claims, whether directly or indirectly, through the use of a product name, website name, metatags, or other means, without rigorous scientific evidence sufficient to substantiate the claims, violates the FTC Act. See Daniel Chapter One, WL 5160000 at *17-19.\u003C\u002Fp>\n\n\u003Cp>The FTC is concerned that one or more of the efficacy claims cited above may not be substantiated by competent and reliable scientific evidence. Notice is hereby given that you must cease and desist from making any claim that a product and prevent, treat, or cure diabetes without competent and reliable scientific evidence consisting of well-controlled human clinical studies substantiating that the claims are true. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction or Administrative Cease and Desist Order. In addition, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of a disease may be subject to a civil penalty of up to $43,792 per violation pursuant to Section 5(m)(1)(B) of the FTC Act, 15 U.S.C. § 45(m)(1)(B), and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). With regard to the advertising claims discussed above, please notify Richard Cleland of the FTC via electronic mail at rcleland@ftc.gov within fifteen (15) working days of receipt of this letter of the specific actions you have taken to address FTC’s concerns.\u003C\u002Fp>\n\n\u003Cp>Sincerely,&nbsp;\u003Cbr>\n\u002FS\u002F\u003Cbr>\nGlenn Bass\u003Cbr>\nActing Deputy Director\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety\u003Cbr>\n&nbsp; &nbsp;and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,&nbsp;\u003Cbr>\n\u002FS\u002F\u003Cbr>\nSerena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nTom Redmond III\n\nRecipient Title\n\nCEO\n\nPharmaganics LLC\n\n8475 Parley Lake Rd\n\nWaconia, MN 55387\n\nUnited States\n\ninfo@diabetesdoctor.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nRE: 614576\n\nDear Mr. Tom Redmond III:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address, www.diabetesdoctor.com, in August 2021 and has determined that you take orders there for your “Diabetes Doctor Pre-Diabetes” and “Diabetes Doctor Blood Sugar 24 Hour” products. We have also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002Fnaturaldiabetesdoctor and https:\u002F\u002Fwww.instagram.com\u002Fdiabetesdoctor\u002F, which direct consumers to your website www.diabetesdoctor.com to purchase your products. Additionally, we reviewed products listings and seller profile on your Walmart webpage on https:\u002F\u002Fwww.walmart.com\u002F, and your product listings and seller profile on your Amazon storefront on https:\u002F\u002Fwww.Amazon.com, both which you operate under the name, “Diabetes Doctor”. You are also advised that the Federal Trade Commission reviewed your websites in August 2021.\n\nThe claims on your website, social media webpages, Amazon storefront, and Walmart webpage establish that your products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nOn your “Diabetes Doctor Pre-Diabetes” product page on your website:\n\n• “Fights Insulin Resistance”\n\n• “Maintain healthy function of vital diabetes organs”\n\n• “Curcumin\u002FTurmeric [ingredient in product]…In a research study of people with pre- diabetes, taking curcumin for 9-months significantly reduced the number of prediabetic individuals who eventually developed Type 2 diabetes. Curcumin treatment appeared to support healthy function of β-cells, the insulin producing cells of the pancreas.”\n\n• “Magnesium [ingredient in product]...Research shows that a 100 mg\u002Fday increase in magnesium intake is associated with a 15% risk reduction for developing type 2 diabetes…”\n\n• “Vitamin D3 [ingredient in product] Clinical research has demonstrated that in people without diabetes, increasing blood levels of vitamin D is associated with a lower risk of developing type 2 diabetes. Our formula uses the activated form of Vitamin D (D3).”\n\nOn your “Diabetes Doctor Blood Sugar 24 Hour” product page on your website:\n\n• “Studies have shown cassia cinnamon [ingredient in product] at high doses can reduce fasting blood sugars by 25mg\u002FdL\n\n• “Milk Thistle [ingredient in product] … has been clinically proven to fight resistance for significant benefits on blood sugar health”\n\no “Lower fasting blood sugars by 11%”\n\no “Lower insulin needs by 14%”\n\no “Lower HbA1C by 1.5%”\n\no “Lower abnormal liver enzymes in patients with non-alcoholic fatty liver disease”\n\no “Lower protein in the urine (marker of kidney damage) in patients with diabetic kidney disease”\n\n• “Bilberry [ingredient in product] …shown improved retinal (eye) circulatory health in adults with diabetic retinopathy after 6 months”\n\n• “Banaba [ingredient in product] acts as a natural insulin sensitizer to support healthy blood sugar and A1C . …[B]anaba can reduce blood sugars by 30%, and A1C by 0.65%”\n\nOn your social media Facebook page:\n\n• “Research shows that cinnamon [ingredient in product] does NOT work to lower blood sugars….. unless used at doses of 500-1000 mg\u002Fday! Blood Sugar 24 Hour Support includes Cinnamon at the right dose (750 mg\u002Fday)” [August 4, 2020]\n\n• In the comments an individual asks, “Can this be taken as a diabetes preventative?” and Diabetes Doctor responds with “Check out our products for Pre Diabetes https:\u002F\u002Fdiabetesdoctor.com\u002Fcollections\u002Fpre-diabetes” [August 4, 2020]\n\nOn your social media Instagram page:\n\n• “[C]omprehensive product that is designed to help you meet your daily diabetes needs from blood sugar control to diabetes specific organ health …. help that insulin function better and cut through insulin resistance …” [March 5, 2021]\n\nOn your Amazon.com storefront product page for your “Diabetes Doctor Pre-Diabetes” product:\n\n• “Diabetes Doctor Early Defense – Pre-Diabetes and Diabetes Support … Stabilize Blood Sugar Levels”\n\n• PROMOTES GOOD HEALTH: “Early Defense is specially designed to support your prediabetes needs.”\n\n• “ESSENTIAL NUTRIENTS: Early Defense contains a blend of key ingredients like Magnesium and Vitamin D3 [ingredients in the product] that are critical in diabetes health.”\n\nOn your Amazon.com storefront product page for your “Diabetes Doctor Blood Sugar 24 Hour” product:\n\n• “Diabetes Doctor Daily Support – 7 in 1 Blend for Daily Diabetes Needs and High Blood Sugar Regulation - Target Insulin Resistance and Sensitivity, Organ Health …”\n\n• “REVOLUTIONARY BLEND AND HIGH DOSES: … natural ingredients needed for daily Diabetes support and blood sugar regulation”\n\n• “COMBAT INSULATION RESISTANCE: Diabetes Doctor's powerful blend of Cinnamon, Banaba, Magnesium, and Chromium helps promote healthy insulin function …”\n\nOn your Walmart.com product listing page for “Diabetes Doctor Blood Sugar 24 Hour”:\n\n• “Take control of your diabetes naturally with the help of Blood Sugar 24 hour Supplement by Diabetes Doctor. Help maintain healthy blood sugar levels …which helps your body’s natural insulin work better.”\n\n• “This product is not only a multivitamin but has been specifically designed to target the root cause of high blood sugar and Type 2 diabetes”\n\nYour “Diabetes Doctor Pre-Diabetes” and “Diabetes Doctor Blood Sugar 24 Hour” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 C.F.R. 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product “Diabetes Doctor Pre-Diabetes” and “Diabetes Doctor Blood Sugar 24 Hour” products are intended for treatment of one or more diseases that, with certain exceptions not applicable here, are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, your “Diabetes Doctor Pre-Diabetes” and “Diabetes Doctor Blood Sugar 24 Hour” products fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply to the above violations should be directed to Aaron Dotson with the FDA via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nFTC Cease and Desist Demand: In addition, the Federal Trade Commission has determined that it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess a reasonable basis consisting of competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. POM Wonderful LLC, 155 F.T.C. 1, 60-61, (2013), aff’d in relevant part, 777 F.3d 478 (D.C. Cir. 2015); Daniel Chapter One, FTC Dkt. No. 9239, 2009 WL 5160000 at *16-19 (F.T.C. Dec. 24, 2009), aff’d, 405 Fed. Appx.505 (D.C. Cir. 2010); Removatron Int'l Corp., 111 F.T.C. 206, 297-99 (1988), aff’d, 884 F.2d 1489, 1496 (1st Cir. 1989); see also, FTC v. Direct Mktg. Concepts, 569 F. Supp. 2d 285, 300, 303 (D. Mass. 2008), aff’d, 624 F.3d 1 (1st Cir. 2010); FTC v. Nat'l Urological Group, Inc., 645 F. Supp. 2d 1167, 1190, 1202 (N.D. Ga. 2008), aff’d, 356 Fed. Appx. 358 (11th Cir. 2009); FTC v. Natural Solution, Inc., No. CV 06-6112-JFW, 2007-2 Trade Cas. (CCH) P75,866, 2007 U.S. Dist. LEXIS 60783, at *11-12 (C.D. Cal. Aug. 7, 2007). More generally, to make or exaggerate such claims, whether directly or indirectly, through the use of a product name, website name, metatags, or other means, without rigorous scientific evidence sufficient to substantiate the claims, violates the FTC Act. See Daniel Chapter One, WL 5160000 at *17-19.\n\nThe FTC is concerned that one or more of the efficacy claims cited above may not be substantiated by competent and reliable scientific evidence. Notice is hereby given that you must cease and desist from making any claim that a product and prevent, treat, or cure diabetes without competent and reliable scientific evidence consisting of well-controlled human clinical studies substantiating that the claims are true. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction or Administrative Cease and Desist Order. In addition, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of a disease may be subject to a civil penalty of up to $43,792 per violation pursuant to Section 5(m)(1)(B) of the FTC Act, 15 U.S.C. § 45(m)(1)(B), and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). With regard to the advertising claims discussed above, please notify Richard Cleland of the FTC via electronic mail at rcleland@ftc.gov within fifteen (15) working days of receipt of this letter of the specific actions you have taken to address FTC’s concerns.\n\nSincerely,\n\n\u002FS\u002F\n\nGlenn Bass\n\nActing Deputy Director\n\nOffice of Compliance\n\nCenter for Food Safety\n\nand Applied Nutrition\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission","Pharmaganics LLC","pharmaganics-llc-614576-09072021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpharmaganics-llc-614576-09072021","2026-10-26T08:09:41.355477+00:00","614576","2022-12-18","Tom Redmond III","2026-08-20T02:36:55.456+00:00","Via Overnight Delivery",{"id":343,"raw":344,"subject":179,"body_html":348,"body_text":349,"firm_name":350,"letter_id":351,"created_at":42,"fei_number":19,"letter_url":352,"updated_at":353,"action_type":22,"case_status":23,"posted_date":354,"marcs_cms_no":355,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":356,"body_fetched_at":357,"delivery_method":134,"recipient_title":19,"reference_number":19,"action_taken_date":358,"medical_device_id":19,"response_letter_date":19},260,[345,346,347,36,275,13,13,13],"\u003Ctime datetime=\"2026-03-17T04:00:00Z\">03\u002F17\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-01T05:00:00Z\">12\u002F01\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapothecary-pharma-llc-717972-12012025\">Apothecary Pharma, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Priyanka Rana\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Chief Pharmacy Officer  \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Apothecary Pharma, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1913 Evans Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cary\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>27513-2041\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>WL # 717972\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 1, 2025\u003C\u002Fp>\u003Cp>Dear Ms. Rana:\u003C\u002Fp>\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> on September 7, 2024, and most recently on January 11, 2025. From May 12, 2025, to May 15, 2025, FDA investigators inspected your facility, Apothecary Pharma, LLC located at 1913 Evans Road, Cary, NC 27513. During the inspection, the investigators noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\u003Cp>FDA issued a Form FDA 483 to your facility on May 15, 2025. FDA acknowledges receipt of your facility’s response, dated June 9, 2025, and related attachments received July 17, 2025. FDA acknowledges that your firm ceased sterile drug production as of May 12, 2025, and notified FDA of an intent to resume sterile drug production on August 1, 2025. Based on this inspection, it appears you produced drugs that violate the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>A. Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\u003Cp>For a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]).\u003C\u002Fp>\u003Cp>In addition, for a compounded drug product to qualify for the exemptions under section 503B, it must be compounded in an outsourcing facility that is in compliance with the registration and reporting requirements in section 503B(b), including the requirement to submit adverse event reports to FDA “in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations)” (section 503B(a)(1), (b)(5) of the FDCA [21 U.S.C. § 353b(a)(1), (b)(5)]).\u003C\u002Fp>\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503B\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the inspection, FDA investigators noted that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigators noted:\u003C\u002Fp>\u003Cp>1. Some of your facility’s drug products, such as Tirzepatide Injection 10 mg\u002FmL and Semaglutide Injection 2.5 mg\u002FmL, did not include the following information on the label: a list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient. Additionally, some of your facility’s drug products did not include the following information on the container: information to facilitate adverse event reporting and directions for use, including, as appropriate, dosage and administration.\u003C\u002Fp>\u003Cp>2. Your facility did not submit adverse event reports to FDA in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations).\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Specifically, your facility’s procedures for reporting adverse events are inadequate. For example, your documented procedures for reporting adverse events do not include a definition of what constitutes a “serious” and “unexpected” adverse event (21 CFR 310.305(b)).\u003C\u002Fp>\u003Cp>Because your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\u003C\u002Fp>\u003Cp>Specific violations are described below.\u003C\u002Fp>\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed:\u003C\u002Fp>\u003Cp>1. An operator blocked first air by placing gloved hands directly over open sterile containers.\u003C\u002Fp>\u003Cp>2. An operator placed components within the ISO 5 work area that had the potential to block the movement of first air to critical in-process operations. Specifically, an operator positioned a second row of exposed vials behind a first row in the ISO 5 \u003Cstrong>(b)(4) \u003C\u002Fstrong>laminar flow hood, obstructing first air to critical surfaces.\u003C\u002Fp>\u003Cp>3. An operator rested their arms on the work surface of the hood during aseptic production. This practice may introduce contamination into the ISO 5 work area.\u003C\u002Fp>\u003Cp>4. An operator placed their gloved hands outside the ISO 5 work area to retrieve supplies without sanitizing their gloved hands before re-entry into the ISO 5 hood.\u003C\u002Fp>\u003Cp>5. Personnel engaged in aseptic processing while exposing skin within the ISO 5 aseptic processing area.\u003C\u002Fp>\u003Cp>6. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\u003C\u002Fp>\u003Cp>7. Personnel moved quickly in a critical area such that unidirectional airflow is likely to be disrupted.\u003C\u002Fp>\u003Cp>8. Production areas or equipment have difficult to clean and visibly rusty equipment or surfaces.\u003C\u002Fp>\u003Cp>9. Lack of disinfection of equipment and supplies at each transition from areas of lower quality air to areas of higher quality air.\u003C\u002Fp>\u003Cp>10. Failing to disinfect or change gloves frequently enough given the nature of the operations to prevent contamination. More specifically, personnel were observed touching equipment or other surfaces located outside of the ISO 5 area with gloved hands and then proceeding with aseptic processing without changing or sanitizing gloves.\u003C\u002Fp>\u003Cp>FDA investigators also noted CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\u003C\u002Fp>\u003Cp>1. Your firm failed to establish written responsibilities and procedures applicable to the quality control unit and to follow written procedures applicable to the quality control unit (21 CFR 211.22(d)).\u003C\u002Fp>\u003Cp>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fp>\u003Cp>3. Your firm failed to ensure that manufacturing personnel wear clothing appropriate to protect drug product from contamination (21 CFR 211.28(a)).\u003C\u002Fp>\u003Cp>4. Your firm failed to establish an adequate system for maintaining equipment used to control the aseptic conditions (21 CFR 211.42(c)(10)(vi)).\u003C\u002Fp>\u003Cp>5. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions (21 CFR 211.42(c)(10)(v)).\u003C\u002Fp>\u003Cp>6. Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\u003C\u002Fp>\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\u003C\u002Fp>\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not have any FDA-approved applications on file for drug products that you compound.\u003Cem>\u003Cstrong>\u003Csup>4 \u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your facility's response to the Form FDA 483. FDA acknowledges that your firm ceased sterile drug production as of May 12, 2025, and notified FDA of an intent to resume sterile drug production on August 1, 2025.\u003C\u002Fp>\u003Cp>Some of your corrective actions appear adequate; however, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\u003C\u002Fp>\u003Cp>1. We acknowledge your corrective actions addressing operating with draft procedures and improper visual inspection techniques, including finalization of SOPs for Quality Unit responsibilities, Corrective and Preventive Action (CAPA), batch record review, out-of-specification (OOS) results, and retraining on the visual inspection SOP. However, your response remains inadequate because draft SOPs for Change Control, Deviations, and Risk Assessment were not addressed, and you did not assure that draft versions will not be used. In addition, you did not provide competency verification or supervisory oversight of retrained inspectors, nor a retrospective review of batches inspected under improper techniques.\u003C\u002Fp>\u003Cp>2. We acknowledge your actions regarding inadequate skin coverage posing a contamination risk to sterile drug products, including internal training to SOP 0003.00 with emphasis on mirror self-inspection. However, the adequacy of your response cannot\u003Cbr>be fully evaluated because you did not provide supporting documentation, competency verification, post-retraining assessments, or updates to SOP 0003.00\u002Fprocedures to enforce mirror checks. Further, although production was halted until August 1, 2025, you did not submit evidence of interim controls or monitoring results demonstrating proper gowning to assure ongoing compliance thereafter.\u003C\u002Fp>\u003Cp>Some of your corrective actions appear deficient:\u003C\u002Fp>\u003Cp>1. Regarding your firm’s failure to establish written responsibilities and procedures applicable to the quality control unit, we acknowledge your voluntary halt of production on May 12, 2025, and your commitment to implementing corrective actions by August 1,\u003Cbr>2025. However, your response is inadequate for the following reasons:\u003C\u002Fp>\u003Cp>a. Your response lacks a retrospective review plan for released batches \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and fails to include a root cause analysis for why incomplete records were initially released. You have not provided training records demonstrating staff understanding of the new SOP 1012.00 procedures or evidence that the enhanced batch record review process addresses all identified deficiencies.\u003C\u002Fp>\u003Cp>b. While you engaged \u003Cstrong>(b)(4)\u003C\u002Fstrong> Air for re-certification, you have not acknowledged \u003Cstrong>(b)(4)\u003C\u002Fstrong>' license revocation since 2014 or provided a plan to validate prior certifications. Your response lacks vendor qualification procedures (e.g., revising SOP 1009.00) and certification review processes. There is no assessment of previously released products manufactured in potentially uncertified environments, which compromises patient safety.\u003C\u002Fp>\u003Cp>2. We acknowledge your engagement of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Air and your retraining efforts related to aseptic operations. However, your response is inadequate because:\u003C\u002Fp>\u003Cp>a. You did not provide detailed protocols to ensure dynamic smoke studies simulate true production with maximum equipment and personnel, nor did you define acceptance criteria or Quality Unit oversight for vendor-conducted studies.\u003C\u002Fp>\u003Cp>b. You failed to conduct a risk assessment for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tirzepatide 10 mg\u002FmL batches released without validated airflow studies, or to provide an impact evaluation or justification for their release.\u003C\u002Fp>\u003Cp>c. Critical validation gaps remain, including no commitment to perform smoke studies in the ISO 7 cleanroom and no methodologies to improve smoke volume, background contrast, or dynamic simulation.\u003C\u002Fp>\u003Cp>d. Aseptic technique retraining did not address specific behaviors that compromise first air (e.g., blocking critical surfaces, resting forearms on ISO 5 surfaces, leaning into hoods and exposing skin).\u003C\u002Fp>\u003Cp>e. You proposed no workspace\u002Fequipment modifications to ensure all vials receive unidirectional airflow, and you did not evaluate equipment configurations to mitigate this risk.\u003C\u002Fp>\u003Cp>3. We acknowledge your retraining to SOP 0003.00 with emphasis on mirror self inspection. However, your response is inadequate because:\u003C\u002Fp>\u003Cp>a. SOP 0003.00 was not updated to reflect the correct gowning sequence or to establish procedures that enforce mirror checks and supervisory oversight.&nbsp;\u003C\u002Fp>\u003Cp>b. You did not provide supporting documentation or competency verification demonstrating proper gowning technique; no post-retraining assessments were submitted.\u003C\u002Fp>\u003Cp>c. You did not address observed deficiencies (e.g., use of safety glasses instead of cleanroom goggles, crossing the demarcation line on the “dirty” side, and masks worn upside down).\u003C\u002Fp>\u003Cp>d. Procedural gaps remain regarding shoe covers over clogs when entering ISO-classified areas.\u003C\u002Fp>\u003Cp>e. Although operations resumed on August 1, 2025, you did not provide evidence of interim controls or monitoring results demonstrating continued compliance after August 1, 2025, or plans to assure ongoing compliance thereafter.\u003Cbr>\u003Cbr>4. We acknowledge your commitment to address the condition of the ISO 5 laminar airflow hood (LAFH) by August 1, 2025. However, your response is inadequate because:\u003C\u002Fp>\u003Cp>a. You did not provide essential supporting documentation such as photographic evidence, maintenance records, or updated SOPs, while providing only vague commitments to repair rust damage without specifying repair methods. No interim controls or monitoring were described to mitigate contamination risk while the compromised LAFH remained in service, including upon resumption of operations on August 1, 2025.\u003C\u002Fp>\u003Cp>b. The root cause analysis attributing rust to \u003Cstrong>(b)(4)\u003C\u002Fstrong> lacked supporting evidence and did not include revised cleaning protocols, verification, or preventive measures; dents and peeling paint were inappropriately characterized as “cosmetic.”\u003C\u002Fp>\u003Cp>c. Reliance on media fills, sterility tests, or prior certifications does not address equipment condition defects that can harbor contamination or disrupt airflow pattern.\u003C\u002Fp>\u003Cp>d. You failed to provide supporting documentation including photographs, maintenance records, engineering assessments, updated SOPs, or qualification protocols, to demonstrate the implementation and effectiveness of your proposed changes. You did not provide an impact assessment for distributed batches compounded on this LAFH or establish a robust preventive maintenance program to prevent recurrence.\u003C\u002Fp>\u003Cp>5. We acknowledge retraining to SOP 0004 (Ideal Conduct in Cleanroom) and SOP 2001.00 (Cleanroom Material Transfer). However, your response is inadequate because:\u003C\u002Fp>\u003Cp>a. You did not revise your SOPs to establish specific disinfection protocols with clear responsibilities and acceptance criteria.\u003C\u002Fp>\u003Cp>b. You did not provide a comprehensive CAPA plan that includes thorough root cause analysis, implementation evidence, or monitoring strategies to verify effectiveness of corrective actions.\u003C\u002Fp>\u003Cp>c. You failed to provide training documentation and competency assessments demonstrating that personnel can correctly perform material transfer procedures and maintain proper glove hygiene practices. The proposed sanitize-able metal tool for trash handling lacks specificity and does not mitigate immediate contamination risks during aseptic operation.\u003C\u002Fp>\u003Cp>d. You did not submit an ongoing compliance plan (e.g., routine observation, audit checklists, personnel monitoring targets) or interim controls upon resumption of operations on August 1, 2025.\u003C\u002Fp>\u003Cp>6. We acknowledge your retraining to SOP 2004 (Visual Inspection). However, your response is inadequate because:\u003C\u002Fp>\u003Cp>a. You failed to revise batch records and procedures to include proper defect classification (critical\u002Fmajor\u002Fminor), Acceptable Quality Levels (AQL) methodology, and acceptance criteria. Additionally, you did not provide an updated Form F-2004.00-01, and AQL documentation continues to be omitted from your quality control processes. You did not submit documentation demonstrating retraining effectiveness (e.g., training curriculum, attendance, competency assessments, completion dates) or supervisory oversight of inspectors.\u003C\u002Fp>\u003Cp>b. You failed to provide impact assessment or retrospective review of distributed lots AP-202505 through AP-202513 to determine whether visual inspection deficiencies affected product quality.\u003C\u002Fp>\u003Cp>c. You failed to provide finalized SOP revisions or evidence of implementation; Annexure-1 lacked sufficient detail to verify changes.\u003C\u002Fp>\u003Cp>d. The referenced CAPA lacked specific corrective actions, milestones, responsible owners, and effectiveness checks.\u003C\u002Fp>\u003Cp>Given the nature and significance of the violations identified, FDA remains concerned that your firm has not yet demonstrated that adequate correction has been properly implemented to sustain sterile drug product manufacturing in a manner fully consistent with CGMP. FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\u003C\u002Fp>\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>All correspondence should refer to the Warning Letter Number above (# 717972) and include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>F. Gail Bormel, JD, RPh\u003Cbr>Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Cem>See\u003C\u002Fem> Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> For more information, see, FDA’s guidance, “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” which can be found at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM434188.pdf.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> The specific products made by your firm are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nPriyanka Rana\n\nRecipient Title\n\nPresident and Chief Pharmacy Officer\n\nApothecary Pharma, LLC\n\n1913 Evans Road\n\nCary, NC 27513-2041\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nWL # 717972\nDecember 1, 2025\nDear Ms. Rana:\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on September 7, 2024, and most recently on January 11, 2025. From May 12, 2025, to May 15, 2025, FDA investigators inspected your facility, Apothecary Pharma, LLC located at 1913 Evans Road, Cary, NC 27513. During the inspection, the investigators noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\nFDA issued a Form FDA 483 to your facility on May 15, 2025. FDA acknowledges receipt of your facility’s response, dated June 9, 2025, and related attachments received July 17, 2025. FDA acknowledges that your firm ceased sterile drug production as of May 12, 2025, and notified FDA of an intent to resume sterile drug production on August 1, 2025. Based on this inspection, it appears you produced drugs that violate the FDCA.\nA. Compounded Drug Products under the FDCA\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.2\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\nFor a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]).\nIn addition, for a compounded drug product to qualify for the exemptions under section 503B, it must be compounded in an outsourcing facility that is in compliance with the registration and reporting requirements in section 503B(b), including the requirement to submit adverse event reports to FDA “in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations)” (section 503B(a)(1), (b)(5) of the FDCA [21 U.S.C. § 353b(a)(1), (b)(5)]).\nB. Failure to Meet the Conditions of Section 503B\nDuring the inspection, FDA investigators noted that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigators noted:\n1. Some of your facility’s drug products, such as Tirzepatide Injection 10 mg\u002FmL and Semaglutide Injection 2.5 mg\u002FmL, did not include the following information on the label: a list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient. Additionally, some of your facility’s drug products did not include the following information on the container: information to facilitate adverse event reporting and directions for use, including, as appropriate, dosage and administration.\n2. Your facility did not submit adverse event reports to FDA in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations).3\nSpecifically, your facility’s procedures for reporting adverse events are inadequate. For example, your documented procedures for reporting adverse events do not include a definition of what constitutes a “serious” and “unexpected” adverse event (21 CFR 310.305(b)).\nBecause your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\nSpecific violations are described below.\nC. Violations of the FDCA\nAdulterated Drug Products\nFDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed:\n1. An operator blocked first air by placing gloved hands directly over open sterile containers.\n2. An operator placed components within the ISO 5 work area that had the potential to block the movement of first air to critical in-process operations. Specifically, an operator positioned a second row of exposed vials behind a first row in the ISO 5 (b)(4) laminar flow hood, obstructing first air to critical surfaces.\n3. An operator rested their arms on the work surface of the hood during aseptic production. This practice may introduce contamination into the ISO 5 work area.\n4. An operator placed their gloved hands outside the ISO 5 work area to retrieve supplies without sanitizing their gloved hands before re-entry into the ISO 5 hood.\n5. Personnel engaged in aseptic processing while exposing skin within the ISO 5 aseptic processing area.\n6. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\n7. Personnel moved quickly in a critical area such that unidirectional airflow is likely to be disrupted.\n8. Production areas or equipment have difficult to clean and visibly rusty equipment or surfaces.\n9. Lack of disinfection of equipment and supplies at each transition from areas of lower quality air to areas of higher quality air.\n10. Failing to disinfect or change gloves frequently enough given the nature of the operations to prevent contamination. More specifically, personnel were observed touching equipment or other surfaces located outside of the ISO 5 area with gloved hands and then proceeding with aseptic processing without changing or sanitizing gloves.\nFDA investigators also noted CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\n1. Your firm failed to establish written responsibilities and procedures applicable to the quality control unit and to follow written procedures applicable to the quality control unit (21 CFR 211.22(d)).\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n3. Your firm failed to ensure that manufacturing personnel wear clothing appropriate to protect drug product from contamination (21 CFR 211.28(a)).\n4. Your firm failed to establish an adequate system for maintaining equipment used to control the aseptic conditions (21 CFR 211.42(c)(10)(vi)).\n5. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions (21 CFR 211.42(c)(10)(v)).\n6. Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\nUnapproved New Drug Products\nYou do not have any FDA-approved applications on file for drug products that you compound.4 Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\nMisbranded Drug Products\nYou compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.5 The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\nD. Corrective Actions\nWe have reviewed your facility's response to the Form FDA 483. FDA acknowledges that your firm ceased sterile drug production as of May 12, 2025, and notified FDA of an intent to resume sterile drug production on August 1, 2025.\nSome of your corrective actions appear adequate; however, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\n1. We acknowledge your corrective actions addressing operating with draft procedures and improper visual inspection techniques, including finalization of SOPs for Quality Unit responsibilities, Corrective and Preventive Action (CAPA), batch record review, out-of-specification (OOS) results, and retraining on the visual inspection SOP. However, your response remains inadequate because draft SOPs for Change Control, Deviations, and Risk Assessment were not addressed, and you did not assure that draft versions will not be used. In addition, you did not provide competency verification or supervisory oversight of retrained inspectors, nor a retrospective review of batches inspected under improper techniques.\n2. We acknowledge your actions regarding inadequate skin coverage posing a contamination risk to sterile drug products, including internal training to SOP 0003.00 with emphasis on mirror self-inspection. However, the adequacy of your response cannot\nbe fully evaluated because you did not provide supporting documentation, competency verification, post-retraining assessments, or updates to SOP 0003.00\u002Fprocedures to enforce mirror checks. Further, although production was halted until August 1, 2025, you did not submit evidence of interim controls or monitoring results demonstrating proper gowning to assure ongoing compliance thereafter.\nSome of your corrective actions appear deficient:\n1. Regarding your firm’s failure to establish written responsibilities and procedures applicable to the quality control unit, we acknowledge your voluntary halt of production on May 12, 2025, and your commitment to implementing corrective actions by August 1,\n2025. However, your response is inadequate for the following reasons:\na. Your response lacks a retrospective review plan for released batches (b)(4), (b)(4) and fails to include a root cause analysis for why incomplete records were initially released. You have not provided training records demonstrating staff understanding of the new SOP 1012.00 procedures or evidence that the enhanced batch record review process addresses all identified deficiencies.\nb. While you engaged (b)(4) Air for re-certification, you have not acknowledged (b)(4)' license revocation since 2014 or provided a plan to validate prior certifications. Your response lacks vendor qualification procedures (e.g., revising SOP 1009.00) and certification review processes. There is no assessment of previously released products manufactured in potentially uncertified environments, which compromises patient safety.\n2. We acknowledge your engagement of (b)(4) Air and your retraining efforts related to aseptic operations. However, your response is inadequate because:\na. You did not provide detailed protocols to ensure dynamic smoke studies simulate true production with maximum equipment and personnel, nor did you define acceptance criteria or Quality Unit oversight for vendor-conducted studies.\nb. You failed to conduct a risk assessment for the (b)(4) Tirzepatide 10 mg\u002FmL batches released without validated airflow studies, or to provide an impact evaluation or justification for their release.\nc. Critical validation gaps remain, including no commitment to perform smoke studies in the ISO 7 cleanroom and no methodologies to improve smoke volume, background contrast, or dynamic simulation.\nd. Aseptic technique retraining did not address specific behaviors that compromise first air (e.g., blocking critical surfaces, resting forearms on ISO 5 surfaces, leaning into hoods and exposing skin).\ne. You proposed no workspace\u002Fequipment modifications to ensure all vials receive unidirectional airflow, and you did not evaluate equipment configurations to mitigate this risk.\n3. We acknowledge your retraining to SOP 0003.00 with emphasis on mirror self inspection. However, your response is inadequate because:\na. SOP 0003.00 was not updated to reflect the correct gowning sequence or to establish procedures that enforce mirror checks and supervisory oversight.\nb. You did not provide supporting documentation or competency verification demonstrating proper gowning technique; no post-retraining assessments were submitted.\nc. You did not address observed deficiencies (e.g., use of safety glasses instead of cleanroom goggles, crossing the demarcation line on the “dirty” side, and masks worn upside down).\nd. Procedural gaps remain regarding shoe covers over clogs when entering ISO-classified areas.\ne. Although operations resumed on August 1, 2025, you did not provide evidence of interim controls or monitoring results demonstrating continued compliance after August 1, 2025, or plans to assure ongoing compliance thereafter.\n\n4. We acknowledge your commitment to address the condition of the ISO 5 laminar airflow hood (LAFH) by August 1, 2025. However, your response is inadequate because:\na. You did not provide essential supporting documentation such as photographic evidence, maintenance records, or updated SOPs, while providing only vague commitments to repair rust damage without specifying repair methods. No interim controls or monitoring were described to mitigate contamination risk while the compromised LAFH remained in service, including upon resumption of operations on August 1, 2025.\nb. The root cause analysis attributing rust to (b)(4) lacked supporting evidence and did not include revised cleaning protocols, verification, or preventive measures; dents and peeling paint were inappropriately characterized as “cosmetic.”\nc. Reliance on media fills, sterility tests, or prior certifications does not address equipment condition defects that can harbor contamination or disrupt airflow pattern.\nd. You failed to provide supporting documentation including photographs, maintenance records, engineering assessments, updated SOPs, or qualification protocols, to demonstrate the implementation and effectiveness of your proposed changes. You did not provide an impact assessment for distributed batches compounded on this LAFH or establish a robust preventive maintenance program to prevent recurrence.\n5. We acknowledge retraining to SOP 0004 (Ideal Conduct in Cleanroom) and SOP 2001.00 (Cleanroom Material Transfer). However, your response is inadequate because:\na. You did not revise your SOPs to establish specific disinfection protocols with clear responsibilities and acceptance criteria.\nb. You did not provide a comprehensive CAPA plan that includes thorough root cause analysis, implementation evidence, or monitoring strategies to verify effectiveness of corrective actions.\nc. You failed to provide training documentation and competency assessments demonstrating that personnel can correctly perform material transfer procedures and maintain proper glove hygiene practices. The proposed sanitize-able metal tool for trash handling lacks specificity and does not mitigate immediate contamination risks during aseptic operation.\nd. You did not submit an ongoing compliance plan (e.g., routine observation, audit checklists, personnel monitoring targets) or interim controls upon resumption of operations on August 1, 2025.\n6. We acknowledge your retraining to SOP 2004 (Visual Inspection). However, your response is inadequate because:\na. You failed to revise batch records and procedures to include proper defect classification (critical\u002Fmajor\u002Fminor), Acceptable Quality Levels (AQL) methodology, and acceptance criteria. Additionally, you did not provide an updated Form F-2004.00-01, and AQL documentation continues to be omitted from your quality control processes. You did not submit documentation demonstrating retraining effectiveness (e.g., training curriculum, attendance, competency assessments, completion dates) or supervisory oversight of inspectors.\nb. You failed to provide impact assessment or retrospective review of distributed lots AP-202505 through AP-202513 to determine whether visual inspection deficiencies affected product quality.\nc. You failed to provide finalized SOP revisions or evidence of implementation; Annexure-1 lacked sufficient detail to verify changes.\nd. The referenced CAPA lacked specific corrective actions, milestones, responsible owners, and effectiveness checks.\nGiven the nature and significance of the violations identified, FDA remains concerned that your firm has not yet demonstrated that adequate correction has been properly implemented to sustain sterile drug product manufacturing in a manner fully consistent with CGMP. FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\nE. Conclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nAll correspondence should refer to the Warning Letter Number above (# 717972) and include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nF. Gail Bormel, JD, RPh\nDirector\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n______________________\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\n3 For more information, see, FDA’s guidance, “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” which can be found at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM434188.pdf.\n4 The specific products made by your firm are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n5 Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).","Apothecary Pharma, LLC","apothecary-pharma-llc-717972-12012025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapothecary-pharma-llc-717972-12012025","2026-10-26T08:07:56.701385+00:00","2026-03-17","717972","Priyanka Rana","2026-08-19T04:50:34.267+00:00","2025-12-01",{"id":360,"raw":361,"subject":366,"body_html":367,"body_text":368,"firm_name":369,"letter_id":370,"created_at":204,"fei_number":19,"letter_url":371,"updated_at":372,"action_type":22,"case_status":23,"posted_date":373,"marcs_cms_no":374,"product_type":375,"closeout_date":19,"issuing_office":365,"recipient_name":376,"body_fetched_at":377,"delivery_method":247,"recipient_title":19,"reference_number":19,"action_taken_date":378,"medical_device_id":19,"response_letter_date":19},1693,[362,363,364,365,366,13,13,13],"\u003Ctime datetime=\"2023-12-14T13:45:00Z\">12\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-30T05:00:00Z\">11\u002F30\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faquarium-pharmacy-llc-667431-11302023\">Aquarium Pharmacy LLC\u003C\u002Fa>","Center for Veterinary Medicine","Unapproved Medically Important Antimicrobials Marketed for Use in Non-food Minor Species","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Cynthia Marie Bounds\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aquarium Pharmacy LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4233 SE 182nd Avenue Ste 312\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gresham\u003C\u002Fspan>, \u003Cspan>OR\u003C\u002Fspan> \u003Cspan>97030-5082\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:aquariumpharmacy@gmail.com\"> aquariumpharmacy@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 30, 2023\u003C\u002Fp>\n\n\u003Cp>Re: 667431\u003C\u002Fp>\n\n\u003Cp>Dear Cynthia Marie Bounds:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm's distribution of veterinary products for use in aquarium fish.\u003C\u002Fp>\n\n\u003Cp>In August 2023, the U.S. Food and Drug Administration (FDA) reviewed your website (https:\u002F\u002Faquariumpharmacy.com\u002F), where you take orders for Aquarium Amoxicillin, Aquarium Amoxicillin Clavulanate, Aquarium Azithromycin, Aquarium Cephalexin, Aquarium Ciprofloxacin, Aquarium Clindamycin HCL, Aquarium Doxycycline, Aquarium Levofloxacin, Aquarium Metronidazole, Aquarium Minocycline, Aquarium Penicillin VK, and Aquarium Sulfamethoxazole\u002F Trimethoprim. The claims on your website establish that these products are intended for use in the cure, mitigation, treatment, or prevention of diseases in animals, which makes them drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. § 321(g)(1)(B)]. In addition, these animal drugs are misbranded under section 502(o) of the FD&amp;C Act [21 U.S.C. § 352(o)] because they have not been drug listed with FDA, nor have they been manufactured in a facility that is registered with FDA in accordance with sections 510(b) and (j) of the FD&amp;C Act [21 U.S.C. § 360(b), (j)]. As discussed below, introducing or delivering these unapproved and misbranded new animal drugs for introduction into interstate commerce violates section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>UNAPPROVED NEW ANIMAL DRUGS\u003C\u002Fstrong>\u003C\u002Fu>\u003Cbr>\nExamples of claims observed on your website (https:\u002F\u002Faquariumpharmacy.com\u002F) that establish the intended use of your products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>Aquarium Amoxicillin\u003C\u002Fstrong>, 250 mg capsules, 500 mg capsules, “Amoxicillin is a semisyntetic [sic] broad spectrum antibiotic. For treatment against many gram-positive and gram-negative microorganisms.” • Aquarium Amoxicillin Clavulanate, 875 mg\u002F125 mg, tablets, “Amoxicillin\u002FClavulanate Potassium is a semisynthetic antibiotic. For treatment against many gram-positive and gram-negative microorganisms.”\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>Aquarium Azithromycin\u003C\u002Fstrong>, 250 mg, tablets, “Azithromycin is a semisynthetic broad spectrum antibiotic. For treatment against many gram-positive and gram-negative microorganisms.”\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>Aquarium Cephalexin\u003C\u002Fstrong>, 250 mg capsules, 500 mg capsules, “Cephalexin is a broad spectrum antibiotic. For treatment against many gram-positive and gram-negative microorganisms.”\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>Aquarium Ciprofloxacin\u003C\u002Fstrong>, 250 mg tablets, 500 mg tablets, 750 mg tablets, “Ciprofloxacin is a synthetic broad spectrum antibiotic. For treatment against many gram-positive and gram-negative microorganisms.”\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>Aquarium Clindamycin HCL\u003C\u002Fstrong>, 150 mg, capsules, “Clindamycin is a semisyntetic [sic] antibiotic. For treatment against many gram-negative and gram-positive microorganisms.”\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>Aquarium Doxycycline\u003C\u002Fstrong>, 100 mg, capsules, “Doxycycline is a broad spectrum antibiotic. For treatment against many gram-negative and gram-positive microorganisms.”\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>Aquarium Levofloxacin\u003C\u002Fstrong>, 500 mg, tablets, “Levofloxacin is a synthetic broad spectrum antibiotic. For treatment against many gram-negative and gram-positive microorganisms.”\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>Aquarium Metronidazole\u003C\u002Fstrong>, 250 mg tablets, 500 mg tablets, “Metronidazole is a synthetic broad spectrum antibiotic. For treatment against many gram-positive and gram-negative microorganisms.”\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>Aquarium Minocycline\u003C\u002Fstrong>, 100 mg, capsules, “Minocycline is a semisyntetic [sic] broad spectrum antibiotic. For treatment against many gram-negative and gram-positive microorganisms.”\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>Aquarium Penicillin VK\u003C\u002Fstrong>, 250 mg tablets, 500 mg tablets, “Penicillin VK is a broad spectrum antibiotic. For treatment against many gram-positive and gram-negative microorganisms.”\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>Aquarium Sulfamethoxazole\u002FTrimethoprim\u003C\u002Fstrong>, 800 mg\u002F160 mg, tablets, “Sulfamethoxazole\u002FTrimethoprim is a synthetic antibiotic. For treatment against many gram-negative and gram-positive microorganisms.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>These products are new animal drugs under section 201(v) of the FD&amp;C Act [21 U.S.C. § 321(v)] because they are for use in nonfood-producing fish, which are minor species as defined by sections 201(nn) and (oo) of the FD&amp;C Act [21 U.S.C. § 321(nn) and (oo)], and are not the subject of a final FDA regulation finding either that the drugs are generally recognized among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the drug’s labeling, or finding that the exception to the criterion in section 201(v)(1) of the FD&amp;C Act has been met.\u003C\u002Fp>\n\n\u003Cp>To be legally marketed, a new animal drug must be the subject of an approved new animal drug application, a conditionally approved new animal drug application, or a listing on the Index of Legally Marketed Unapproved New Animal Drugs for Minor Species (“index listing”) under section 512, 571, or 572 of the FD&amp;C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. The FDA approval and index listing processes allow FDA to ensure that there is adequate evidence to demonstrate that new animal drugs are safe, properly manufactured, accurately labeled, and meet the relevant effectiveness standard. The animal drugs named above have not been approved, conditionally approved, or index listed.\u003C\u002Fp>\n\n\u003Cp>Animal drugs that lack the required approval or index listing are considered unsafe and adulterated under sections 512(a) and 501(a)(5) of the FD&amp;C Act [21 U.S.C. §§ 360b(a) and 351(a)(5)]. Introduction or delivery for introduction of an adulterated animal drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>FDA is particularly concerned about your unapproved animal drugs because they raise public health concerns. Available as over-the-counter drugs, they contain antimicrobials that are considered medically important in the treatment of human disease.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Concern about the development of resistance to antimicrobials important in human medicine has led FDA to promote more judicious use of animal drugs containing medically important antimicrobials, including working toward ensuring that these drugs can be used in animals only under the supervision of a licensed veterinarian.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>MISBRANDED NEW ANIMAL DRUGS\u003C\u002Fstrong>\u003C\u002Fu>\u003Cbr>\nSections 510(b)(1) and (j)(1) of the FD&amp;C Act [21 U.S.C. § 360(b), (j)] require that manufacturers (which includes repackers and relabelers) of drugs, including animal drugs, register their manufacturing establishments with FDA and provide the agency with a list of all the drug products they manufacture. Drugs that are manufactured in unregistered establishments or that have not been listed with FDA are misbranded under section 502(o) of the FD&amp;C Act. None of the animal drugs in this letter are drug listed with FDA, nor have they been manufactured in a facility that is registered with FDA. Accordingly, these animal drugs are misbranded. Introduction or delivery for introduction of a misbranded animal drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product(s). You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal or regulatory action, including without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>You should be aware that if we take enforcement action against any of the drugs named above or other unapproved\u002Funindexed products you market that contain medically important antimicrobials, we may take action against all of your products that violate the FD&amp;C Act at the same time, including but not limited to enjoining the manufacturing and distribution of all of your unapproved\u002Funindexed products.\u003C\u002Fp>\n\n\u003Cp>We have the following comments:\u003C\u002Fp>\n\n\u003Cp>1. You can legally market the products named above if you obtain an index listing, approval, or conditional approval. Information about the processes and requirements for obtaining an index listing and various types of animal drug approval is available on the FDA website at\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>https:\u002F\u002Fwww.fda.gov\u002Fanimal-veterinary\u002Fdevelopment-approval-process\u002Fminor-useminor-species and\u003C\u002Fli>\n\t\u003Cli>https:\u002F\u002Fwww.fda.gov\u002Fanimal-veterinary\u002Fdevelopment-approval-process\u002Fnew-animal-drug-applications\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The index listing process was added to the FD&amp;C Act in 2004 as a streamlined alternative process that addresses the challenges of obtaining FDA approval for drugs for minor species (which are any animal species other than horses, cattle, pigs, dogs, cats, chickens, and turkeys). Drugs intended for use in minor species not used for human or animal food are eligible for index listing. Because the above-named products are intended for use in nonfood-producing fish, you may wish to explore the index listing process. The approval process can also be used for drugs for use in these species.\u003C\u002Fp>\n\n\u003Cp>2. Information on establishment registration and drug listing is available on the FDA website at:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>https:\u002F\u002Fwww.fda.gov\u002Findustry\u002Ffda-basics-industry\u002Fregistration-and-listing\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Within fifteen (15) working days of receiving this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to Dr. Vic Boddie, United States Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance, by emailing CVMUnapprovedDrugs@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Neal Bataller, ME, DVM\u003Cbr>\nDirector Division of Drug Compliance\u003Cbr>\nOffice of Surveillance and Compliance\u003Cbr>\nCenter for Veterinary Medicine\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>A list of medically important drug classes of antimicrobials can be found in Guidance for Industry (GFI) # 152, “Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern,” available at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FAnimalVeterinary\u002FGuidanceComplianceEnforcement\u002FGuidanceforIndustry\u002FUCM052519.pdf\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nCynthia Marie Bounds\n\nRecipient Title\n\nExecutive Officer\n\nAquarium Pharmacy LLC\n\n4233 SE 182nd Avenue Ste 312\n\nGresham, OR 97030-5082\n\nUnited States\n\naquariumpharmacy@gmail.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\n\nNovember 30, 2023\n\nRe: 667431\n\nDear Cynthia Marie Bounds:\n\nThis letter concerns your firm's distribution of veterinary products for use in aquarium fish.\n\nIn August 2023, the U.S. Food and Drug Administration (FDA) reviewed your website (https:\u002F\u002Faquariumpharmacy.com\u002F), where you take orders for Aquarium Amoxicillin, Aquarium Amoxicillin Clavulanate, Aquarium Azithromycin, Aquarium Cephalexin, Aquarium Ciprofloxacin, Aquarium Clindamycin HCL, Aquarium Doxycycline, Aquarium Levofloxacin, Aquarium Metronidazole, Aquarium Minocycline, Aquarium Penicillin VK, and Aquarium Sulfamethoxazole\u002F Trimethoprim. The claims on your website establish that these products are intended for use in the cure, mitigation, treatment, or prevention of diseases in animals, which makes them drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. § 321(g)(1)(B)]. In addition, these animal drugs are misbranded under section 502(o) of the FD&C Act [21 U.S.C. § 352(o)] because they have not been drug listed with FDA, nor have they been manufactured in a facility that is registered with FDA in accordance with sections 510(b) and (j) of the FD&C Act [21 U.S.C. § 360(b), (j)]. As discussed below, introducing or delivering these unapproved and misbranded new animal drugs for introduction into interstate commerce violates section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nUNAPPROVED NEW ANIMAL DRUGS\n\nExamples of claims observed on your website (https:\u002F\u002Faquariumpharmacy.com\u002F) that establish the intended use of your products as drugs include, but may not be limited to, the following:\n\nAquarium Amoxicillin, 250 mg capsules, 500 mg capsules, “Amoxicillin is a semisyntetic [sic] broad spectrum antibiotic. For treatment against many gram-positive and gram-negative microorganisms.” • Aquarium Amoxicillin Clavulanate, 875 mg\u002F125 mg, tablets, “Amoxicillin\u002FClavulanate Potassium is a semisynthetic antibiotic. For treatment against many gram-positive and gram-negative microorganisms.”\n\nAquarium Azithromycin, 250 mg, tablets, “Azithromycin is a semisynthetic broad spectrum antibiotic. For treatment against many gram-positive and gram-negative microorganisms.”\n\nAquarium Cephalexin, 250 mg capsules, 500 mg capsules, “Cephalexin is a broad spectrum antibiotic. For treatment against many gram-positive and gram-negative microorganisms.”\n\nAquarium Ciprofloxacin, 250 mg tablets, 500 mg tablets, 750 mg tablets, “Ciprofloxacin is a synthetic broad spectrum antibiotic. For treatment against many gram-positive and gram-negative microorganisms.”\n\nAquarium Clindamycin HCL, 150 mg, capsules, “Clindamycin is a semisyntetic [sic] antibiotic. For treatment against many gram-negative and gram-positive microorganisms.”\n\nAquarium Doxycycline, 100 mg, capsules, “Doxycycline is a broad spectrum antibiotic. For treatment against many gram-negative and gram-positive microorganisms.”\n\nAquarium Levofloxacin, 500 mg, tablets, “Levofloxacin is a synthetic broad spectrum antibiotic. For treatment against many gram-negative and gram-positive microorganisms.”\n\nAquarium Metronidazole, 250 mg tablets, 500 mg tablets, “Metronidazole is a synthetic broad spectrum antibiotic. For treatment against many gram-positive and gram-negative microorganisms.”\n\nAquarium Minocycline, 100 mg, capsules, “Minocycline is a semisyntetic [sic] broad spectrum antibiotic. For treatment against many gram-negative and gram-positive microorganisms.”\n\nAquarium Penicillin VK, 250 mg tablets, 500 mg tablets, “Penicillin VK is a broad spectrum antibiotic. For treatment against many gram-positive and gram-negative microorganisms.”\n\nAquarium Sulfamethoxazole\u002FTrimethoprim, 800 mg\u002F160 mg, tablets, “Sulfamethoxazole\u002FTrimethoprim is a synthetic antibiotic. For treatment against many gram-negative and gram-positive microorganisms.”\n\nThese products are new animal drugs under section 201(v) of the FD&C Act [21 U.S.C. § 321(v)] because they are for use in nonfood-producing fish, which are minor species as defined by sections 201(nn) and (oo) of the FD&C Act [21 U.S.C. § 321(nn) and (oo)], and are not the subject of a final FDA regulation finding either that the drugs are generally recognized among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the drug’s labeling, or finding that the exception to the criterion in section 201(v)(1) of the FD&C Act has been met.\n\nTo be legally marketed, a new animal drug must be the subject of an approved new animal drug application, a conditionally approved new animal drug application, or a listing on the Index of Legally Marketed Unapproved New Animal Drugs for Minor Species (“index listing”) under section 512, 571, or 572 of the FD&C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. The FDA approval and index listing processes allow FDA to ensure that there is adequate evidence to demonstrate that new animal drugs are safe, properly manufactured, accurately labeled, and meet the relevant effectiveness standard. The animal drugs named above have not been approved, conditionally approved, or index listed.\n\nAnimal drugs that lack the required approval or index listing are considered unsafe and adulterated under sections 512(a) and 501(a)(5) of the FD&C Act [21 U.S.C. §§ 360b(a) and 351(a)(5)]. Introduction or delivery for introduction of an adulterated animal drug into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nFDA is particularly concerned about your unapproved animal drugs because they raise public health concerns. Available as over-the-counter drugs, they contain antimicrobials that are considered medically important in the treatment of human disease.1 Concern about the development of resistance to antimicrobials important in human medicine has led FDA to promote more judicious use of animal drugs containing medically important antimicrobials, including working toward ensuring that these drugs can be used in animals only under the supervision of a licensed veterinarian.\n\nMISBRANDED NEW ANIMAL DRUGS\n\nSections 510(b)(1) and (j)(1) of the FD&C Act [21 U.S.C. § 360(b), (j)] require that manufacturers (which includes repackers and relabelers) of drugs, including animal drugs, register their manufacturing establishments with FDA and provide the agency with a list of all the drug products they manufacture. Drugs that are manufactured in unregistered establishments or that have not been listed with FDA are misbranded under section 502(o) of the FD&C Act. None of the animal drugs in this letter are drug listed with FDA, nor have they been manufactured in a facility that is registered with FDA. Accordingly, these animal drugs are misbranded. Introduction or delivery for introduction of a misbranded animal drug into interstate commerce is prohibited under section 301(a) of the FD&C Act.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product(s). You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal or regulatory action, including without limitation, seizure and injunction.\n\nYou should be aware that if we take enforcement action against any of the drugs named above or other unapproved\u002Funindexed products you market that contain medically important antimicrobials, we may take action against all of your products that violate the FD&C Act at the same time, including but not limited to enjoining the manufacturing and distribution of all of your unapproved\u002Funindexed products.\n\nWe have the following comments:\n\n1. You can legally market the products named above if you obtain an index listing, approval, or conditional approval. Information about the processes and requirements for obtaining an index listing and various types of animal drug approval is available on the FDA website at\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fanimal-veterinary\u002Fdevelopment-approval-process\u002Fminor-useminor-species and\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fanimal-veterinary\u002Fdevelopment-approval-process\u002Fnew-animal-drug-applications\n\nThe index listing process was added to the FD&C Act in 2004 as a streamlined alternative process that addresses the challenges of obtaining FDA approval for drugs for minor species (which are any animal species other than horses, cattle, pigs, dogs, cats, chickens, and turkeys). Drugs intended for use in minor species not used for human or animal food are eligible for index listing. Because the above-named products are intended for use in nonfood-producing fish, you may wish to explore the index listing process. The approval process can also be used for drugs for use in these species.\n\n2. Information on establishment registration and drug listing is available on the FDA website at:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Findustry\u002Ffda-basics-industry\u002Fregistration-and-listing\n\nWithin fifteen (15) working days of receiving this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to Dr. Vic Boddie, United States Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance, by emailing CVMUnapprovedDrugs@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nNeal Bataller, ME, DVM\n\nDirector Division of Drug Compliance\n\nOffice of Surveillance and Compliance\n\nCenter for Veterinary Medicine\n\n_____________________\n\n1 A list of medically important drug classes of antimicrobials can be found in Guidance for Industry (GFI) # 152, “Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern,” available at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FAnimalVeterinary\u002FGuidanceComplianceEnforcement\u002FGuidanceforIndustry\u002FUCM052519.pdf","Aquarium Pharmacy LLC","aquarium-pharmacy-llc-667431-11302023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faquarium-pharmacy-llc-667431-11302023","2026-10-26T08:07:57.112105+00:00","2023-12-14","667431","Animal & VeterinaryDrugs","Cynthia Marie Bounds","2026-08-20T00:26:16.409+00:00","2023-11-30",{"id":380,"raw":381,"subject":122,"body_html":385,"body_text":386,"firm_name":387,"letter_id":388,"created_at":298,"fei_number":19,"letter_url":389,"updated_at":390,"action_type":22,"case_status":23,"posted_date":391,"marcs_cms_no":392,"product_type":47,"closeout_date":19,"issuing_office":76,"recipient_name":393,"body_fetched_at":394,"delivery_method":190,"recipient_title":19,"reference_number":19,"action_taken_date":395,"medical_device_id":19,"response_letter_date":19},2122,[382,383,384,76,122,13,13,13],"\u003Ctime datetime=\"2023-04-25T13:20:00Z\">04\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-04-13T04:00:00Z\">04\u002F13\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpharmaplast-sae-648883-04132023\">Pharmaplast S.A.E.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Wassim Attia\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President of Quality\u002FRegulatory\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Pharmaplast S.A.E.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Amria Free Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>30 Beside Lord International Factory Building\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alexandria Governorate\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>21599\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Egypt\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:wasim.gad@pharmaplast-online.com\"> wasim.gad@pharmaplast-online.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-23-14\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 13, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Attia:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Pharmaplast S.A.E., FEI 3003767891, at Amria Free Zone, 30 Beside Lord International Factory Building, Alexandria from November 6 to November 10, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your December 11, 2022 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to perform adequate identity testing for each component lot used in the production of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products, including ethanol, your active pharmaceutical ingredient (API). Additionally, your API, ethanol, is not tested for methanol content, and your procedures did not ensure that you test glycerin for presence of diethylene glycol (DEG) or ethylene glycol (EG). For example, you failed to test your incoming components for identity prior to manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong> Gel, batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\n\u003Cbr>\nComponent testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your incoming components conform to appropriate specifications before use in the manufacture of drug products.\u003C\u002Fp>\n\n\u003Cp>In your response, you provide a corrective action and preventive action (CAPA) that states samples of your raw materials in your warehouse will be tested for conformance to the supplier’s certificate of analysis (COA). You also state that glycerin will be tested for DEG and EG.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because it fails to include a detailed plan for how raw materials will be tested such as test method and review of compendial requirements. Your proposed action plan does not include a strategy to implement corrective actions. Also, you do not provide a detailed plan to ensure that previously distributed drug products were manufactured with incoming components that meet the identity and impurity testing requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Products Contain Glycerin\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture drugs that contain glycerin. The use of glycerin contaminated with diethylene glycol (DEG) has resulted in various lethal poisoning incidents in humans worldwide.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Testing of Glycerin for Diethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing glycerin at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-diethylene-glycol\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-diethylene-glycol\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Products Contain Ethanol\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19)\u003C\u002Fem> at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>Results of tests for DEG and EG in retain samples of all glycerin lots used to manufacture your drug products.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that contain glycerin and are within expiry in the U.S. market. Take prompt corrective actions and preventive actions and detail your future actions to ensure appropriate selection of your suppliers, ongoing scrutiny of their supply chain, and appropriate incoming lot controls.\u003C\u002Fli>\n\t\u003Cli>Limit test of methanol and test results for all \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches released and distributed.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to include all pieces of product-contact equipment used for manufacturing your drug and device products in your cleaning validation protocols and procedures. Your cleaning validation protocols and procedures did not include the transfer carriage vessels that are used for moving drug and chemical device component during manufacturing, creating a risk of cross contamination.\u003C\u002Fp>\n\n\u003Cp>In your response, you provide a CAPA and cleaning validation for the transfer carriage vessel. Your CAPA contains a list of products evaluated for use of the transfer carriage vessel.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because the list of products provided in the CAPA contained products without “orders” and therefore lacks a complete evaluation of all possible uses of the transfer carriage vessel. You state that \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished products are the worst-case product to clean. Your response, however, does not provide information on products listed in your CAPA without “orders,” whether those products use the transfer carriage vessel, and what impact those products had on your worst-case product selection.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Maximum hold times before cleaning\u003Cbr>\n\u003Cbr>\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on April 4, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Pharmaplast S.A.E., Amria Free Zone, 30 Beside Lord International Factory Building, Alexandria into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003767891 and ATTN: Sarah Rhoades, Compliance Officer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Wassim Attia\n\nRecipient Title\n\nVice President of Quality\u002FRegulatory\n\nPharmaplast S.A.E.\n\nAmria Free Zone\n\n30 Beside Lord International Factory Building\n\nAlexandria Governorate\n\n21599\n\nEgypt\n\nwasim.gad@pharmaplast-online.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-14\n\nApril 13, 2023\n\nDear Mr. Attia:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Pharmaplast S.A.E., FEI 3003767891, at Amria Free Zone, 30 Beside Lord International Factory Building, Alexandria from November 6 to November 10, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your December 11, 2022 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).\n\nYou failed to perform adequate identity testing for each component lot used in the production of your (b)(4) drug products, including ethanol, your active pharmaceutical ingredient (API). Additionally, your API, ethanol, is not tested for methanol content, and your procedures did not ensure that you test glycerin for presence of diethylene glycol (DEG) or ethylene glycol (EG). For example, you failed to test your incoming components for identity prior to manufacturing (b)(4) Gel, batch (b)(4).\n\nComponent testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your incoming components conform to appropriate specifications before use in the manufacture of drug products.\n\nIn your response, you provide a corrective action and preventive action (CAPA) that states samples of your raw materials in your warehouse will be tested for conformance to the supplier’s certificate of analysis (COA). You also state that glycerin will be tested for DEG and EG.\n\nYour response is inadequate because it fails to include a detailed plan for how raw materials will be tested such as test method and review of compendial requirements. Your proposed action plan does not include a strategy to implement corrective actions. Also, you do not provide a detailed plan to ensure that previously distributed drug products were manufactured with incoming components that meet the identity and impurity testing requirements.\n\nProducts Contain Glycerin\n\nYou manufacture drugs that contain glycerin. The use of glycerin contaminated with diethylene glycol (DEG) has resulted in various lethal poisoning incidents in humans worldwide.\n\nSee FDA’s guidance document Testing of Glycerin for Diethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing glycerin at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-diethylene-glycol.\n\nProducts Contain Ethanol\n\nYou manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide.\n\nSee FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19) at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nResults of tests for DEG and EG in retain samples of all glycerin lots used to manufacture your drug products.\n\nA full risk assessment for drug products that contain glycerin and are within expiry in the U.S. market. Take prompt corrective actions and preventive actions and detail your future actions to ensure appropriate selection of your suppliers, ongoing scrutiny of their supply chain, and appropriate incoming lot controls.\n\nLimit test of methanol and test results for all (b)(4) batches released and distributed.\n\n2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nYou failed to include all pieces of product-contact equipment used for manufacturing your drug and device products in your cleaning validation protocols and procedures. Your cleaning validation protocols and procedures did not include the transfer carriage vessels that are used for moving drug and chemical device component during manufacturing, creating a risk of cross contamination.\n\nIn your response, you provide a CAPA and cleaning validation for the transfer carriage vessel. Your CAPA contains a list of products evaluated for use of the transfer carriage vessel.\n\nYour response is inadequate because the list of products provided in the CAPA contained products without “orders” and therefore lacks a complete evaluation of all possible uses of the transfer carriage vessel. You state that (b)(4) and (b)(4) finished products are the worst-case product to clean. Your response, however, does not provide information on products listed in your CAPA without “orders,” whether those products use the transfer carriage vessel, and what impact those products had on your worst-case product selection.\n\nIn response to this letter, provide:\n\nA detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\nA summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on April 4, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Pharmaplast S.A.E., Amria Free Zone, 30 Beside Lord International Factory Building, Alexandria into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003767891 and ATTN: Sarah Rhoades, Compliance Officer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","Pharmaplast S.A.E.","pharmaplast-sae-648883-04132023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpharmaplast-sae-648883-04132023","2026-10-26T08:09:41.440758+00:00","2023-04-25","648883","Mr. Wassim Attia","2026-08-20T01:08:39.944+00:00","2023-04-13",173,{"510k":398,"classification":399,"enforcement":400,"event":401,"event_backfill":402,"pma":403,"warning_letter":404},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]